Variant Annotation ID	Variant/Haplotypes	Drug(s)	Phenotype Category	Significance	Sentence	Allele Of Frequency In Cases	Allele Of Frequency In Controls	P Value	Ratio Stat Type	Ratio Stat	Confidence Interval Start	Confidence Interval Stop
1448997750	CYP2B6*1, CYP2B6*18	efavirenz	Metabolism/PK	yes	CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.			< 0.0001	OR			
1183632366	CYP2D6*1, CYP2D6*4	codeine	Metabolism/PK	yes	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to CYP2D6 *1/*1 + *1/*4.			= 0.01	Unknown			
982047720	CYP2D6*2, CYP2D6*2xN	codeine	Metabolism/PK	not stated	CYP2D6 *2/*2xN is associated with increased metabolism of codeine.				Unknown			
827566506	CYP2D6*2, CYP2D6*2xN, CYP2D6*41	codeine	Metabolism/PK	yes	CYP2D6 *2xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.02	Unknown			
1451330400	CYP2D6*1, CYP2D6*10	propafenone	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with increased concentrations of propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	*10		< 0.05	Unknown			
1451330363	CYP2D6*1, CYP2D6*10	propafenone	Efficacy	yes	CYP2D6 *10/*10 is associated with increased response to propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	*10		< 0.05	Unknown			
1449716526	CYP3A4*1, CYP3A4*36	fentanyl	Metabolism/PK	yes	CYP3A4 *36/*36 is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.01	OR			
1449716742	CYP3A4*1, CYP3A4*36	fentanyl	Dosage	yes	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.05	OR			
1451153720	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	(R)-methadone,(S)-methadone	Metabolism/PK	yes	CYP2D6 *1/*1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .			= 0.024				
1451153720	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	(R)-methadone,(S)-methadone	Metabolism/PK	yes	CYP2D6 *1/*1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .			= 0.033				
1451161371	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	methadone	Efficacy	yes	CYP2D6 *1/*2xN + *2/*2xN are associated with increased response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 *1/*1.			= 0.032				
1451161472	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	methadone	Dosage	yes	CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.			= 0.043				
1451161540	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	methadone	Metabolism/PK	yes	CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.			= 0.002				
1451153754	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*6	methadone	Efficacy	no	CYP2D6 *1/*1xN is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .			= 0.103				
1451161360	CYP3A5*1, CYP3A5*3	methadone	Efficacy	no	CYP3A5 *3/*3 is not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP3A5 *1/*1 + *1/*3.			= 1				
1451161620	CYP3A5*1, CYP3A5*3	methadone	Dosage	no	CYP3A5 *3/*3 is not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP3A5 *1/*1 + *1/*3.			= 0.312				
1184989377	CYP2C9*1, CYP2C9*3	phenytoin	Dosage	no	CYP2C9 *3 is not associated with dose of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.			> 0.05	OR			
1448994156	CYP2C9*1, CYP2C9*3	phenytoin	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	*3		= 0.01	OR			
1184989363	CYP2C9*1, CYP2C9*3	phenytoin	Metabolism/PK	yes	CYP2C9 *3 is associated with increased concentrations of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.			= 0.022	OR			
1445388514	CYP2C9*1, CYP2C9*2	phenytoin	Metabolism/PK	no	CYP2C9 *1/*1 + *1/*2 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.	*2		> 0.05	OR			
1451162800	UGT1A1*1, UGT1A1*28	raloxifene 6-glucuronide,raloxifene-4′-glucuronide	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with increased concentrations of raloxifene 6-glucuronide and raloxifene-4′-glucuronide in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.			= 0.012	Unknown			
1451162800	UGT1A1*1, UGT1A1*28	raloxifene 6-glucuronide,raloxifene-4′-glucuronide	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with increased concentrations of raloxifene 6-glucuronide and raloxifene-4′-glucuronide in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.			= 0.021	Unknown			
1451162800	UGT1A1*1, UGT1A1*28	raloxifene 6-glucuronide,raloxifene-4′-glucuronide	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with increased concentrations of raloxifene 6-glucuronide and raloxifene-4′-glucuronide in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.			= 0.025	Unknown			
1451162940	CYP2A6*1A, CYP2A6*2, CYP2A6*9, CYP2A6*17	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*2 + *1A/*9 + *1A/*17 (assigned as reduced metabolizers phenotype) are associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A (assigned as normal metabolizers phenotype) .			< 0.05				
1451154280	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17	tramadol	Metabolism/PK	yes	CYP2D6 *1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.			= 0.018				
1451162952	CYP2A6*1A, CYP2A6*2, CYP2A6*9, CYP2A6*17	metronidazole	Metabolism/PK	yes	CYP2A6 *1A/*2 + *1A/*9 + *1A/*17 (assigned as reduced metabolizers phenotype) are associated with decreased metabolism of metronidazole in healthy individuals as compared to CYP2A6 *1A/*1A (assigned as normal metabolizers phenotype) .			< 0.01				
1451206740	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	no	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.25	Unknown			
1451206740	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	no	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.45	Unknown			
1451206740	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	no	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.51	Unknown			
1451206740	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	no	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.62	Unknown			
1451164240	UGT1A1*1, UGT1A1*28	atazanavir	Metabolism/PK	no	UGT1A1 *28 is not associated with concentrations of atazanavir in people with HIV Infections as compared to UGT1A1 *1.			= 0.98	OR			
1451155780	CYP2D6*1, CYP2D6*4, CYP2D6*6	tramadol	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*6 are associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 *1/*1.			< 0.02				
1451207688	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		< 0.01	Unknown			
1451207780	CYP3A5*1, CYP3A5*3	Dabigatran	Metabolism/PK	yes	CYP3A5 *1/*1 is associated with decreased exposure to Dabigatran in healthy individuals as compared to CYP3A5 *1/*3 + *3/*3.			= 0.03				
1451156440	CYP2D6*1, CYP2D6*3, CYP2D6*4	methadone	Metabolism/PK	no	CYP2D6 *3/*4 + *4/*4 are not associated with concentrations of methadone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.							
1451207940	CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*41	tramadol	Metabolism/PK	no	CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41 (assigned as normal metabolizer phenotype) .							
1451156500	CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7	(S)-methadone	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.			= 0.034				
1451156620	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4	tramadol	Metabolism/PK	not stated	CYP2D6 *1/*1xN is associated with decreased concentrations of tramadol in healthy individuals as compared to CYP2D6 *1/*2 + *2/*4.							
1451208380	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10	o-desmethyltramadol	Metabolism/PK	not stated	CYP2D6 *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of o-desmethyltramadol as compared to CYP2D6 *1/*1 + *1/*4 + *1/*6 + *1/*10 + *4/*10 + *10/*10.							
1451339940	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.							
1451156680	CYP2D6*2, CYP2D6*2xN	codeine	Metabolism/PK	not stated	CYP2D6 *2/*2xN is associated with increased metabolism of codeine in women.							
1451343120	CYP2C19*1, CYP2C19*2	rabeprazole	Efficacy	no	CYP2C19 *1/*1 + *1/*2 are not associated with response to rabeprazole in people with Peptic Ulcer as compared to CYP2C19 *2/*2.			= 0.961				
1451343120	CYP2C19*1, CYP2C19*2	rabeprazole	Efficacy	no	CYP2C19 *1/*1 + *1/*2 are not associated with response to rabeprazole in people with Peptic Ulcer as compared to CYP2C19 *2/*2.			= 0.987				
1451340000	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.							
1451340007	CYP2C9*1, CYP2C9*5	warfarin	Dosage	yes	CYP2C9 *1/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.							
1451340040	CYP2C9*1, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *1/*11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.							
1451157920	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9	tramadol	Metabolism/PK	yes	CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .			= 0.02				
1451157968	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9	tramadol	Dosage	no	CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is not associated with dose of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .							
1451343340	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Ulcer as compared to CYP2C19 *1.			> 0.05				
1451340220	UGT1A3*1, UGT1A3*2	telmisartan	Metabolism/PK	yes	UGT1A3 *2 is associated with decreased concentrations of telmisartan in healthy individuals as compared to UGT1A3 *1/*1.			= 3.83e-22				
1451208948	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.			= 0.03	Unknown			
1451208980	UGT1A1*1, UGT1A1*28	bilirubin	Other	yes	UGT1A1 *28/*28 is associated with increased bilirubin in people with Neoplasms as compared to UGT1A1 *1/*1.			= 3.0E-4	Unknown			
1451344540	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.							
1451344540	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.							
1451344548	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.							
1451344650	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole,rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to esomeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.							
1451344650	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole,rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to esomeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.							
1451209187	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	7		= 0.001	Unknown			
1451344640	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1.							
1451344680	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.							
1451209365	UGT1A1*1, UGT1A1*28	carvedilol	Metabolism/PK	yes	UGT1A1 *28 is associated with increased metabolism of carvedilol in people with Angina Pectoris as compared to UGT1A1 *1.			< 0.05	Unknown			
1451209820	UGT1A1*1, UGT1A1*28	cisplatin,irinotecan	Efficacy	no	UGT1A1 *1/*28 is not associated with response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	(TA)6		= 0.531	OR			
1451209847	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	no	UGT1A1 *1/*28 is not associated with dose of irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	(TA)6		= 0.312	Unknown			
1451346608	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.			= 0.421				
1451346700	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.			= 0.311				
1451346726	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.			= 0.974				
1451159180	CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*41	oxycodone	Metabolism/PK	no	CYP2D6 *1/*1xN is associated with decreased exposure to oxycodone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41.							
1451211740	UGT1A1*1, UGT1A1*28	axitinib	Metabolism/PK	no	UGT1A1 *28 is not associated with metabolism of axitinib in healthy individuals as compared to UGT1A1 *1.			= 1	OR			
1451212381	UGT1A1*1, UGT1A1*28, UGT1A1*37	carvedilol,metoprolol	Efficacy	no	UGT1A1 *28/*28 is not associated with increased response to carvedilol or metoprolol in people with Heart Failure as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.			= 0.21	Unknown			
1451212360	UGT1A1*1, UGT1A1*28, UGT1A1*37	carvedilol,metoprolol	Dosage	no	UGT1A1 *28/*28 is not associated with dose of carvedilol or metoprolol in people with Heart Failure as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.			= 0.58	Unknown			
1451212360	UGT1A1*1, UGT1A1*28, UGT1A1*37	carvedilol,metoprolol	Dosage	no	UGT1A1 *28/*28 is not associated with dose of carvedilol or metoprolol in people with Heart Failure as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.			= 0.6	Unknown			
1451213020	UGT1A1*1, UGT1A1*28	FOLFIRI	Dosage	no	UGT1A1 *1/*1 + *1/*28 is associated with increased dose of FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *28/*28.	7/7						
1451213120	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *28 is associated with increased concentrations of SN-38 in people with Colonic Neoplasms as compared to UGT1A1 *1.	(TA)7		= 1.9E-4	OR			
1451213340	UGT1A1*1, UGT1A1*28	irinotecan	Efficacy	no	UGT1A1 *1/*28 + *28/*28 is not associated with increased response to irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.			= 0.91	OR	1.03	0.59	1.82
1451213545	UGT1A1*1, UGT1A1*28	letermovir	Metabolism/PK	no	UGT1A1 *1/*28 + *28/*28 is not associated with increased exposure to letermovir as compared to UGT1A1 *1/*1.			= 0.419				
1451213721	UGT1A1*1, UGT1A1*28	tipifarnib	Metabolism/PK	no	UGT1A1 *28 is not associated with increased metabolism of tipifarnib in people with Neoplasms as compared to UGT1A1 *1.			= 0.79	Unknown			
1451352842	SLCO1B1*1, SLCO1B1*15	atorvastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.026				
1451213915	UGT1A1*1, UGT1A1*28	irinotecan	Efficacy	no	UGT1A1 *1/*28 + *28/*28 is not associated with decreased response to irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.			= 0.7	OR	1.12	0.62	2.02
1451213915	UGT1A1*1, UGT1A1*28	irinotecan	Efficacy	no	UGT1A1 *1/*28 + *28/*28 is not associated with decreased response to irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.			= 0.9	OR	0.98	0.77	1.25
1451214031	UGT1A1*1, UGT1A1*28	FOLFIRI,irinotecan	Efficacy	no	UGT1A1 *28 is not associated with increased response to FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.			= 0.286	OR			
1451214031	UGT1A1*1, UGT1A1*28	FOLFIRI,irinotecan	Efficacy	no	UGT1A1 *28 is not associated with increased response to FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.			= 0.578	OR			
1451214044	UGT1A1*1, UGT1A1*28	warfarin	Dosage	yes	UGT1A1 *1/*28 + *28/*28 is associated with increased dose of warfarin in people with Thromboembolism as compared to UGT1A1 *1/*1.			= 0.029	OR	1.83	0.63	5.4
1183699846	CYP3A5*1, CYP3A5*6	tacrolimus	Metabolism/PK	yes	CYP3A5 *6 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.			= 6.12E-8	OR			
1184515509	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.			= 6.12E-8	OR			
1183699855	CYP3A5*1, CYP3A5*7	tacrolimus	Metabolism/PK	yes	CYP3A5 *7 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.			= 6.12E-8	OR			
1183699824	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *22 is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.			= 0.34	OR			
1447674199	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.001	OR			
1447947417	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	*1		< 0.01	OR			
1184514878	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.001	OR			
1184514878	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.001	OR			
1184514878	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.001	OR			
1184514878	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		= 0.01	OR			
1184514921	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.			< 0.0001	OR			
1449750413	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.				OR			
1449747930	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.			= 0.013	OR			
1184514927	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	not stated	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.				OR			
1447946747	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.003	OR			
1447946747	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.004	OR			
1448819488	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	*1		< 0.0005	OR			
1448819488	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	*1		< 0.001	OR			
1184515198	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.	*3		< 0.01	OR			
1184515210	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.001	OR			
1447520652	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.001	OR			
1448358416	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	*1		< 0.05	OR			
1449183240	CYP3A5*1, CYP3A5*3	cyclosporine,tacrolimus	Metabolism/PK	no	CYP3A5 *1 is not associated with metabolism of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.				OR			
1449171475	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	not stated	CYP3A5 *1/*1 + *1/*3 are associated with concentrations of tacrolimus.	*1			OR			
1184515204	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	not stated	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1			OR			
1448260935	UGT1A1*1, UGT1A1*28, UGT1A1*60	belinostat	Dosage	not stated	UGT1A1 *28/*28 + *1/*60 + *60/*60 are associated with decreased dose of belinostat in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.				OR			
1451229760	CYP2B6*1, CYP2B6*6	tramadol	Metabolism/PK	not stated	CYP2B6 *6 is not associated with metabolism of tramadol in people with Neoplasms and Pain as compared to CYP2B6 *1.			> 0.05				
1451229766	CYP3A5*1, CYP3A5*3	tramadol	Metabolism/PK	not stated	CYP3A5 *3 is not associated with metabolism of tramadol in people with Neoplasms and Pain as compared to CYP3A5 *1.			> 0.05				
1451214860	UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37	moxifloxacin	Metabolism/PK	yes	UGT1A1 *1/*36 is associated with decreased clearance of moxifloxacin in people with Tuberculosis as compared to UGT1A1 *1/*1 + *1/*28 + *28/*28 + *28/*37.	*36		= 0.001	OR			
1451216440	CYP2A6*1A, CYP2A6*4C, CYP2A6*11	tegafur	Metabolism/PK	not stated	CYP2A6 *11/*4C is associated with decreased metabolism of tegafur in people with Stomach Neoplasms as compared to CYP2A6 *1A/*1A.				Unknown			
1184654383	CYP2C9*1, CYP2C9*2	warfarin	Dosage,Efficacy	yes	CYP2C9 *2/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.				OR			
1183701514	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.	*3		< 0.0001	OR			
827919897	CYP2C9*1, CYP2C9*3	simvastatin,warfarin	Dosage,Metabolism/PK	yes	CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin.			= 9.0E-4	Unknown			
827919905	CYP2C9*1, CYP2C9*2	simvastatin,warfarin	Dosage,Metabolism/PK	no	CYP2C9 *2 is not associated with decreased dose of warfarin when treated with simvastatin and warfarin.			= 0.62	Unknown			
827919924	CYP2C9*1, CYP2C9*3	warfarin	Dosage,Metabolism/PK	yes	CYP2C9 *3 is associated with decreased dose of warfarin.			< 1.0E-4	Unknown			
1448267984	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation.	*3		< 0.001	OR			
1184510026	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.			< 0.001	OR			
827919910	CYP2C9*1, CYP2C9*2	warfarin	Dosage,Metabolism/PK	yes	CYP2C9 *2 is associated with decreased dose of warfarin.			< 1.0E-4	Unknown			
1451226420	SLCO1B1*1, SLCO1B1*15	atorvastatin	Metabolism/PK	not stated	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.							
1449750276	TPMT*1, TPMT*3C	mercaptopurine	Dosage,Toxicity	no	TPMT *1/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*3C		= 0.038	OR			
1448576445	TPMT*1, TPMT*2, TPMT*3A	mercaptopurine	Dosage	yes	TPMT *1/*2 + *1/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*3A		< 0.05	OR			
1333193294	TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		< 0.0001	OR			
1333193294	TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.0002	OR			
1333193294	TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.007	OR			
1184747085	UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60	SN-38	Metabolism/PK	yes	UGT1A1 *6/*60 + *6/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.				OR			
1183619415	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1449748829	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.			= 0.0002	OR			
1449748829	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	*1		= 0.0003	OR			
1183701311	CYP2C9*1, CYP2C9*2	warfarin	Dosage	not stated	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1449732457	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.			= 0.009	OR			
1449732457	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.			= 0.028	OR			
1183701419	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.			< 0.0001	OR			
1183701419	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*3	< 0.0001	OR			
1183701419	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*3	= 0.16	OR			
1449748855	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	*1		< 0.05	OR			
1184471382	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	*1		< 0.01	OR			
1184471393	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	*1		< 0.01	OR			
1184471403	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	*1		< 0.05	OR			
1448601760	CYP2A6*1A, CYP2A6*1B1	nicotine	Metabolism/PK	yes	CYP2A6 *1B1/*1B1 is associated with increased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.	*1B1		= 0.002	OR			
1448601760	CYP2A6*1A, CYP2A6*1B1	nicotine	Metabolism/PK	yes	CYP2A6 *1B1/*1B1 is associated with increased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.	*1B1		= 0.02	OR			
1449748938	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1183848923	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2		< 0.05	OR			
1183848923	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2		< 0.05	OR			
1449748921	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1183848916	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*17		< 0.05	OR			
1183848916	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*17		= 0.58	OR			
1183701537	CYP2C19*1, CYP2C19*2	citalopram	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with clearance of citalopram in healthy individuals as compared to CYP2C19 *1/*1.			= 0.071	OR			
1449716224	CYP3A5*1, CYP3A5*3	fentanyl	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.021	OR			
1449716224	CYP3A5*1, CYP3A5*3	fentanyl	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.048	OR			
1183701546	CYP2D6*1, CYP2D6*10	citalopram	Metabolism/PK	yes	CYP2D6 *1/*10 + *10/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.			= 0.036	OR			
1451092520	CYP2C9*1, CYP2C9*3	piroxicam	Metabolism/PK	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased metabolism of piroxicam in healthy individuals as compared to CYP2C9 *1/*1.							
1183701501	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1.	*2		< 0.0003	OR			
1450814028	CYP2C9*1, CYP2C9*2, CYP2C9*24	warfarin	Dosage	not stated	CYP2C9 *2/*24 is associated with decreased clearance of warfarin in women with Cardiomyopathies as compared to CYP2C9 *1/*2.							
1184471670	CYP1A2*1A, CYP1A2*1C, CYP1A2*1D, CYP1A2*1E, CYP1A2*1L	prasugrel	Efficacy	no	CYP1A2 *1A/*1C + *1C/*1D + *1C/*1E + *1C/*1C (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP1A2 *1A/*1A + *1A/*1D + *1A/*1E + *1D/*1D + *1D/*1E + *1D/*1L + *1E/*1L + *1L/*1L (assigned as normal metabolizers phenotype) .			= 0.11	HR	1.42	0.72	2.81
1184471670	CYP1A2*1A, CYP1A2*1C, CYP1A2*1D, CYP1A2*1E, CYP1A2*1L	prasugrel	Efficacy	no	CYP1A2 *1A/*1C + *1C/*1D + *1C/*1E + *1C/*1C (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP1A2 *1A/*1A + *1A/*1D + *1A/*1E + *1D/*1D + *1D/*1E + *1D/*1L + *1E/*1L + *1L/*1L (assigned as normal metabolizers phenotype) .				OR			
1183849063	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluvoxamine,paroxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			= 0.026	OR			
1183849063	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluvoxamine,paroxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			= 0.058	OR			
1451092564	CYP2C9*1, CYP2C9*2, CYP2C9*3	meloxicam	Metabolism/PK	yes	CYP2C9 *1/*3 + *2/*2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.0001				
1183701565	CYP2C9*1, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*3			OR			
1448257532	CYP2C19*2, CYP2C19*3, CYP2C19*17	bupropion	Metabolism/PK	yes	CYP2C19 *2 + *3 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are associated with decreased metabolism of bupropion in women with Pregnancy as compared to CYP2C19 *17 (assigned as normal metabolizer genotype phenotype) .			< 0.05	OR			
1183701573	CYP2C9*1, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *1/*3 is associated with decreased dose of warfarin.				OR			
1183849008	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) .	*17		= 0.002	OR			
1183849008	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) .	*17	*2	< 0.05	OR			
1447520262	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.0015	Unknown			
1448257516	CYP2B6*1, CYP2B6*6	bupropion	Metabolism/PK	no	CYP2B6 *6 is associated with increased steady-state concentration of bupropion in women with Pregnancy as compared to CYP2B6 *1.			= 0.077	OR			
1450814021	CYP2C9*1, CYP2C9*2, CYP2C9*24	warfarin	Dosage	not stated	CYP2C9 *2/*24 is associated with decreased dose of warfarin in women with Cardiomyopathies as compared to CYP2C9 *1/*2.							
1448257502	CYP2B6*1, CYP2B6*6	bupropion	Metabolism/PK	no	CYP2B6 *6 is associated with decreased metabolism of bupropion in women with Pregnancy as compared to CYP2B6 *1.			= 0.086	OR			
1183849125	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	paroxetine	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele).			= 0.018	OR			
1183849112	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	paroxetine	Efficacy	no	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele).			> 0.05	OR			
1451092600	CYP2C9*1, CYP2C9*3	meloxicam	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.05				
1451141840	CYP2D6*5, CYP2D6*17	hydromorphone	Metabolism/PK	not stated	CYP2D6 *5/*17 is associated with decreased concentrations of hydromorphone in women.							
1449716420	CYP3A4*1, CYP3A4*18	fentanyl	Dosage	no	CYP3A4 *18 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1.	*18		> 0.05	OR			
1451141860	CYP2D6*5, CYP2D6*17	hydrocodone,tramadol	Efficacy	not stated	CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.							
1451092660	CYP2C9*1, CYP2C9*2, CYP2C9*3	meloxicam	Metabolism/PK	yes	CYP2C9 *3 + *2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.001				
1451092671	CYP2C9*1, CYP2C9*13	meloxicam	PD,Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.001				
1449716437	CYP3A5*1, CYP3A5*3	fentanyl	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.006	OR			
1448257366	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.001	OR			
1449749340	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	*1		< 0.001	OR			
1448617711	CYP2D6*1, CYP2D6*5, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *5/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *10/*10.			< 0.001	OR			
1448617702	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *1/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1448617690	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10.			< 0.001	OR			
1448617678	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1448257212	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 4.98e-11	OR			
1448995403	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	not stated	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.				OR			
1448257202	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 1.77e-22	OR			
1446897307	CYP2D6*1, CYP2D6*2xN	debrisoquine	Metabolism/PK	not stated	CYP2D6 *1/*2xN is associated with increased metabolism of debrisoquine in healthy individuals.				OR			
1184521242	TPMT*1, TPMT*3A, TPMT*3C	azathioprine,mercaptopurine,purine analogues	Dosage,Efficacy,Toxicity	yes	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.			= 0.0006	OR			
1183849398	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2		< 0.05	OR			
1183702049	CYP2C9*1, CYP2C9*3	meloxicam	Metabolism/PK	yes	CYP2C9 *3/*3 is associated with decreased clearance of meloxicam in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3.			< 0.05	OR			
1449749486	CYP3A5*1, CYP3A5*3	tacrolimus	Efficacy	no	CYP3A5 *3/*3 is not associated with response to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.				OR			
1448995845	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.			< 0.05	OR			
1451125741	CYP1A2*1A, CYP1A2*1F	clozapine	Efficacy	no	CYP1A2 *1F is not associated with response to clozapine in people with Schizophrenia as compared to CYP1A2 *1A.			= 0.178				
1449749543	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.				OR			
982044655	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.			= 0.028	Unknown			
1448257090	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3/*3 + *1/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1449749518	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.				OR			
982044677	CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.			= 0.0	Unknown			
1183849453	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in patients with decreased concentrations of voriconazole.			= 0.01	OR			
1183849453	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in patients with decreased concentrations of voriconazole.			= 0.03	OR			
1448995871	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.				OR			
1448568334	GSTM1 non-null, GSTM1 null	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	GSTM1 null is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to GSTM1 non-null.			> 0.05	OR			
1448568324	GSTT1 non-null, GSTT1 null	bevacizumab,capecitabine,cisplatin,docetaxel,epirubicin,oxaliplatin,trastuzumab	Efficacy	no	GSTT1 null is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to GSTT1 non-null.			> 0.05	OR			
1183620160	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1446897141	CYP2D6*4xN, CYP2D6*36	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4xN/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.				OR			
1446897151	CYP2D6*2, CYP2D6*36	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *2/*36 (assigned as normal metabolizer phenotype) is not associated with decreased metabolism of dextromethorphan.				OR			
1448125906	CYP2C19*2, CYP2C19*3, CYP2C19*17	esomeprazole,pantoprazole	Metabolism/PK	yes	CYP2C19 *17/*17 is associated with increased clearance of esomeprazole and pantoprazole in healthy individuals as compared to CYP2C19 *2/*3.	*17			OR			
1449749618	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.001	OR			
982047968	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *2 + *3 are associated with dose of warfarin in children as compared to CYP2C9 *1.			= 0.0370	OR			
982047968	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *2 + *3 are associated with dose of warfarin in children as compared to CYP2C9 *1.	*1		= 0.1582	OR			
1448256976	CYP2C19*1, CYP2C19*2, CYP2C19*3	aspirin,clopidogrel	Efficacy	yes	CYP2C19 *2 + *3 are associated with decreased response to aspirin and clopidogrel as compared to CYP2C19 *1/*1.			= 0.02	OR			
1448633804	CYP2C19*1, CYP2C19*17	clopidogrel	Efficacy	no	CYP2C19 *17 is not associated with response to clopidogrel as compared to CYP2C19 *1/*1.			= 0.375	OR			
1448996001	CYP2B6*1, CYP2B6*4	efavirenz	Metabolism/PK	yes	CYP2B6 *1/*4 are associated with decreased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.04	OR			
1448633778	CYP2B6*1, CYP2B6*9	clopidogrel	Efficacy	no	CYP2B6 *9 is not associated with response to clopidogrel as compared to CYP2B6 *1/*1.			= 0.64	OR			
1448996011	CYP2B6*1, CYP2B6*5	efavirenz	Metabolism/PK	no	CYP2B6 *1/*5 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.01	OR			
1448996021	CYP2B6*1, CYP2B6*22	efavirenz	Metabolism/PK	no	CYP2B6 *1/*22 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.01	OR			
1448633755	CYP2C19*1, CYP2C19*3	clopidogrel	Efficacy	no	CYP2C19 *3 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.			= 0.215	OR			
1448996035	HLA-C*01:02:01, HLA-C*02:02:01, HLA-C*03:02, HLA-C*04:01:01:01, HLA-C*05:01:01:01, HLA-C*06:02:01:01, HLA-C*07:01:01, HLA-C*08:01, HLA-C*12:02:01, HLA-C*14:02:01, HLA-C*15:02:01, HLA-C*16:01:01, HLA-C*17:01:01:01	peginterferon alfa-2b,ribavirin	Efficacy	yes	HLA-C *02:02:01 + *04:01:01:01 + *05:01:01:01 + *06:02:01:01 + *15:02:01 + *17:01:01:01 is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to HLA-C *01:02:01 + *03:02 + *07:01:01 + *08:01 + *12:02:01 + *14:02:01 + *16:01:01.	*01:02:01		= 0.024	OR	1.52	1.05	2.2
1184472326	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluvoxamine,pindolol	Efficacy	no	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) is not associated with response to fluvoxamine and pindolol in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			= 0.05	OR			
1446897010	CYP3A5*1, CYP3A5*3	simvastatin,simvastatin acid	Metabolism/PK	no	CYP3A5 *3 is not associated with concentrations of simvastatin or simvastatin acid in people with Hypercholesterolemia as compared to CYP3A5 *1.			= 0.119	OR			
1446897010	CYP3A5*1, CYP3A5*3	simvastatin,simvastatin acid	Metabolism/PK	no	CYP3A5 *3 is not associated with concentrations of simvastatin or simvastatin acid in people with Hypercholesterolemia as compared to CYP3A5 *1.			= 0.534	OR			
1184472345	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluvoxamine	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).			= 0.029	OR			
1184472347	CYP2C19*1, CYP2C19*2	aspirin,clopidogrel	Efficacy	yes	CYP2C19 *2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	*2		= 0.003	HR	2.3	1.3	3.9
1448633723	CYP2C19*1, CYP2C19*2	clopidogrel	Efficacy	yes	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.			< 0.001	OR			
1184472237	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	fluoxetine	Efficacy	no	CYP2D6 *1/*1 is not associated with response to fluoxetine in children with Depressive Disorder as compared to CYP2D6 *5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6.				OR			
1184472258	CYP2C9*1, CYP2C9*2, CYP2C9*3	fluoxetine	Efficacy	no	CYP2C9 *1/*1 is not associated with response to fluoxetine in children with Depressive Disorder as compared to CYP2C9 *2/*3 + *3/*3.				OR			
1446896996	CYP3A4*1, CYP3A4*22	simvastatin	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with increased concentrations of simvastatin in people with Hypercholesterolemia as compared to CYP3A4 *1/*1.			= 0.006	OR			
1184472274	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluvoxamine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			< 0.05	OR			
1448568122	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage,Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.0002	OR			
1449747633	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with dose of tacrolimus in children with henoch-schonlein purpura nephritis as compared to CYP3A5 *3/*3.	*1		= 0.67	OR			
1447814438	CYP2D6*1, CYP2D6*10	atomoxetine	Metabolism/PK	yes	CYP2D6 *10/*10 + *1/*10 are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1447814438	CYP2D6*1, CYP2D6*10	atomoxetine	Metabolism/PK	yes	CYP2D6 *10/*10 + *1/*10 are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1448568092	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Metabolism/PK	yes	CYP2C9 *2 + *3 are associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1.			< 0.001	OR			
1184472450	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	citalopram	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			= 0.68	OR			
1184472453	CYP2C19*1, CYP2C19*2	clopidogrel	Metabolism/PK	not stated	CYP2C19 *2/*2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.				OR			
1184472455	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5	warfarin	Dosage	yes	CYP2C9 *3 + *5 + *2 + *1 is associated with dose of warfarin.			= 0.03	OR			
1447519521	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*2.			< 0.001	OR			
1451228826	CYP2C19*1, CYP2C19*2	methadone	Metabolism/PK	no	CYP2C19 *2/*2 is not associated with concentrations of methadone as compared to CYP2C19 *1/*1.			= 0.053				
1183619532	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.01	Unknown			
1183619521	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.01	Unknown			
1447814409	CYP2D6*1, CYP2D6*10	atomoxetine	Metabolism/PK	yes	CYP2D6 *10/*10 + *1/*10 are associated with increased concentrations of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1447814409	CYP2D6*1, CYP2D6*10	atomoxetine	Metabolism/PK	yes	CYP2D6 *10/*10 + *1/*10 are associated with increased concentrations of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1450814783	SLCO1B1*1, SLCO1B1*15	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.0002				
1450814783	SLCO1B1*1, SLCO1B1*15	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.002				
1450814783	SLCO1B1*1, SLCO1B1*15	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.004				
1450814783	SLCO1B1*1, SLCO1B1*15	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.004				
1450814783	SLCO1B1*1, SLCO1B1*15	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.527				
1450814783	SLCO1B1*1, SLCO1B1*15	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.929				
1447519494	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.05	OR			
1183619918	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*2		= 0.001	Unknown			
1183619889	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*2		= 0.0001	Unknown			
1447519445	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1447519456	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1449192875	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*33	methadone	Metabolism/PK	no	CYP2D6 *1xN is not associated with clearance of methadone in people with Opioid-Related Disorders or Pain as compared to CYP2D6 *1 + *2 + *33.				OR			
1447681058	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 + *2/*2 is not associated with dose of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.051	OR			
1447681058	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 + *2/*2 is not associated with dose of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.251	OR			
1183623314	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to omeprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1450372533	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of voriconazole in people with as compared to CYP2C19 *1/*1.	*2	*3	= 0.008	OR			
1450372533	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of voriconazole in people with as compared to CYP2C19 *1/*1.	*2	*3	= 0.041	OR			
1445143678	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Lupus Nephritis as compared to CYP3A5 *1/*3 + *1/*1.	*1		= 0.002	OR			
1447519344	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1448567934	CYP3A5*1, CYP3A5*3	sirolimus	Metabolism/PK	no	CYP3A5 *1 is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	*1		> 0.05	OR			
1448109167	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41	3,4-methylenedioxymethamphetamine	Efficacy	yes	CYP2D6 *4/*4 + *3/*5 is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.			< 0.01	OR			
1184996788	CYP2C9*1, CYP2C9*2	acenocoumarol	Dosage	not stated	CYP2C9 *1/*2 + *2/*2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.				OR			
1184472493	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Metabolism/PK	not stated	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .				OR			
1184996801	CYP2C9*1, CYP2C9*3	acenocoumarol	Dosage	not stated	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.				OR			
1447945286	UGT1A1*1, UGT1A1*6, UGT1A1*28	irinotecan	Efficacy	no	UGT1A1 *6/*6 + *6/*28 + *28/*28 is not associated with response to irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28.				OR			
1451208192	CYP2D6*1, CYP2D6*10	fentanyl	Dosage	yes	CYP2D6 *10/*10 is associated with increased dose of fentanyl in people with Gastrointestinal Neoplasms and Pain, Postoperative as compared to CYP2D6 *1/*1.			< 0.05				
1183622736	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		> 0.05	Unknown			
1183622736	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.13	Unknown			
1183622736	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.19	Unknown			
1448567850	CYP3A5*1, CYP3A5*3	sirolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*3		< 0.05	OR			
1444930553	CYP2D6*1, CYP2D6*10	4-hydroxytamoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			= 0.04	OR			
1183620712	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183620712	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1444930567	CYP2D6*1, CYP2D6*10	tamoxifen	Metabolism/PK	no	CYP2D6 *10/*10 is not associated with decreased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			= 0.78	OR			
1451241020	CYP2A6*1A, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*12	letrozole	Metabolism/PK	yes	CYP2A6 *1A/*1A (assigned as normal metabolizer phenotype) is associated with decreased concentrations of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1A/*2 + *1A/*4A + *1A/*9 + *1A/*12 + *9/*9 (assigned as poor metabolizers and intermediate metabolizers phenotype) .			< 0.0001	OR		22.63	50.47
1448109032	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41	3,4-methylenedioxymethamphetamine	Metabolism/PK	yes	CYP2D6 *4/*4 + *3/*5 is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.			< 0.05	OR			
1447945146	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5	mercaptopurine	Metabolism/PK	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*5 + *2/*3 + *3/*3 + *3/*5 (assigned as intermediate and low activity phenotype) .			= 2.2E-8	OR			
1447945146	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5	mercaptopurine	Metabolism/PK	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*5 + *2/*3 + *3/*3 + *3/*5 (assigned as intermediate and low activity phenotype) .			= 7.7E-5	OR			
1447945146	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5	mercaptopurine	Metabolism/PK	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*5 + *2/*3 + *3/*3 + *3/*5 (assigned as intermediate and low activity phenotype) .			= 2.9E-4	OR			
1184469950	CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17	prasugrel	Efficacy,Metabolism/PK	no	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is not associated with response to prasugrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .			> 0.05	OR			
1448567727	CYP3A5*1, CYP3A5*3	sirolimus	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with metabolism of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.				OR			
1450815182	CYP2D6*4, CYP2D6*5	venlafaxine	Metabolism/PK	not stated	CYP2D6 *4/*5 is associated with decreased metabolism of venlafaxine.							
1448567714	CYP3A4*1, CYP3A4*22	sirolimus	Metabolism/PK	no	CYP3A4 *1/*22 + *22/*22 are not associated with metabolism of sirolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.				OR			
1183679954	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		> 0.05	OR			
1450372838	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	*3			OR			
1184472866	CYP2C9*1, CYP2C9*2	warfarin	Dosage	no	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.			= 0.51	OR			
1449275114	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.			< 0.001	OR			
1449275114	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.			= 0.015	OR			
1449275114	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.			= 0.228	OR			
1444930474	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41	4-hydroxytamoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.			= 0.06	OR			
1444930474	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41	4-hydroxytamoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.			= 0.13	OR			
1444930474	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41	4-hydroxytamoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.			= 0.39	OR			
1448568158	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 + *22/*22 are not associated with metabolism of tacrolimus in children with liver transplantation as compared to CYP3A4 *1/*1.	*22			OR			
1450372870	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.0001	OR			
1450372870	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.000856	OR			
1450372870	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.0027	OR			
1446896464	CYP2D6*21, CYP2D6*36xN	debrisoquine	Metabolism/PK	not stated	CYP2D6 *21/*36xN (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine.				OR			
1447681039	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 + *2/*2 is not associated with dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.222	OR			
1447681039	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 + *2/*2 is not associated with dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.448	OR			
1183620899	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0388	Unknown			
1183620899	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0388	Unknown			
1183620883	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0176	Unknown			
1183620883	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0446	Unknown			
1447945037	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5	mercaptopurine	Dosage	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .			= 4.45E-8	OR			
1447945037	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5	mercaptopurine	Dosage	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .			= 2.1E-5	OR			
1447945037	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5	mercaptopurine	Dosage	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .			= 0.0054	OR			
1447945037	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5	mercaptopurine	Dosage	yes	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .			= 0.021	OR			
1448567637	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin in people with heart valve replacement as compared to CYP2C9 *1/*1.			< 0.01	OR			
1449275137	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in children with Nephrotic Syndrome as compared to CYP3A5 *1/*1.			= 0.005	OR			
1444930388	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41	endoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.			= 0.0001	OR			
1449750346	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6	mercaptopurine	Dosage,Toxicity	no	NUDT15 *1/*3 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 + *1/*5 + *1/*6 + *1/*2.				OR			
1447813900	CYP2D6*1, CYP2D6*10	atomoxetine	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.			= 0.002	OR			
1447814077	NAT1*3, NAT1*4, NAT1*10	mesalazine,thioguanine	Metabolism/PK	yes	NAT1 *10 is associated with decreased concentrations of mesalazine and thioguanine in children with Colitis, Ulcerative, Crohn Disease and Inflammatory Bowel Diseases as compared to NAT1 *4 + *3.			= 0.033	OR			
1183620937	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,lansoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to famotidine and lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0388	Unknown			
1183620937	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,lansoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to famotidine and lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183620915	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0285	Unknown			
1183620915	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1448567540	CYP3A5*1, CYP3A5*3	pioglitazone	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with metabolism of pioglitazone as compared to CYP3A5 *1/*1.			> 0.05	OR			
1449750363	NUDT15*1, NUDT15*3, NUDT15*5	mercaptopurine	Dosage,Toxicity	no	NUDT15 *3/*3 + *3/*5 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*1.				OR			
1448567530	CYP2C9*1, CYP2C9*3	pioglitazone	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with increased metabolism of pioglitazone as compared to CYP2C9 *1.			< 0.05	OR			
1449750401	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.				OR			
1449750388	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.				OR			
1183702193	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	risperidone	Metabolism/PK	yes	CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .			= 0.003	OR			
1184471333	CYP3A4*1, CYP3A4*22	tacrolimus	Dosage	no	CYP3A4 *1/*22 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.093	OR			
1448108691	CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41	paroxetine	Metabolism/PK	no	CYP2D6 *10/*10 is not associated with metabolism of paroxetine as compared to CYP2D6 *10/*41 + *41/*41 + *1/*10 + *1/*41 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.			= 0.059	OR			
1447682700	CYP4F2*1, CYP4F2*3	warfarin	Dosage	yes	CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.	*3	*1	= 0.014	OR			
1449750499	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.05	OR			
1451399960	CYP2C8*1, CYP2C8*2, CYP2C8*3, CYP2C8*4	ibuprofen	Efficacy	no	CYP2C8 *2/*3 + *3/*4 are associated with decreased response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 *1/*1.			= 0.08				
1451399980	CYP2C9*1, CYP2C9*2, CYP2C9*3	ibuprofen	Efficacy	no	CYP2C9 *2/*2 + *2/*3 + *3/*3 are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C9 *1/*1.			= 0.46				
1183619642	CYP2D6*1, CYP2D6*4, CYP2D6*5	risperidone	Metabolism/PK	yes	CYP2D6 *4 + *5 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.			= 0.05	Unknown			
1183620333	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14	risperidone	Metabolism/PK	yes	CYP2D6 *4 + *5 + *10 +*14 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.			= 0.001	Unknown			
1447682605	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*1	= 0.014	OR			
1447682605	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	*3	*1	= 0.015	OR			
1447682605	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	*8	*1	= 0.098	OR			
1451208780	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.001	Unknown			
1451208780	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		< 0.001	Unknown			
1451208780	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.005	Unknown			
1451208780	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	(TA)6		= 0.014	Unknown			
1183621225	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.0001	OR	4.03	1.97	8.28
1183621202	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole,omeprazole,rabeprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.15	OR	1.35	0.89	2.07
1448616465	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *2 + *3 are associated with increased exposure to voriconazole in healthy individuals as compared to CYP2C19 *1 + *17.				OR			
827705098	CYP2A6*1A, CYP2A6*1B1	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*1B1 is associated with increased clearance of nicotine as compared to CYP2A6 *1A/*1A.			< 0.05	Unknown			
1447682561	CYP2C9*1, CYP2C9*3	ibuprofen	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	*3		< 0.001	OR			
1183621191	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole,omeprazole,rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.0001	OR	1.9	1.38	2.6
1448616451	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *1 + *17 are associated with decreased exposure to voriconazole in healthy individuals as compared to CYP2C19 *2 + *3.				OR			
1183621166	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole,omeprazole,rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.001	OR	2.7	1.46	4.98
1447682551	CYP2C9*1, CYP2C9*2	ibuprofen	Metabolism/PK	yes	CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	*2		< 0.01	OR			
1183621271	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.93	OR	1.04	0.33	2.46
1183621246	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.25	OR	1.8	0.67	4.35
1450373276	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Arthritis, Rheumatoid or Colitis, Ulcerative as compared to CYP3A5 *3/*3.	*1		< 0.05	OR			
1451208840	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with decreased clearance of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.			< 0.01	Unknown			
1183703264	CYP2C9*1, CYP2C9*13	lornoxicam	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.01	OR			
1183620172	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05	Unknown			
1183620172	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05				
1183620224	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.01	Unknown			
1183620224	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05	Unknown			
1183620224	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05	Unknown			
1183620224	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05				
1183620224	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05				
1183620224	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	*1		= 0.05				
1183620365	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.001	Unknown			
1183620365	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183620365	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183619844	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	*1		= 0.05	Unknown			
1183621341	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.08	OR	1.71	0.93	3.13
1183621354	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 is not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.19	OR	0.66	0.36	1.23
827704985	CYP2A6*4A, CYP2A6*10	pilocarpine	Metabolism/PK	yes	CYP2A6 *4A/*10 is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.01	Unknown			
827704985	CYP2A6*4A, CYP2A6*10	pilocarpine	Metabolism/PK	yes	CYP2A6 *4A/*10 is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.05	Unknown			
827704987	CYP2A6*1A, CYP2A6*4A, CYP2A6*7	pilocarpine	Metabolism/PK	yes	CYP2A6 *4A/*7 is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.01	Unknown			
827704987	CYP2A6*1A, CYP2A6*4A, CYP2A6*7	pilocarpine	Metabolism/PK	yes	CYP2A6 *4A/*7 is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.05	Unknown			
1183621329	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.03	OR	2.24	1.09	4.61
827704983	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	pilocarpine	Metabolism/PK	yes	CYP2A6 *4A/*9A is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.01	Unknown			
827704983	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	pilocarpine	Metabolism/PK	yes	CYP2A6 *4A/*9A is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.05	Unknown			
827704977	CYP2A6*1A, CYP2A6*7, CYP2A6*9A	pilocarpine	Metabolism/PK	yes	CYP2A6 *7/*9A is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.01	Unknown			
827704977	CYP2A6*1A, CYP2A6*7, CYP2A6*9A	pilocarpine	Metabolism/PK	yes	CYP2A6 *7/*9A is associated with decreased metabolism of pilocarpine in healthy individuals.			< 0.05	Unknown			
1183703257	CYP2C9*1, CYP2C9*13	lornoxicam	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.01	OR			
1183703229	CYP2C9*1, CYP2C9*3	lornoxicam	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.05	OR			
1183621319	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.0006	OR	2.12	1.38	3.25
1183703238	CYP2C9*1, CYP2C9*3	lornoxicam	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.01	OR			
1449718023	CYP3A5*1, CYP3A5*3	aspirin,clopidogrel	Efficacy	no	CYP3A5 *3 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP3A5 *1.	*3		= 0.506	OR			
1451340012	CYP2C9*1, CYP2C9*6	warfarin	Dosage	yes	CYP2C9 *1/*6 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.							
1183621387	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.51	OR	0.73	0.28	1.88
1448255788	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*3 + *3/*3 are associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	*1		< 0.05	OR			
1183621366	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.13	OR	1.59	0.87	2.88
1449718041	CYP2C19*1, CYP2C19*2	aspirin,clopidogrel	Efficacy	no	CYP2C19 *2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	*2		= 0.219	OR			
1448276267	CYP2C9*2, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *2 + *3 are associated with dose of warfarin in people with Stroke.				OR			
1184764277	CYP2D6*5, CYP2D6*8	sparteine	Metabolism/PK	not stated	CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1183617359	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	venlafaxine	Metabolism/PK	yes	CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased metabolism of venlafaxine as compared to CYP2D6 *1/*1.			= 0.05	Unknown			
1449713965	CYP3A5*1, CYP3A5*3	alfentanil	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with clearance of alfentanil in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.	*3			OR			
1448603925	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is associated with trough concentration of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.			= 0.0061	OR			
1184764290	CYP2D6*4, CYP2D6*11	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1184764284	CYP2D6*4, CYP2D6*12	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1447948565	CYP2D6*1, CYP2D6*10, CYP2D6*36	gefitinib	Metabolism/PK	no	CYP2D6 *1/*1 is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*10 + *1/*36 + *10/*10 + *10/*36 + *36/*36.				OR			
1183699285	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.	*3		< 0.001	OR			
1184747909	CYP2C9*1, CYP2C9*2	propofol	Metabolism/PK	yes	CYP2C9 *1/*1 + *1/*2 is associated with decreased concentrations of propofol in people with as compared to CYP2C9 *2/*2.	*2		= 0.02	OR			
1448603912	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.24	OR			
981501231	TPMT*1, TPMT*3A	mercaptopurine,methotrexate	Dosage	no	TPMT *1/*1 is associated with increased dose of mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*3A.			= 0.19	Unknown			
1184764302	CYP2D6*4, CYP2D6*59	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*59 is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1447948553	CYP3A5*1, CYP3A5*3	gefitinib	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP3A5 *3/*3.				OR			
1448276214	CYP2C9*1, CYP2C9*3	warfarin	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with clearance of warfarin in people with Heart Diseases as compared to CYP2C9 *1/*1.	*3			OR			
1184747936	UGT1A1*1, UGT1A1*28	gepirone hydrochloride	Metabolism/PK	no	UGT1A1 *28 is not associated with clearance of gepirone hydrochloride in people with Asthma as compared to UGT1A1 *1.				OR			
1449713997	CYP3A5*1, CYP3A5*3	fentanyl	Dosage	no	CYP3A5 *3 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A5 *1.	*3			OR			
1183617444	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole,omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	*1		= 0.001	Unknown			
1183617434	CYP2D6*1, CYP2D6*4	citalopram,escitalopram,fluoxetine,fluvoxamine,paroxetine,sertraline	Dosage,Efficacy	yes	CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.	*1		= 0.03	Unknown			
1448603849	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.0001	OR			
1449157016	CYP2B6*1, CYP2B6*2	efavirenz	Metabolism/PK	no	CYP2B6 *2 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.				OR			
1184469338	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 is associated with increased dose of warfarin as compared to CYP2C9 *1/*1.	*1	*2	= 0.00	OR			
1184469338	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 is associated with increased dose of warfarin as compared to CYP2C9 *1/*1.	*1	*2	< 0.001	OR			
1183699310	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.	*2		= 0.001	OR			
1183699417	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	risperidone	Metabolism/PK	yes	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.			= 0.001	OR			
1183699417	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	risperidone	Metabolism/PK	yes	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.			< 0.001	OR			
1183699417	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	risperidone	Metabolism/PK	yes	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.			< 0.001	OR			
1183699417	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	risperidone	Metabolism/PK	yes	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.			> 0.1	OR			
1451406180	CYP3A4*1, CYP3A4*22	ibuprofen	Efficacy	no	CYP3A4 *1/*22 is associated with decreased response to ibuprofen in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.059				
1451406180	CYP3A4*1, CYP3A4*22	ibuprofen	Efficacy	no	CYP3A4 *1/*22 is associated with decreased response to ibuprofen in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.345				
1451406180	CYP3A4*1, CYP3A4*22	ibuprofen	Efficacy	no	CYP3A4 *1/*22 is associated with decreased response to ibuprofen in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.603				
1451406180	CYP3A4*1, CYP3A4*22	ibuprofen	Efficacy	no	CYP3A4 *1/*22 is associated with decreased response to ibuprofen in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.821				
1448276106	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.			< 0.05	OR			
1448276095	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.			< 0.05	OR			
1449157093	TPMT*1, TPMT*3A, TPMT*3C	thioguanine	Metabolism/PK	yes	TPMT *1/*3A + *1/*3C are associated with increased concentrations of thioguanine in people with Crohn Disease as compared to TPMT *1/*1.	*3A		< 0.001	OR		0.13	0.577
1184747953	CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*39	paroxetine	Metabolism/PK	no	CYP2D6 *2/*10 + *10/*39 + *10/*10 + *5/*10 is not associated with concentrations of paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *39/*39 + *5/*39.			= 0.122	OR			
1183945249	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	not stated	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in human liver microsomes as compared to CYP3A5 *3/*3.	*3			OR			
1451406341	CYP3A4*1, CYP3A4*22	tramadol	Efficacy	no	CYP3A4 *1/*22 is not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.332				
1451406341	CYP3A4*1, CYP3A4*22	tramadol	Efficacy	no	CYP3A4 *1/*22 is not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.455				
1451406341	CYP3A4*1, CYP3A4*22	tramadol	Efficacy	no	CYP3A4 *1/*22 is not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.644				
1451406341	CYP3A4*1, CYP3A4*22	tramadol	Efficacy	no	CYP3A4 *1/*22 is not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A4 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.813				
1449173523	CYP3A4*1, CYP3A4*20	tacrolimus	Dosage	no	CYP3A4 *1/*20 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*20			OR			
1448423497	CYP2C19*1, CYP2C19*2, CYP2C19*3	proguanil	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased metabolism of proguanil in children with Malaria as compared to CYP2C19 *1/*1.			< 0.001	OR			
1184518608	TPMT*1, TPMT*3A, TPMT*3C	mercaptopurine	Dosage	yes	TPMT *1/*3A + *1/*3C + *3A/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.042	OR	3.03	1.03	7.42
1183699464	CYP3A7*1A, CYP3A7*1C	risperidone	Metabolism/PK	no	CYP3A7 *1C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to CYP3A7 *1A.	*1C			OR			
1448489015	CYP3A4*1, CYP3A4*22	exemestane	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with increased concentrations of exemestane in women with Breast Neoplasms as compared to CYP3A4 *1/*1.	*22		< 0.01	OR			
1451123305	CYP2B6*1, CYP2B6*6	lumefantrine	Metabolism/PK	no	CYP2B6 *6/*6 is not associated with metabolism of lumefantrine in healthy individuals as compared to CYP2B6 *1/*1.			= 0.683				
1451123300	CYP2B6*1, CYP2B6*6	artemether	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with decreased metabolism of artemether in healthy individuals as compared to CYP2B6 *1/*1.			= 0.011				
1447948288	CYP2D6*1, CYP2D6*5, CYP2D6*10	gefitinib	Metabolism/PK	no	CYP2D6 *1/*5 + *1/*10 + *5/*10 + *10/*10 are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1.			> 0.05	OR			
1184748190	CYP2C19*1, CYP2C19*2, CYP2C19*3	citalopram,escitalopram	Metabolism/PK	yes	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .			< 0.0001	OR			
1000539548	CYP3A5*1, CYP3A5*3	vincristine	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with clearance of vincristine in children with Neoplasms as compared to CYP3A5 *3/*3.	*3			Unknown			
1448993424	CYP3A4*1, CYP3A4*22	antipsychotics,aripiprazole,haloperidol,pimozide,risperidone	Metabolism/PK	no	CYP3A4 *22 is not associated with dose-adjusted trough concentrations of antipsychotics, aripiprazole, haloperidol, pimozide or risperidone in people with Psychotic Disorders as compared to CYP3A4 *1.	*22		= 0.35	OR			
1449190032	CYP2C19*1, CYP2C19*17	n-desmethylclozapine	Metabolism/PK	yes	CYP2C19 *17 is associated with increased concentrations of n-desmethylclozapine in people with schizoaffective disorder and Schizophrenia as compared to CYP2C19 *1.			= 0.049	OR			
1448603574	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41	oxymorphone	Metabolism/PK	yes	CYP2D6 *1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2 (assigned as normal metabolizers phenotype) is associated with increased exposure to oxymorphone in children with as compared to CYP2D6 *1/*4 + *1/*6 + *17/*41 + *2/*4 + *2/*5 + *4/*41 (assigned as poor metabolizers and intermediate metabolizers phenotype) .			= 0.0162	OR			
1448603574	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41	oxymorphone	Metabolism/PK	yes	CYP2D6 *1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2 (assigned as normal metabolizers phenotype) is associated with increased exposure to oxymorphone in children with as compared to CYP2D6 *1/*4 + *1/*6 + *17/*41 + *2/*4 + *2/*5 + *4/*41 (assigned as poor metabolizers and intermediate metabolizers phenotype) .			= 0.02	OR			
1449157325	CYP2B6*1, CYP2B6*6	cyclophosphamide	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 *1/*1.			< 0.01	OR			
1184748315	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	citalopram,escitalopram	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .			< 0.05	OR			
1449157340	CYP2B6*1, CYP2B6*30	cyclophosphamide	Metabolism/PK	yes	CYP2B6 *1/*30 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 *1/*1.			< 0.01	OR			
1184748329	CYP2C19*1, CYP2C19*17	citalopram,escitalopram	Metabolism/PK	yes	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .			< 0.0001	OR			
1184469799	CYP2C19*1, CYP2C19*2, CYP2C19*3	aspirin,clopidogrel	Efficacy,Toxicity	no	CYP2C19 *1/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *1/*3.				OR			
1449157351	CYP2B6*1, CYP2B6*29	cyclophosphamide	Metabolism/PK	yes	CYP2B6 *1/*29 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 *1/*1.			< 0.01	OR			
1183617822	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.001	Unknown			
1446899532	CYP2D6*1, CYP2D6*4	debrisoquine	Metabolism/PK	not stated	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.				OR			
1450664704	CYP2C19*1, CYP2C19*2, CYP2C19*3	prasugrel	Metabolism/PK	no	CYP2C19 *2/*2 + *2/*3 are not associated with metabolism of prasugrel in healthy individuals as compared to CYP2C19 *1/*1.				OR			
1449157368	CYP2C19*1, CYP2C19*2	cyclophosphamide	Metabolism/PK	yes	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2C19 *1/*1.			< 0.01	OR			
1450664694	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Metabolism/PK	not stated	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.				OR			
1449157385	CYP2C19*1, CYP2C19*2	cyclophosphamide	Efficacy	yes	CYP2C19 *1/*2 + *2/*2 are associated with decreased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2C19 *1/*1.			= 0.001	OR			
1448603457	CYP3A4*1, CYP3A4*22, CYP3A4*36	pantoprazole	Efficacy	no	CYP3A4 *1 (assigned as normal metabolizers phenotype) is not associated with response to pantoprazole in people with Helicobacter Infections as compared to CYP3A4 *36 + *22.	*1	*1	= 1.0	OR			
1450664729	CYP2C19*1, CYP2C19*2, CYP2C19*3	prasugrel	Efficacy	no	CYP2C19 *2/*2 + *2/*3 are not associated with response to prasugrel in healthy individuals as compared to CYP2C19 *1/*1.				OR			
1448259384	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1/*1.			< 0.05	OR			
1447520463	CYP1A2*1A, CYP1A2*1C, CYP1A2*1F	quetiapine	Metabolism/PK	yes	CYP1A2 *1A/*1C + *1C/*1F is associated with increased exposure to quetiapine in healthy individuals as compared to CYP1A2 *1A/*1A + *1F/*1F.			= 0.026	OR			
1447980818	UGT1A4*1a, UGT1A4*3a	testosterone	Efficacy,Metabolism/PK	yes	UGT1A4 *3a is associated with increased clearance of testosterone as compared to UGT1A4 *1a.			< 0.05	Unknown			
1449157437	CYP3A5*1, CYP3A5*3	cyclophosphamide	Efficacy	yes	CYP3A5 *1/*3 + *3/*3 are associated with increased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP3A5 *1/*1.			< 0.0001	OR			
1184469900	CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17	prasugrel	Efficacy,Metabolism/PK	no	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is not associated with metabolism of prasugrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .			= 0.6361	OR			
1447980797	UGT1A4*1a, UGT1A4*2, UGT1A4*3a	tamoxifen	Efficacy,Metabolism/PK	no	UGT1A4 *2 + *3a are not associated with decreased clearance of tamoxifen as compared to UGT1A4 *1a.				Unknown			
1448259338	CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *2 + *3 is associated with dose of acenocoumarol.			< 0.0001	OR			
1447980787	UGT1A4*1a, UGT1A4*2	testosterone	Efficacy,Metabolism/PK	no	UGT1A4 *2 is not associated with increased clearance of testosterone as compared to UGT1A4 *1a.				Unknown			
1184748337	CYP2C19*1, CYP2C19*17	citalopram,escitalopram	Metabolism/PK	yes	CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .			< 0.05	OR			
1451156368	CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7	quetiapine	Metabolism/PK	no	CYP2B6 *6/*6 is not associated with concentrations of quetiapine as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.							
1447980777	UGT1A4*1a, UGT1A4*2, UGT1A4*3a	lamotrigine	Efficacy,Metabolism/PK	yes	UGT1A4 *2 + *3a are associated with decreased clearance of lamotrigine as compared to UGT1A4 *1a.			< 0.005	Unknown			
1451409400	CYP2C19*1, CYP2C19*2, CYP2C19*17	phenytoin	Metabolism/PK	no	CYP2C19 *1/*2 + *1/*17 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.			> 0.05	OR			
1450664831	CYP2C19*1, CYP2C19*2	amitriptyline	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.			= 0.033	OR			
1451409603	CYP2A6*1A, CYP2A6*12	3-hydroxycotinine	Metabolism/PK	yes	CYP2A6 *1A/*12 is associated with decreased concentrations of 3-hydroxycotinine as compared to CYP2A6 *1A/*1A.	*12		= 0.014				
1184469836	CYP2C19*2, CYP2C19*3	aspirin,clopidogrel	Efficacy,Toxicity	no	CYP2C19 *2/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *2/*3.				OR			
1183699837	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.			= 6.12E-8	OR			
1446897275	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) .			< 0.05	OR			
1184469857	CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17	clopidogrel	Efficacy,Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .			= 0.0015	OR			
1451156360	CYP2D6*1, CYP2D6*3, CYP2D6*4	quetiapine	Metabolism/PK	no	CYP2D6 *3/*4 + *4/*4 are not associated with concentrations of quetiapine as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.							
1450664844	CYP2C19*1, CYP2C19*2	amitriptyline	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.			= 0.059	OR			
1449157557	CYP2D6*1, CYP2D6*10, CYP2D6*49	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*49 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.019	OR			
1184748535	CYP2C19*1, CYP2C19*2	voriconazole	Dosage,Metabolism/PK	yes	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .			= 0.04	OR			
1449157567	CYP2D6*1, CYP2D6*49	dextromethorphan	Metabolism/PK	no	CYP2D6 *1/*49 is not associated with metabolism of dextromethorphan in healthy individuals.			> 0.05	OR			
1449157575	CYP2D6*1, CYP2D6*10, CYP2D6*49, CYP2D6*52	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *10/*52 + *49/*52 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.				OR			
1449157587	CYP2D6*1, CYP2D6*10, CYP2D6*49	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*49 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10.			< 0.05	OR			
1448308356	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	*1	*1	< 0.05	OR			
1451254722	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	citalopram,fluoxetine,paroxetine	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			= 0.617	OR	1.095	0.758	1.561
1043859096	CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46	metoprolol	Toxicity,Metabolism/PK	yes	CYP2D6 *9 + *29 + *45 + *46 + *17 + *10 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.			< 0.007	Unknown			
1184469934	CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17	clopidogrel	Efficacy,Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .			< 0.05	OR			
1183699996	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	escitalopram	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased clearance of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.			< 0.005	OR			
1184748470	CYP2C19*1, CYP2C19*17	voriconazole	Dosage,Metabolism/PK	yes	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*17	= 0.02	OR			
1183699984	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.0005	OR			
1043859051	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	metoprolol	Toxicity,Metabolism/PK	yes	CYP2D6 *4 + *3 + *5 + *6 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.			< 0.007	Unknown			
1451205300	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.			< 0.001	Unknown			
1451205300	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.			< 0.001	Unknown			
1451205300	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.			= 0.002	Unknown			
1184748497	CYP2C19*1, CYP2C19*17	voriconazole	Dosage,Metabolism/PK	no	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is not associated with dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*17	= 0.95	OR			
1451273761	CYP2C19*1, CYP2C19*17	esomeprazole	Efficacy	yes	CYP2C19 *17 is associated with decreased response to esomeprazole in children with eosinophilic esophagitis as compared to CYP2C19 *1/*1.			= 0.02	OR	0.12	0.02	0.67
1451273860	CYP2C19*1, CYP2C19*17	esomeprazole	Efficacy	no	CYP2C19 *17 is not associated with response to esomeprazole in children with eosinophilic esophagitis as compared to CYP2C19 *1/*1.			= 0.65	OR	1.38	0.34	5.61
1183699973	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.0005	OR			
1184748512	CYP2C19*1, CYP2C19*2	voriconazole	Dosage,Metabolism/PK	yes	CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*17	= 0.04	OR			
1447945228	UGT1A1*1, UGT1A1*6, UGT1A1*28	irinotecan	Dosage	yes	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with decreased dose of irinotecan in people with Neoplasms as compared to UGT1A1 *1/*28 + *1/*6.	*28	*6	< 0.01	OR			
1449747475	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	yes	CYP2C9 *2 + *3 is associated with decreased dose of phenprocoumon in children as compared to CYP2C9 *1.			= 0.028	OR			
1451157820	CYP2D6*1, CYP2D6*1xN	tramadol	Metabolism/PK	yes	CYP2D6 *1/*1xN is associated with increased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.			< 0.001				
1451208680	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	no	UGT1A1 *28/*28 is associated with increased concentrations of SN-38 in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	7	6		Unknown			
1446899262	CYP2D6*4, CYP2D6*59	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*59 (assigned as intermediate metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.				OR			
1446899270	CYP2D6*2, CYP2D6*59	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *2/*59 (assigned as normal metabolizers phenotype) is not associated with decreased metabolism of dextromethorphan.				OR			
1183700066	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.000000000000010	OR			
1451414380	CYP2C19*1, CYP2C19*2, CYP2C19*17	pantoprazole	Efficacy	no	CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1 + *1/*2.			= 0.20	OR	1.99	0.68	5.83
1451414540	CYP2C19*1, CYP2C19*2, CYP2C19*3	pantoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.			= 0.65				
1184473220	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			< 0.001	OR			
1451414900	UGT1A4*1a, UGT1A4*1b	lamotrigine	Metabolism/PK	yes	UGT1A4 *1b is associated with decreased concentrations of lamotrigine in people with Epilepsy as compared to UGT1A4 *1a.			< 0.05				
1183629904	CYP2D6*1, CYP2D6*5, CYP2D6*10	haloperidol	Metabolism/PK	yes	CYP2D6 *5 + *10 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.			= 0.05	Unknown			
1183622259	CYP2D6*1, CYP2D6*3, CYP2D6*4	haloperidol	Metabolism/PK	yes	CYP2D6 *3 + *4 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.			= 0.006	Unknown			
1183623024	CYP2D6*1, CYP2D6*2, CYP2D6*10	haloperidol	Metabolism/PK	no	CYP2D6 *2 + *10 are not associated with increased metabolism of haloperidol as compared to CYP2D6 *1.				Unknown			
1451430400	CYP2D6*1, CYP2D6*3, CYP2D6*4	zuclopenthixol	Metabolism/PK	yes	CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.			= 0.014				
1451430400	CYP2D6*1, CYP2D6*3, CYP2D6*4	zuclopenthixol	Metabolism/PK	yes	CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.			= 0.02				
1451430400	CYP2D6*1, CYP2D6*3, CYP2D6*4	zuclopenthixol	Metabolism/PK	yes	CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.			= 0.03				
1451430400	CYP2D6*1, CYP2D6*3, CYP2D6*4	zuclopenthixol	Metabolism/PK	yes	CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.			= 0.03				
1448519775	CYP3A4*1, CYP3A4*3	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	CYP3A4 *1 + *3 are not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms.	*1B	*3	> 0.01	OR			
1183698704	CYP3A4*1, CYP3A4*18	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*18 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*18B		< 0.05	OR			
1183698757	CYP3A4*1, CYP3A4*18	cyclosporine	Metabolism/PK	yes	CYP3A4 *18/*18 is associated with increased metabolism of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*1 + *1/*18.	*18B		< 0.05	OR			
1183698757	CYP3A4*1, CYP3A4*18	cyclosporine	Metabolism/PK	yes	CYP3A4 *18/*18 is associated with increased metabolism of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*1 + *1/*18.	*18B		> 0.05	OR			
1449715317	CYP3A4*1, CYP3A4*18	fentanyl	Dosage,Efficacy	yes	CYP3A4 *18/*18 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	*18B		= 0.032	OR			
1449715317	CYP3A4*1, CYP3A4*18	fentanyl	Dosage,Efficacy	yes	CYP3A4 *18/*18 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	*18B		= 0.432	OR			
1449715329	CYP3A4*1, CYP3A4*18	fentanyl	Dosage	no	CYP3A4 *18 is not associated with dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1.			> 0.05	OR			
1449715329	CYP3A4*1, CYP3A4*18	fentanyl	Dosage	no	CYP3A4 *18 is not associated with dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1.			> 0.05				
1444843685	CYP3A4*1, CYP3A4*18	cyclosporine	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with increased concentrations of cyclosporine in men as compared to CYP3A4 *1/*18.	*18B		= 0.023	OR			
1449576542	CYP2C8*1, CYP2C8*4	montelukast	Metabolism/PK	yes	CYP2C8 *4 is associated with increased concentrations of montelukast in healthy individuals as compared to CYP2C8 *1/*1.	*4		= 0.0184	OR			
1184166991	CYP2C8*1, CYP2C8*3	everolimus	Dosage	no	CYP2C8 *1/*1 is not associated with dose of everolimus in people with heart transplantation as compared to CYP2C8 *1/*3.	*3			OR			
1451335353	CYP2C8*1, CYP2C8*2, CYP2C8*3	olanzapine	Metabolism/PK	no	CYP2C8 *2 + *3 are not associated with exposure to olanzapine in healthy individuals as compared to CYP2C8 *1.			> 0.05				
1449576530	CYP2C8*1, CYP2C8*3	montelukast	Metabolism/PK	yes	CYP2C8 *3 is associated with decreased concentrations of montelukast in healthy individuals as compared to CYP2C8 *1/*1.	*3		= 0.00659	OR			
1449171705	CYP2C8*1, CYP2C8*3	tacrolimus	Metabolism/PK	yes	CYP2C8 *1/*3 + *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1/*1.	*3		< 0.05	OR			
1449713492	CYP2C8*1, CYP2C8*3	pioglitazone	Metabolism/PK	no	CYP2C8 *1/*1 is not associated with metabolism of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.			> 0.05	OR			
1449713480	CYP2C8*1, CYP2C8*3	pioglitazone	Metabolism/PK	no	CYP2C8 *1/*1 is not associated with metabolism of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.			= 0.85	OR			
1450367891	CYP2C8*1, CYP2C8*3	ibuprofen	Dosage	yes	CYP2C8 *1/*3 is associated with decreased dose of ibuprofen.			= 0.00872	OR			
1450935194	CYP2C8*1, CYP2C8*3	rosiglitazone	Metabolism/PK	yes	CYP2C8 *1/*3 is associated with decreased concentrations of rosiglitazone in healthy individuals as compared to CYP2C8 *1/*1.			= 0.002				
1183680757	CYP2C8*1, CYP2C8*2, CYP2C8*3, CYP2C8*4	celecoxib	Metabolism/PK	no	CYP2C8 *1/*1 is not associated with metabolism of celecoxib in healthy individuals as compared to CYP2C8 *1/*2 + *1/*3 + *1/*4 + *3/*4 + *4/*4.	*3		> 0.05	OR			
1450935268	CYP2C8*1, CYP2C8*3	ibuprofen	Metabolism/PK	yes	CYP2C8 *3 is associated with decreased metabolism of ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.			= 0.025				
1450935112	CYP2C8*1, CYP2C8*3	rosiglitazone	Metabolism/PK	no	CYP2C8 *1/*3 + *3/*3 are associated with decreased concentrations of rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to CYP2C8 *1/*1.			= 0.06				
1449713452	CYP2C8*1, CYP2C8*3	pioglitazone	Metabolism/PK	no	CYP2C8 *1/*1 is not associated with concentrations of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.			= 0.22	OR			
1451111440	CYP2C8*1, CYP2C8*3, CYP2C8*4	hydroxychloroquine	Efficacy	no	CYP2C8 *1/*3 + *3/*3 + *3/*4 + *1/*4 is not associated with decreased response to hydroxychloroquine in people with Lupus Erythematosus, Discoid as compared to CYP2C8 *1/*1.			= 0.18	OR	1.55	0.82	2.96
1451353463	CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18	methadone	Metabolism/PK	yes	CYP2B6 *1/*6 + *1/*18 + *6/*6 + *6/*18 are associated with decreased metabolism of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*5 + *1/*7.			= 0.012				
1451446260	CYP3A4*1, CYP3A4*36	sufentanil	Dosage	no	CYP3A4 *36 is not associated with dose of sufentanil as compared to CYP3A4 *1.			= 0.435				
1451447480	SLCO1B1*1, SLCO1B1*15	rosuvastatin	Efficacy	no	SLCO1B1 *15/*15 + *1/*15 are not associated with decreased response to rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.169				
1451448720	CYP3A5*1, CYP3A5*3	atorvastatin	Metabolism/PK	yes	CYP3A5 *1/*3 + *3/*3 are associated with decreased concentrations of atorvastatin in healthy individuals as compared to CYP3A5 *1/*1.			= 0.018				
1451448741	SLCO1B1*1, SLCO1B1*5	atorvastatin	Metabolism/PK	yes	SLCO1B1 *1/*5 + *5/*5 are associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.			< 0.001				
1451450620	SLCO1B1*1, SLCO1B1*15	pravastatin	Efficacy	yes	SLCO1B1 *1/*15 is associated with decreased response to pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.			< 0.05				
1451451060	SLCO1B1*1, SLCO1B1*15	pravastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.			< 0.01	Unknown			
1451451080	SLCO1B1*1, SLCO1B1*15	pitavastatin,pravastatin	Metabolism/PK	yes	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.			< 0.01				
1451451102	SLCO1B1*1, SLCO1B1*15	fluvastatin	Metabolism/PK	no	SLCO1B1 *15/*15 is not associated with increased concentrations of fluvastatin in healthy individuals as compared to SLCO1B1 *1/*1.							
1451491077	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5	acyclovir	Efficacy	yes	NUDT15 *2/*2 +*2/*3 +*3/*3 + *5/*5 (assigned as poor metabolizer phenotype) are associated with increased response to aciclovir as compared to NUDT15 *1/*1 (assigned as normal metabolizer phenotype) .			= 0.015				
981954745	CYP2D6*2, CYP2D6*10	ondansetron	Efficacy	no	CYP2D6 *2/*2 + *2/*10 are not associated with response to ondansetron in people with Neoplasms.			= 0.12	Unknown			
981954745	CYP2D6*2, CYP2D6*10	ondansetron	Efficacy	no	CYP2D6 *2/*2 + *2/*10 are not associated with response to ondansetron in people with Neoplasms.			= 0.98	Unknown			
1451499146	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	praziquantel	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased exposure to praziquantel in children with Schistosomiasis as compared to CYP2C19 *1/*1 + *1/*17.			= 0.01				
1451499146	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	praziquantel	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased exposure to praziquantel in children with Schistosomiasis as compared to CYP2C19 *1/*1 + *1/*17.			= 0.04				
1451503480	CYP2D6*1, CYP2D6*4, CYP2D6*10	fluoxetine	Metabolism/PK	yes	CYP2D6 *1/*1 + *10/*10 + *1/*4 + *1/*10 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP2D6 *10/*4 (assigned as intermediate metabolizer phenotype) .			= 0.01				
1451503480	CYP2D6*1, CYP2D6*4, CYP2D6*10	fluoxetine	Metabolism/PK	yes	CYP2D6 *1/*1 + *10/*10 + *1/*4 + *1/*10 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP2D6 *10/*4 (assigned as intermediate metabolizer phenotype) .			= 0.026				
1451516060	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon,warfarin	Dosage	no	CYP2C9 *2 + *3 are not associated with dose of phenprocoumon or warfarin as compared to CYP2C9 *1.			= 0.35	Unknown			
1444707881	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	no	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.			= 0.221	OR			
1444707881	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	no	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.			= 0.559	OR			
1451504060	CYP2A6*1A, CYP2A6*2, CYP2A6*9, CYP2A6*10	3-hydroxycotinine,3-hydroxycotinine glucuronide	Metabolism/PK	yes	CYP2A6 *1A + *2 (assigned as intermediate metabolizer and normal metabolizer phenotype) is associated with increased concentrations of 3-hydroxycotinine and 3-hydroxycotinine glucuronide in people with Tobacco Use Disorder as compared to CYP2A6 *10 + *9 (assigned as poor metabolizers phenotype) .			= 5.1e-06				
1450935228	SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*16	rosiglitazone	Metabolism/PK	no	SLCO1B1 *5 + *15 + *16 are not associated with concentrations of rosiglitazone in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.26				
1451499840	CYP2E1*1, CYP2E1*5B	acetaminophen sulfate	Metabolism/PK	yes	CYP2E1 *1/*5B is associated with increased concentrations of acetaminophen sulfate in infants with Ductus Arteriosus, Patent and Preterm Infant as compared to CYP2E1 *1/*1.			< 0.05				
1184748435	SLCO1B1*1, SLCO1B1*14	fluvastatin	Efficacy	yes	SLCO1B1 *14 is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.			= 0.0005	OR			
1184748435	SLCO1B1*1, SLCO1B1*14	fluvastatin	Efficacy	yes	SLCO1B1 *14 is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.			= 0.005	OR			
1184747049	SLCO1B1*1, SLCO1B1*31, SLCO1B1*37	methotrexate	Metabolism/PK	yes	SLCO1B1 *31 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.			< 0.03	OR			
1184747071	SLCO1B1*1, SLCO1B1*20, SLCO1B1*37	methotrexate	Metabolism/PK	yes	SLCO1B1 *20 is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.			< 0.007	OR			
1184747038	SLCO1B1*1, SLCO1B1*23, SLCO1B1*37	methotrexate	Metabolism/PK	yes	SLCO1B1 *23 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.			< 0.009	OR			
1184747027	SLCO1B1*1, SLCO1B1*15, SLCO1B1*37	methotrexate	Metabolism/PK	yes	SLCO1B1 *15 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.			= 9.2e-9	OR			
982043808	SLCO1B1*15, SLCO1B1*37	rosuvastatin	Metabolism/PK	yes	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.			< 0.05	Unknown			
1451505380	CYP2C19*1, CYP2C19*2, CYP2C19*3	escitalopram	Metabolism/PK	yes	CYP2C19 *2/*2 +*3/*3 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased exposure to escitalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			< 0.001				
1451505380	CYP2C19*1, CYP2C19*2, CYP2C19*3	escitalopram	Metabolism/PK	yes	CYP2C19 *2/*2 +*3/*3 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased exposure to escitalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.003				
1451533063	SLCO1B1*1, SLCO1B1*15	atorvastatin	Metabolism/PK	yes	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.			= 0.012				
1451165020	SLCO1B1*1, SLCO1B1*15, SLCO1B1*37	atorvastatin	Metabolism/PK	yes	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.			< 0.05				
1451533240	SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37	atrasentan	Metabolism/PK	yes	SLCO1B1 *15/*15 + *1/*15 + *15/*37 + *14/*37 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased concentrations of atrasentan as compared to SLCO1B1 *1/*1 + *37/*37 + *1/*37 (assigned as normal metabolizer phenotype) .			= 0.0244				
1451535480	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased steady-state concentration of tacrolimus in people with Transplantation as compared to CYP3A5 *3/*3.			= 0.017				
1451535660	CYP3A5*1, CYP3A5*3	bisoprolol	Efficacy	no	CYP3A5 *3 is not associated with response to bisoprolol in people with Hypertension as compared to CYP3A5 *1.							
1451581400	CYP3A5*1, CYP3A5*3	3,4-dehydrocilostazol	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of 3,4-dehydrocilostazol in people with Cerebral Infarction as compared to CYP3A5 *3/*3.			= 0.00157				
1451548621	CYP3A5*1, CYP3A5*3	aripiprazole	Metabolism/PK	no	CYP3A5 *1 is not associated with concentrations of aripiprazole as compared to CYP3A5 *3.							
1451548640	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41	aripiprazole	Metabolism/PK	yes	CYP2D6 *3 + *4 + *4xN + *5 + *6 + *10 + *41 are associated with increased concentrations of aripiprazole as compared to CYP2D6 *1 + *1xN.			< 0.0001				
1451552540	CYP2D6*1, CYP2D6*4, CYP2D6*9	tramadol	Metabolism/PK	yes	CYP2D6 *1/*4 + *1/*9 (assigned as intermediate metabolizer genotype phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.005				
1451554440	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.0001				
1451554440	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.0001				
1451565700	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10	n-desmethyltramadol	Metabolism/PK	yes	CYP2D6 *1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.			= 0.003				
1451638720	CYP2D6*1, CYP2D6*4	tramadol	Efficacy	yes	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.			= 0.035				
1451638720	CYP2D6*1, CYP2D6*4	tramadol	Efficacy	yes	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.			= 0.054				
1451638720	CYP2D6*1, CYP2D6*4	tramadol	Efficacy	yes	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.			= 0.125				
1451638720	CYP2D6*1, CYP2D6*4	tramadol	Efficacy	yes	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.			= 0.273				
1451638720	CYP2D6*1, CYP2D6*4	tramadol	Efficacy	yes	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.			= 0.278				
1451638720	CYP2D6*1, CYP2D6*4	tramadol	Efficacy	yes	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.			= 0.994				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.002				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.004				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.012				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.026				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.108				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.146				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.337				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.411				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.708				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.755				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.882				
1451638800	CYP2C9*1, CYP2C9*2, CYP2C9*3	ketorolac	Efficacy	yes	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.			= 0.887				
1451648260	CYP3A4*1, CYP3A4*22	endoxifen	Metabolism/PK	yes	CYP3A4 *22/*22 is associated with decreased concentrations of endoxifen in people with Breast Neoplasms as compared to CYP3A4 *1/*1 + *1/*22.			< 0.05				
1451643200	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased clearance of midazolam in people with Neoplasms as compared to CYP3A5 *3/*3.			= 0.03				
1451643241	CYP3A5*1, CYP3A5*3	docetaxel	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with decreased clearance of docetaxel in people with Neoplasms as compared to CYP3A5 *3/*3.			= 0.11				
1451643262	CYP2C19*1, CYP2C19*17	citalopram,escitalopram,sertraline	Toxicity	no	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer genotype phenotype) are not associated with response to citalopram, escitalopram or sertraline in women with Depression and Pregnancy as compared to CYP2C19 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.87				
1451643250	CYP2C19*1, CYP2C19*2, CYP2C19*17	citalopram,escitalopram,sertraline	Toxicity	no	CYP2C19 *1/*2 + *2/*17 + *2/*2 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are not associated with response to citalopram, escitalopram or sertraline in women with Depression and Pregnancy as compared to CYP2C19 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.87				
1451648462	CYP3A4*1, CYP3A4*22	quetiapine	Metabolism/PK	yes	CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of quetiapine in people with Psychotic Disorders as compared to CYP3A4 *1/*1.	*22		= 0.01				
1451643140	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41	paroxetine	Toxicity	no	CYP2D6 *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*9 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are not associated with response to paroxetine in women with Depression and Pregnancy as compared to CYP2D6 *1/*1 + *1/*2 + *1/*4 + *1/*9 + *1/*10 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *2/*41 (assigned as normal metabolizer genotype phenotype) .			= 0.87				
1451646320	CYP2C19*1, CYP2C19*2	tamoxifen	Metabolism/PK	not stated	CYP2C19 *1/*2 + *2/*2 is associated with decreased metabolism of tamoxifen as compared to CYP2C19 *1/*1.							
1451646240	CYP3A4*1, CYP3A4*22	n-desmethyltamoxifen	Metabolism/PK	not stated	CYP3A4 *1/*22 + *22/*22 is associated with decreased metabolism of n-desmethyltamoxifen as compared to CYP3A4 *1/*1.	*22						
1451646392	CYP2B6*1, CYP2B6*6	tamoxifen	Metabolism/PK	not stated	CYP2B6 *6/*6 is associated with decreased metabolism of tamoxifen as compared to CYP2B6 *1/*1 + *1/*6.							
1451652220	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.001				
1451647340	CYP3A4*1, CYP3A4*22	oxycodone	Metabolism/PK	yes	CYP3A4 *22 is associated with decreased metabolism of oxycodone as compared to CYP3A4 *1.			= 6.91E-17				
1451678271	CYP3A4*1, CYP3A4*36	fentanyl	Metabolism/PK	no	CYP3A4 *36 is not associated with clearance of fentanyl in children as compared to CYP3A4 *1 (assigned as normal metabolizer genotype phenotype) .							
1451678262	CYP3A5*1, CYP3A5*3, CYP3A5*6	fentanyl	Metabolism/PK	yes	CYP3A5 *1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are associated with decreased clearance of fentanyl in children as compared to CYP3A5 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.046				
1451660364	CYP3A4*1, CYP3A4*20	midazolam	Metabolism/PK	no	CYP3A4 *1/*20 is associated with decreased clearance of midazolam as compared to CYP3A4 *1/*1.							
1451662800	CYP2A6*1A, CYP2A6*4A	nicotine	Metabolism/PK	yes	CYP2A6 *4A/*4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.			< 0.001				
1451663040	CYP2A6*1A, CYP2A6*1B1, CYP2A6*4A	nicotine	Metabolism/PK	not stated	CYP2A6 *4A/*4A is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A + *1A/*1B1 + *1A/*4A.							
1451664492	CYP2C19*1, CYP2C19*2	desvenlafaxine	Metabolism/PK	not stated	CYP2C19 *1/*2 is associated with decreased concentrations of desvenlafaxine in women with Depressive Disorder.							
1451664820	CYP2A6*1A, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*12	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*2 + *1A/*4A + *1A/*9 + *1A/*12 + *4A/*9 + *9/*9 + *9/*12 are associated with decreased clearance of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.			< 0.05				
1451664980	CYP2A6*1A, CYP2A6*4A, CYP2A6*7, CYP2A6*9, CYP2A6*10	coumarin,nicotine	Metabolism/PK	yes	CYP2A6 *1A/*4A + *1A/*7 + *1A/*9 + *1A/*10 + *4A/*4A + *7/*7 + *9/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.			< 0.05				
1451665040	CYP2A6*1A, CYP2A6*4A, CYP2A6*7, CYP2A6*9	coumarin,nicotine	Metabolism/PK	not stated	CYP2A6 *4A/*7 + *4A/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.							
1451665280	CYP2A6*1A, CYP2A6*1B1	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*1B1 + *1B1/*1B1 are associated with increased metabolism of nicotine as compared to CYP2A6 *1A/*1A.			< 0.01				
1451665300	CYP2A6*1A, CYP2A6*1B1, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24A, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28A, CYP2A6*35	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*2 + *1A/*4A + *1A/*9 + *1A/*12 + *1A/*17 + *1A/*20 + *1A/*23 + *1A/*24A + *1A/*25 + *1A/*26 + *1A/*27 + *1A/*28A + *1A/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 (assigned as intermediate and low activity phenotype) are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A +*1A/*1B1 + *1B1/*1B1 (assigned as normal metabolizer phenotype) .			< 0.001				
1451665780	CYP2A6*1A, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*12A, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24A, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28A, CYP2A6*35	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*2 + *1A/*4A + *1A/*17 + *1A/*20 + *1A/*23 + *1A/*24A + *1A/*25 + *1A/*26 + *1A/*27 + *1A/*28A + *1A/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*9 + *1A/*12A.			< 0.01				
1451666225	CYP2A6*1A, CYP2A6*35	nicotine	Metabolism/PK	not stated	CYP2A6 *35/*35 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.							
1451666180	CYP2A6*1A, CYP2A6*9A, CYP2A6*17, CYP2A6*35	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*35 + *9A/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.			= 0.003				
1451666180	CYP2A6*1A, CYP2A6*9A, CYP2A6*17, CYP2A6*35	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*35 + *9A/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.			= 0.02				
982043792	SLCO1B1*1, SLCO1B1*15	rosuvastatin	Metabolism/PK	yes	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.			= 0.0253	Unknown			
1451666680	CYP2C9*1, CYP2C9*3	fluvastatin	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.			= 0.003092				
1451666721	CYP2C9*1, CYP2C9*3	fluvastatin	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.			= 0.043				
1451674400	SLCO1B1*15, SLCO1B1*37	pitavastatin	Metabolism/PK	yes	SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.			< 0.01				
1451674540	CYP2C9*1, CYP2C9*3	pitavastatin	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with increased concentrations of pitavastatin in healthy individuals as compared to CYP2C9 *1/*1.			< 0.05				
1451675720	CYP2A6*1A, CYP2A6*1B1, CYP2A6*1D, CYP2A6*1H, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*14, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *1B1 + *1D + *1H + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.			< 2.00E-16				
1451675720	CYP2A6*1A, CYP2A6*1B1, CYP2A6*1D, CYP2A6*1H, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*14, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *1B1 + *1D + *1H + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.			< 2.00E-16				
1451675720	CYP2A6*1A, CYP2A6*1B1, CYP2A6*1D, CYP2A6*1H, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*14, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *1B1 + *1D + *1H + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.			= 3.2E-12				
1451675720	CYP2A6*1A, CYP2A6*1B1, CYP2A6*1D, CYP2A6*1H, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*14, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *1B1 + *1D + *1H + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.			= 4.2E-11				
1451675720	CYP2A6*1A, CYP2A6*1B1, CYP2A6*1D, CYP2A6*1H, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*14, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *1B1 + *1D + *1H + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.			= 1.8E-5				
1451675720	CYP2A6*1A, CYP2A6*1B1, CYP2A6*1D, CYP2A6*1H, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*14, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *1B1 + *1D + *1H + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.			< 3.2E-4				
1451675840	CYP2A6*1A, CYP2A6*1B1, CYP2A6*9, CYP2A6*12, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1B1.			< 4.4E-9				
1451675840	CYP2A6*1A, CYP2A6*1B1, CYP2A6*9, CYP2A6*12, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1B1.			= 1.0E-7				
1451675840	CYP2A6*1A, CYP2A6*1B1, CYP2A6*9, CYP2A6*12, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1B1.			= 9.2E-7				
1451675840	CYP2A6*1A, CYP2A6*1B1, CYP2A6*9, CYP2A6*12, CYP2A6*38	nicotine	Metabolism/PK	yes	CYP2A6 *1A + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1B1.			= 6.2E-4				
1451726202	CYP3A4*1, CYP3A4*22	paclitaxel	Efficacy	no	CYP3A4 *1/*22 is not associated with response to paclitaxel in people with Neoplasms as compared to CYP3A4 *1/*1.	*22						
1451726260	CYP3A4*1, CYP3A4*22	docetaxel	Efficacy	no	CYP3A4 *1/*22 is not associated with response to docetaxel in people with Neoplasms as compared to CYP3A4 *1/*1.	*22						
1451726280	CYP3A5*1, CYP3A5*3	docetaxel	Efficacy	no	CYP3A5 *1/*3 is not associated with response to docetaxel in people with Neoplasms as compared to CYP3A5 *1/*1.	*3						
1451726420	CYP2C8*1, CYP2C8*3, CYP2C8*4	paclitaxel	Efficacy	no	CYP2C8 *3 + *4 are not associated with response to paclitaxel in people with Neoplasms as compared to CYP2C8 *1.							
1449748460	CYP3A4*1, CYP3A4*36	tacrolimus	Efficacy	no	CYP3A4 *36 is not associated with response to tacrolimus in people with Nephrotic Syndrome as compared to CYP3A4 *1.	*36		= 0.125	OR	3.347	0.819	13.67
1447948367	CYP3A4*1, CYP3A4*36	gefitinib	Metabolism/PK	no	CYP3A4 *1/*36 + *36/*36 are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP3A4 *1/*1.			> 0.05	OR			
1451134880	CYP3A4*1, CYP3A4*36	sufentanil	Dosage	yes	CYP3A4 *36/*36 is associated with decreased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.05				
1450824004	CYP3A4*1, CYP3A4*36	clopidogrel	Efficacy	no	CYP3A4 *1/*36 is not associated with metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP3A4 *1/*1.	*36		> 0.293				
1450823962	CYP3A4*1, CYP3A4*36	fentanyl	Dosage	yes	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.05				
1447520683	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *36 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*36		< 0.02	OR			
1447948541	CYP3A4*1, CYP3A4*36	gefitinib	Metabolism/PK	no	CYP3A4 *1/*36 + *36/*36 is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP3A4 *1/*1.				OR			
1449715407	CYP3A4*1, CYP3A4*36	sufentanil	Dosage	yes	CYP3A4 *36/*36 is associated with decreased dose of sufentanil in women with Pain as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.05	OR			
1448633769	CYP3A4*1, CYP3A4*36	clopidogrel	Efficacy	no	CYP3A4 *36 is not associated with response to clopidogrel as compared to CYP3A4 *1/*1.			= 0.324	OR			
1183689729	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36.	*36		< 0.01	OR			
1451134740	CYP3A4*1, CYP3A4*36	sufentanil	Efficacy	yes	CYP3A4 *36/*36 is associated with increased response to sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.05				
827812461	CYP3A4*1, CYP3A4*36	tacrolimus	Other,Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*36 + *36/*36.	*1		= 0.009	Unknown			
1450928466	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	no	CYP3A4 *36 is not associated with concentrations of tacrolimus in children with proteinuria as compared to CYP3A4 *1/*1.			= 0.011				
1450823997	CYP3A4*1, CYP3A4*36	clopidogrel	Efficacy	no	CYP3A4 *1/*36 is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to CYP3A4 *1/*1.	*36		= 0.484				
1183689778	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.	*36		< 0.001	OR			
1183689778	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.			< 0.001				
1183689778	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.	*36		< 0.01	OR			
1183689778	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.			< 0.01				
1183689778	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.	*36		< 0.05	OR			
981843814	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*36 + *36/*36 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.			< 0.001	Unknown			
981843814	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*36 + *36/*36 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.			< 0.001				
1445584912	CYP3A4*1, CYP3A4*36	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*36 + *36/*36.			< 0.0001	OR			
1449715394	CYP3A4*1, CYP3A4*36	sufentanil	Metabolism/PK	yes	CYP3A4 *36/*36 is associated with decreased concentrations of sufentanil in women with Pain as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.01	OR			
1449716632	CYP3A4*1, CYP3A4*36	fentanyl	Dosage	yes	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.			< 0.05	OR			
1184510805	CYP2C9*1, CYP2C9*3, CYP2C9*8	diclofenac	Metabolism/PK	yes	CYP2C9 *1/*3 + *1/*8 are associated with decreased metabolism of diclofenac in healthy individuals as compared to CYP2C9 *1/*1.	*8		= 0.033	OR			
1184510805	CYP2C9*1, CYP2C9*3, CYP2C9*8	diclofenac	Metabolism/PK	yes	CYP2C9 *1/*3 + *1/*8 are associated with decreased metabolism of diclofenac in healthy individuals as compared to CYP2C9 *1/*1.	*3		= 0.048	OR			
1451774741	UGT1A1*1, UGT1A1*6, UGT1A1*28	dolutegravir	Metabolism/PK	yes	UGT1A1 *28/*28 + *6/*6 is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to UGT1A1 *1/*1.			= 0.009				
1451775982	CYP2C19*1, CYP2C19*2, CYP2C19*3	tacrolimus	Dosage,Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 + *2/*2 +*2/*3 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP2C19 *1/*1 (assigned as normal metabolizer genotype phenotype) .			= 0.0395				
1451781260	CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18	(S)-methadone	Metabolism/PK	yes	CYP2B6 *6 + *7 + *9 + *18 is associated with decreased clearance of (S)-methadone in children with Scoliosis as compared to CYP2B6 *1/*1.			= 0.02				
1356539101	TPMT*1, TPMT*3C	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*3C is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.04	OR			
1353450854	TPMT*1, TPMT*3A	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*3A is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		< 0.0001	OR			
1353450854	TPMT*1, TPMT*3A	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*3A is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.0009	OR			
1353450854	TPMT*1, TPMT*3A	mercaptopurine,thioguanine	Dosage	yes	TPMT *1/*3A is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.01	OR			
981501641	NAT2*4, NAT2*5A, NAT2*5B, NAT2*6B, NAT2*7A	sulfapyridine	Metabolism/PK	yes	NAT2 *5A/*5A +*5A/*5B + *5A/*6B + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with increased concentrations of sulfapyridine in healthy individuals as compared to NAT2 *4/*4.	*5		< 0.05	Unknown			
1451793682	NAT2*4, NAT2*5A, NAT2*5B, NAT2*5C, NAT2*5D, NAT2*6A, NAT2*6B, NAT2*7A, NAT2*7B, NAT2*11A, NAT2*12A, NAT2*12C, NAT2*13, NAT2*13A	caffeine	Metabolism/PK	not stated	NAT2 *4/*5B + *11A/*5C + *12A/*5A + *12C/*5D + *4/*6A + *13/*6B + *4/*7B + *13A/*7A + *13A/*6A (assigned as rapid acetylator phenotype) is associated with increased metabolism of caffeine in men.				Unknown			
1451139042	NAT2*5D, NAT2*6B, NAT2*7A, NAT2*14A	dipyrone	Metabolism/PK	yes	NAT2 *5D + *6B + *7A + *14A (assigned as slow acetylator phenotype) are associated with decreased metabolism of dipyrone in healthy individuals.			= 0.001				
1451136500	NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A	hydralazine	Metabolism/PK	not stated	NAT2 *5D/*5D + *5D/*6B + *5D/*7A (assigned as slow acetylator phenotype) are associated with decreased metabolism of hydralazine in healthy individuals as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .							
1184174568	NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A, NAT2*12A, NAT2*13A, NAT2*14A	hydralazine	Efficacy	no	NAT2 *4/*14A + *4/*5D + *4/*6B + *4/*7A + *5D/*12A + *5D/*13A + *6B/*12A + *6B/*13A (assigned as intermediate acetylator phenotype) is not associated with response to hydralazine in people with resistant hypertension.			> 0.05	OR			
1184174554	NAT2*4, NAT2*12A, NAT2*13A	hydralazine	Efficacy	no	NAT2 *12A/*12A + *13A/*13A + *4/*12A + *4/*13A + *4/*4 (assigned as rapid acetylator phenotype) is not associated with response to hydralazine in people with resistant hypertension.			> 0.05	OR			
981851641	NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A, NAT2*14A, NAT2*19	isoniazid	Dosage,Metabolism/PK	yes	NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased dose of isoniazid in people with Tuberculosis as compared to NAT2 *19 + *14A + *5D + *6B + *7A (assigned as slow acetylator phenotype) .			= 0.003	OR			
981851641	NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A, NAT2*14A, NAT2*19	isoniazid	Dosage,Metabolism/PK	yes	NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased dose of isoniazid in people with Tuberculosis as compared to NAT2 *19 + *14A + *5D + *6B + *7A (assigned as slow acetylator phenotype) .			= 0.015	RR	0.274	0.097	0.776
1183702439	NAT2*4, NAT2*5A, NAT2*6B, NAT2*7A	isoniazid	Metabolism/PK	yes	NAT2 *5A/*5A + *5A/*6B + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .			< 0.01	OR			
981476160	NAT2*4, NAT2*5A, NAT2*6B, NAT2*7A, NAT2*12A, NAT2*13A, NAT2*14A	isoniazid	Metabolism/PK	not stated	NAT2 *5A + *6B + *7A + *14A is associated with decreased clearance of isoniazid in children with HIV Infections as compared to NAT2 *4 + *12A + *13A.				Unknown			
827704864	CYP2A6*1A, CYP2A6*1B1, CYP2A6*4A, CYP2A6*7, CYP2A6*9	letrozole	Metabolism/PK	not stated	CYP2A6 *1A/*1B1 + *1A/*1B1 + *1B1/*1B1 are associated with increased clearance of letrozole in women as compared to CYP2A6 *1A/*4A + *1A/*9 + *1B1/*4A + *1B1/*7 + *1B1/*9 + *4A/*7 + *4A/*9 + *7/*9 + *9/*9.				Unknown			
1449713987	CYP3A4*1, CYP3A4*18	fentanyl	Dosage	no	CYP3A4 *18 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1.	*18			OR			
1449716539	CYP3A4*1, CYP3A4*36	fentanyl	Dosage	yes	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	*36		< 0.05	OR			
1451125720	CYP1A2*1A, CYP1A2*1F	clozapine	Metabolism/PK	no	CYP1A2 *1F is not associated with concentrations of clozapine in people with Schizophrenia as compared to CYP1A2 *1A.			= 0.317				
1448422916	UGT1A1*1, UGT1A1*6, UGT1A1*28	irinotecan	Efficacy	no	UGT1A1 *6 + *28 are not associated with response to irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	*28	*6		OR			
1451156540	CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7	(R)-methadone	Metabolism/PK	no	CYP2B6 *6/*6 is not associated with concentrations of (R)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.			= 0.10				
1450812567	CYP2D6*1, CYP2D6*2, CYP2D6*10	dextropropoxyphene,nordextropropoxyphene	Metabolism/PK	no	CYP2D6 *2/*2 + *1/*10 + *2/*10 + *10/*10 are not associated with exposure to dextropropoxyphene or nordextropropoxyphene in healthy individuals as compared to CYP2D6 *1/*1.			> 0.05				
1449747593	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in children with henoch-schonlein purpura nephritis as compared to CYP3A5 *3/*3.	*1		= 0.048	OR			
1183700115	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.000000000000010	OR			
1448635857	CYP2C19*1, CYP2C19*2, CYP2C19*3	escitalopram	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 are associated with increased response to escitalopram in people with Panic Disorder as compared to CYP2C19 *1/*1.			< 0.05	OR			
1450812582	CYP3A5*1, CYP3A5*3	dextropropoxyphene	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased exposure to dextropropoxyphene in healthy individuals as compared to CYP3A5 *1/*3.			< 0.05				
1183700123	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.000000000000010	OR			
1183700096	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.000000000000010	OR			
1448603080	CYP3A5*1, CYP3A5*3	felodipine	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased exposure to felodipine in healthy individuals as compared to CYP3A5 *1/*3.			= 0.035	OR			
1183700106	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.000000000000010	OR			
1449747623	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with trough concentration of tacrolimus in children with henoch-schonlein purpura nephritis as compared to CYP3A5 *3/*3.	*1		= 0.11	OR			
1448603056	CYP3A5*1, CYP3A5*3	sirolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with decreased concentrations of sirolimus as compared to CYP3A5 *3/*3.			= 0.003	OR			
1184175334	TPMT*1, TPMT*3A, TPMT*3C	azathioprine	Dosage	yes	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine in people with Transplantation as compared to TPMT *1/*1.			= 0.04	OR			
982010090	CYP2C9*1, CYP2C9*2	acenocoumarol	Dosage	no	CYP2C9 *1/*2 is not associated with dose of acenocoumarol.	*1		= 0.904	Unknown			
1448993987	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.0331	OR			
1450812588	CYP3A5*1, CYP3A5*3	nordextropropoxyphene	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with exposure to nordextropropoxyphene in healthy individuals as compared to CYP3A5 *1/*3.			> 0.05				
1184470291	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.			= 0.016	OR	2.8	1.2	6.5
1446899066	CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17	clopidogrel	Efficacy	yes	CYP2C19 *2 + *4 are associated with decreased response to clopidogrel as compared to CYP2C19 *1 + *17.			< 0.0001	OR			
1451112060	CYP4F2*1, CYP4F2*3	Vitamin K1	Metabolism/PK	yes	CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1.			= 0.007				
1451112060	CYP4F2*1, CYP4F2*3	Vitamin K1	Metabolism/PK	yes	CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1.			= 0.010				
1451112060	CYP4F2*1, CYP4F2*3	Vitamin K1	Metabolism/PK	yes	CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1.			= 0.016				
1451112060	CYP4F2*1, CYP4F2*3	Vitamin K1	Metabolism/PK	yes	CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1.			= 0.029				
1446902725	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41	nortriptyline	Metabolism/PK	yes	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.			< 0.05	OR			
1447148428	CYP2D6*1, CYP2D6*5, CYP2D6*10	tropisetron	Metabolism/PK	yes	CYP2D6 *10/*10 + *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05	OR			
1183680197	CYP2C9*1, CYP2C9*3	benzbromarone	Metabolism/PK	not stated	CYP2C9 *3/*3 is associated with decreased metabolism of benzbromarone in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3.	*3			OR			
1447984004	CYP2C19*1, CYP2C19*17	voriconazole	Dosage	not stated	CYP2C19 *1/*17 is associated with increased dose of voriconazole in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.				OR			
1184515869	CYP3A5*1, CYP3A5*3	tacrolimus	Efficacy	yes	CYP3A5 *3/*3 is associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.	*1		= 0.045	OR			
1184515869	CYP3A5*1, CYP3A5*3	tacrolimus	Efficacy	yes	CYP3A5 *3/*3 is associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.	*1		= 0.046	OR			
1447672688	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	< 0.05	OR			
1447148415	CYP2D6*1, CYP2D6*10	tropisetron	Metabolism/PK	yes	CYP2D6 *1/*10 is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05	OR			
1447672698	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	< 0.01	OR			
1446902626	CYP2C19*1, CYP2C19*2	amitriptyline	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.			= 0.001	OR			
1446902626	CYP2C19*1, CYP2C19*2	amitriptyline	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.			= 0.004	OR			
1446902626	CYP2C19*1, CYP2C19*2	amitriptyline	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.			= 0.019	OR			
1446902544	CYP2C19*1, CYP2C19*2, CYP2C19*3	imipramine	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			< 0.01	OR			
1447148309	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.001	OR			
1447148324	CYP2C9*1, CYP2C9*2	warfarin	Dosage	no	CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.001	OR			
1446902570	CYP2C19*1, CYP2C19*2, CYP2C19*3	imipramine	Efficacy	no	CYP2C19 *2/*2 + *2/*3 are not associated with response to imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.				OR			
1451161400	CYP2B6*1, CYP2B6*4, CYP2B6*6	methadone	Efficacy	no	CYP2B6 *1/*4 + *1/*6 + *4/*6 + *6/*6 are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1.			= 0.751				
1444707113	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *1/*3 + *2/*3 + *2/*2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.			= 0.003	OR			
1451161493	CYP2B6*1, CYP2B6*6	methadone	Dosage	no	CYP2B6 *6/*6 is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1.			= 0.372				
1451161460	CYP2C9*1, CYP2C9*2, CYP2C9*3	methadone	Efficacy	no	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2.			= 0.779				
1451161481	CYP2C19*1, CYP2C19*2	methadone	Efficacy	no	CYP2C19 *1/*2 + *2/*2 are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2C19 *1/*1.			= 0.260				
1444706957	CYP2C9*1, CYP2C9*2	acenocoumarol	Dosage	no	CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol.			= 0.731	OR			
1444936352	CYP2C19*1, CYP2C19*17	aspirin,clopidogrel	Efficacy	no	CYP2C19 *17 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	*17	*17	= 0.2	OR			
1444706981	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.			< 0.0001	OR			
1184483370	UGT1A8*1a, UGT1A8*2, UGT1A8*3	raloxifene	Metabolism/PK	yes	UGT1A8 *1a/*3 (assigned as poor metabolizer phenotype) is associated with increased metabolism of raloxifene in women as compared to UGT1A8 *1a/*1a + *1a/*2 + *2/*2 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	*3		= 0.001	OR			
1184483370	UGT1A8*1a, UGT1A8*2, UGT1A8*3	raloxifene	Metabolism/PK	yes	UGT1A8 *1a/*3 (assigned as poor metabolizer phenotype) is associated with increased metabolism of raloxifene in women as compared to UGT1A8 *1a/*1a + *1a/*2 + *2/*2 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	*3		= 0.001	OR			
1184483370	UGT1A8*1a, UGT1A8*2, UGT1A8*3	raloxifene	Metabolism/PK	yes	UGT1A8 *1a/*3 (assigned as poor metabolizer phenotype) is associated with increased metabolism of raloxifene in women as compared to UGT1A8 *1a/*1a + *1a/*2 + *2/*2 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	*3		= 0.0025	OR			
1444936241	CYP2D6*1, CYP2D6*5, CYP2D6*10	n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10/*10 + *5/*5 are not associated with decreased concentrations of n-desmethyltamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.			> 0.05	OR			
1450948626	CYP2C19*1, CYP2C19*17	phenazepam	Efficacy	yes	CYP2C19 *17 is associated with decreased clinical benefit to phenazepam in men with Alcoholism and Anxiety Disorders as compared to CYP2C19 *1.			< 0.05				
1450948626	CYP2C19*1, CYP2C19*17	phenazepam	Efficacy	yes	CYP2C19 *17 is associated with decreased clinical benefit to phenazepam in men with Alcoholism and Anxiety Disorders as compared to CYP2C19 *1.			< 0.05				
1451161642	CYP2C9*1, CYP2C9*2, CYP2C9*3	methadone	Dosage	no	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2.			= 0.483				
1184516039	G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham	daunorubicin	Metabolism/PK	not stated	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham is associated with decreased metabolism of daunorubicin.			= 0.001	OR			
1451161580	CYP2B6*1, CYP2B6*6	(S)-methadone	Metabolism/PK	no	CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1.			= 0.608				
1184483284	CYP2C9*1, CYP2C9*12	warfarin	Dosage	not stated	CYP2C9 *1/*12 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	*12			OR			
1445296737	CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.02	OR			
1445296737	CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.11	OR			
1444608497	CYP2C19*1, CYP2C19*2, CYP2C19*3	valproic acid	Metabolism/PK	no	CYP2C19 *2 + *3 are not associated with clearance of valproic acid in people with Epilepsy as compared to CYP2C19 *1.	*2	*3		OR			
1183680618	CYP2D6*4, CYP2D6*41	codeine	Metabolism/PK	not stated	CYP2D6 *4/*41 is associated with decreased metabolism of codeine in healthy individuals.				OR			
1184483446	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	sertraline	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	HTTLPR long form (L allele)		= 0.01	OR			
1183680612	CYP2D6*4, CYP2D6*6	codeine	Metabolism/PK	not stated	CYP2D6 *4/*6 is associated with decreased metabolism of codeine in healthy individuals.				OR			
1451161687	CYP2C19*1, CYP2C19*2	methadone	Dosage	no	CYP2C19 *1/*2 + *2/*2 are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2C19 *1/*1.			= 0.420				
1184483457	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.			< 0.001	OR			
1451161695	CYP2C19*1, CYP2C19*2	methadone	Metabolism/PK	no	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2C19 *1/*1.			= 0.578				
1184483473	UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37	dolutegravir	Metabolism/PK	not stated	UGT1A1 *28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37 is associated with decreased clearance of dolutegravir as compared to UGT1A1 *1/*1 + *1/*36.	*1			OR			
1451161652	CYP2C9*1, CYP2C9*2, CYP2C9*3	methadone	Metabolism/PK	no	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2.			= 0.158				
1451161660	CYP3A5*1, CYP3A5*3	methadone	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP3A5 *1/*1 + *1/*3.			= 0.540				
1446902225	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5	imipramine	Dosage	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.			< 0.0001	OR			
1446902225	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5	imipramine	Dosage	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.			< 0.0017	OR			
1446902225	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5	imipramine	Dosage	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.			< 0.0029	OR			
1446902201	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN	imipramine	Dosage	yes	CYP2D6 *1/*1xN + *1/*2xN (assigned as ultra-metabolizer phenotype phenotype) are associated with increased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.			< 0.0001	OR			
1450375324	CYP2B6*1, CYP2B6*6	nicotine	Metabolism/PK	not stated	CYP2B6 *6 is associated with decreased metabolism of nicotine as compared to CYP2B6 *1.				OR			
1184467037	TPMT*3A, TPMT*3C	mercaptopurine	Dosage,Efficacy,Toxicity	not stated	TPMT *3A/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.				OR			
1183680733	CYP2C9*1, CYP2C9*3	celecoxib	Metabolism/PK	yes	CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*3.	*3		< 0.05	OR			
982029525	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	venlafaxine	Metabolism/PK	yes	CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.			< 0.05	Unknown			
1448262059	GSTM1 non-null, GSTM1 null	azathioprine	Metabolism/PK	yes	GSTM1 null is associated with increased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to GSTM1 non-null.			= 0.012	OR			
1448262059	GSTM1 non-null, GSTM1 null	azathioprine	Metabolism/PK	yes	GSTM1 null is associated with increased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to GSTM1 non-null.			= 0.022	OR			
1184483570	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	sertraline	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			> 0.05	OR			
1449310381	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14	paroxetine	Metabolism/PK	not stated	CYP2D6 *5/*10 + *10/*10 + *10/*14 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.				OR			
1446902165	CYP2D6*4, CYP2D6*5	desipramine,imipramine	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1446902165	CYP2D6*4, CYP2D6*5	desipramine,imipramine	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.			< 0.0017	OR			
1446902165	CYP2D6*4, CYP2D6*5	desipramine,imipramine	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.			< 0.0026	OR			
1448573342	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.0001	OR			
1183697100	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*3	< 0.01	OR			
1183697100	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*3	= 0.57	OR			
1183680725	CYP2C9*1, CYP2C9*3	celecoxib	Metabolism/PK	yes	CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	*3		< 0.05	OR			
1183680709	CYP2C9*1, CYP2C9*3	celecoxib	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	*3		< 0.05	OR			
1184483616	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	escitalopram	Efficacy	yes	SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			= 0.045	OR			
1446902114	TPMT*1, TPMT*3A, TPMT*3C	mercaptopurine	Other	yes	TPMT *1/*3A + *1/*3C + *3A/*3A is associated with increased discontinuation of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.028	OR	3.18	1.39	7.44
1448573256	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.003	OR			
1448573256	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.1	OR			
1446902063	CYP2C19*1, CYP2C19*2	desipramine	Metabolism/PK	no	CYP2C19 *2 is not associated with concentrations of desipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			= 0.18	OR			
1446902063	CYP2C19*1, CYP2C19*2	desipramine	Metabolism/PK	no	CYP2C19 *2 is not associated with concentrations of desipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			= 0.94	OR			
1446902080	CYP2C19*1, CYP2C19*2	imipramine	Metabolism/PK	no	CYP2C19 *2 is not associated with dose of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			= 0.081	OR			
1446902080	CYP2C19*1, CYP2C19*2	imipramine	Metabolism/PK	no	CYP2C19 *2 is not associated with dose of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			= 0.15	OR			
1447954729	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41	primaquine	Efficacy	yes	CYP2D6 *4/*41 + *5/*6 are associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.			= 0.002	OR			
1447954729	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41	primaquine	Efficacy	yes	CYP2D6 *4/*41 + *5/*6 are associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.			= 0.008	OR			
1446906094	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	no	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is not associated with metabolism of clopidogrel in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			= 0.328	OR			
1446906094	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	no	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is not associated with metabolism of clopidogrel in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			= 0.407	OR			
1446906094	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	no	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is not associated with metabolism of clopidogrel in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			= 0.633	OR			
1446906094	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	no	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is not associated with metabolism of clopidogrel in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			= 0.707	OR			
1444710685	CYP2D6*1, CYP2D6*5, CYP2D6*10	4-hydroxytamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10 + *5 is not associated with concentrations of 4-hydroxytamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			= 0.001	OR			
1444710685	CYP2D6*1, CYP2D6*5, CYP2D6*10	4-hydroxytamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10 + *5 is not associated with concentrations of 4-hydroxytamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			= 0.022	OR			
1444710685	CYP2D6*1, CYP2D6*5, CYP2D6*10	4-hydroxytamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *10 + *5 is not associated with concentrations of 4-hydroxytamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			> 0.05	OR			
1446906082	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	yes	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with metabolism of clopidogrel in healthy individuals.			= 0.020	OR			
1446906082	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	yes	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with metabolism of clopidogrel in healthy individuals.			= 0.029	OR			
1184987641	CYP2C19*1, CYP2C19*2	clopidogrel	Efficacy	yes	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.			= 0.001	OR			
1184987661	CYP2C19*1, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *3 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.			= 0.001	OR			
1447741578	CYP2C19*1, CYP2C19*2	tamoxifen	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.			< 0.001	OR			
1183693321	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*3		< 0.001	OR			
1446905879	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	doxepin	Metabolism/PK	yes	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1446905879	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	doxepin	Metabolism/PK	yes	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1446905879	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	doxepin	Metabolism/PK	yes	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1446905879	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	doxepin	Metabolism/PK	yes	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.			= 0.002	OR			
1446905879	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5	doxepin	Metabolism/PK	yes	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.			= 0.012	OR			
1444710414	HLA-DRB1*04:01:01, HLA-DRB1*04:01:02, HLA-DRB1*04:01:03, HLA-DRB1*04:01:04, HLA-DRB1*04:01:05, HLA-DRB1*04:01:06, HLA-DRB1*04:01:07, HLA-DRB1*04:01:08, HLA-DRB1*15:01:01:01, HLA-DRB1*15:02:01	adalimumab,etanercept,infliximab,Tumor necrosis factor alpha (TNF-alpha) inhibitors	Efficacy	yes	HLA-DRB1 *04:01:01 + *04:01:02 + *04:01:03 + *04:01:04 + *04:01:05 + *04:01:06 + *04:01:07 + *04:01:08 are associated with increased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to HLA-DRB1 *15:01:01:01 + *15:02:01.			= 0.04	OR	1.14	1.01	1.3
1450822217	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41	mephedrone	Metabolism/PK	yes	CYP2D6 *1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.			= 0.001				
1448265676	CYP2C19*2, CYP2C19*17	voriconazole	Dosage	yes	CYP2C19 *2 + *17 are associated with dose of voriconazole in children with hemopoietic stem cell transplant.			= 0.0001	OR			
1446905772	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41	doxepin	Metabolism/PK	yes	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.			< 0.001	OR			
1446905772	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41	doxepin	Metabolism/PK	yes	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.			= 0.002	OR			
1446905772	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41	doxepin	Metabolism/PK	yes	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.			= 0.003	OR			
1446905772	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41	doxepin	Metabolism/PK	yes	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.			= 0.07	OR			
1446905772	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41	doxepin	Metabolism/PK	yes	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.				OR			
1446905772	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41	doxepin	Metabolism/PK	yes	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.				OR			
1184987748	CYP2C19*1, CYP2C19*2	clopidogrel	Other	yes	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.				OR	2.1	1.74	2.53
1184987748	CYP2C19*1, CYP2C19*2	clopidogrel	Other	yes	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.				OR	2.22	1.85	2.65
1184987748	CYP2C19*1, CYP2C19*2	clopidogrel	Other	yes	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.				OR	2.33	1.62	3.36
1451346620	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole	Efficacy	no	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.			= 0.76				
1446905682	CYP2D6*3, CYP2D6*4	doxepin	Metabolism/PK	not stated	CYP2D6 *3/*4 is associated with decreased metabolism of doxepin.				OR			
1184512708	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	venlafaxine	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).				OR			
1448265505	CYP2C19*2, CYP2C19*3	phenytoin	Dosage	yes	CYP2C19 *2 + *3 is associated with dose of phenytoin in children with Epilepsy.			< 0.001	OR			
1184168799	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	methylphenidate	Efficacy	no	SLC6A4 HTTLPR short form (S allele) is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to SLC6A4 HTTLPR long form (L allele).				Unknown			
1184168791	SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T	clozapine	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C is associated with decreased response to clozapine in people with Schizophrenia as compared to SLC6A4 L allele-rs25531T.				Unknown			
1184168783	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluoxetine	Dosage,Efficacy	no	SLC6A4 HTTLPR short form (S allele) is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).				Unknown			
1184168762	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	antipsychotics,haloperidol,olanzapine,risperidone	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	HTTLPR short form (S allele)	HTTLPR long form (L allele)	= 0.05	Unknown			
1184168856	CYP2C19*1, CYP2C19*3	clopidogrel	Efficacy	no	CYP2C19 *1/*3 + *3/*3 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	*2		= 0.004	HR	1.74	1.25	2.42
1184168844	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	*3		= 0.14	HR	1.48	0.83	2.92
1184168830	CYP2C19*1, CYP2C19*2	clopidogrel	Efficacy	yes	CYP2C19 *1/*2 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	*2		= 0.004	HR	1.74	1.25	2.42
1446905463	CYP2C19*1, CYP2C19*2, CYP2C19*3	imipramine	Dosage	no	CYP2C19 *2/*2 + *2/*3 are not associated with dose of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.				OR			
1448101486	CYP2C19*1, CYP2C19*2	clopidogrel	Metabolism/PK	not stated	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.			< 0.008	OR			
1448101486	CYP2C19*1, CYP2C19*2	clopidogrel	Metabolism/PK	not stated	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.			< 0.01	OR			
1450806291	CYP3A4*1, CYP3A4*22	ticagrelor	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with increased concentrations of ticagrelor in healthy individuals as compared to CYP3A4 *1/*1.			= 0.004	OR			
1450806301	CYP3A5*1, CYP3A5*3	ticagrelor	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with concentrations of ticagrelor in healthy individuals as compared to CYP3A5 *1/*1.			= 0.377	OR			
1450806311	CYP3A4*1, CYP3A4*22	clopidogrel	Metabolism/PK	no	CYP3A4 *1/*22 is not associated with exposure to clopidogrel in healthy individuals as compared to CYP3A4 *1/*1.			= 0.426	OR			
981954547	CYP2D6*1, CYP2D6*1xN	ondansetron	Metabolism/PK	yes	CYP2D6 *1/*1xN is associated with increased metabolism of ondansetron.			= 0.003	Unknown			
981954547	CYP2D6*1, CYP2D6*1xN	ondansetron	Metabolism/PK	yes	CYP2D6 *1/*1xN is associated with increased metabolism of ondansetron.			= 0.03	Unknown			
1450806336	CYP3A4*1, CYP3A4*22	prasugrel	Metabolism/PK	no	CYP3A4 *1/*22 is not associated with exposure to prasugrel in healthy individuals as compared to CYP3A4 *1/*1.			= 0.092	OR			
1450806345	CYP3A5*1, CYP3A5*3	prasugrel	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with exposure to prasugrel in healthy individuals as compared to CYP3A5 *1/*1.			= 0.706	OR			
981954714	CYP2D6*1, CYP2D6*1xN	ondansetron,tropisetron	Efficacy	yes	CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.			< 0.001	Unknown			
981954714	CYP2D6*1, CYP2D6*1xN	ondansetron,tropisetron	Efficacy	yes	CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.			< 0.03	Unknown			
1449004146	CYP3A5*1, CYP3A5*3	cyclosporine,tacrolimus	Metabolism/PK	yes	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.			= 2.7E-7	OR			
1449004146	CYP3A5*1, CYP3A5*3	cyclosporine,tacrolimus	Metabolism/PK	yes	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.			= 6E-4	OR			
1449004146	CYP3A5*1, CYP3A5*3	cyclosporine,tacrolimus	Metabolism/PK	yes	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.			= 0.004	OR			
1449004146	CYP3A5*1, CYP3A5*3	cyclosporine,tacrolimus	Metabolism/PK	yes	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.			= 0.039	OR			
1449577638	CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14	fluvoxamine	Metabolism/PK	no	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *10/*14 + *5/*10 are associated with increased steady-state concentration of fluvoxamine as compared to CYP2D6 *1/*1.				OR			
1448576430	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6	mercaptopurine	Dosage	yes	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	*2		< 0.05	OR			
1449577681	CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14	fluvoxamine	Metabolism/PK	no	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *10/*14 + *5/*10 are not associated with increased concentrations of fluvoxamine as compared to CYP2D6 *1/*1.			= 0.54	OR			
1184988346	CYP2B6*1, CYP2B6*18	efavirenz	Metabolism/PK	yes	CYP2B6 *1/*18 is associated with decreased metabolism of efavirenz in people with HIV.			= 0.016	OR			
1184988354	CYP2B6*1, CYP2B6*9	efavirenz	Metabolism/PK	yes	CYP2B6 *1/*9 is associated with decreased metabolism of efavirenz in people with HIV.			= 0.016	OR			
1184513231	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluoxetine,sertraline	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).			= 0.003	OR			
1450806529	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	clopidogrel	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.			= 0.007	OR			
1449266489	CYP2C19*2, CYP2C19*3	methadone	Metabolism/PK	no	CYP2C19 *2 + *3 are not associated with concentrations of methadone in people with Opioid-Related Disorders.			> 0.1	OR			
1444709550	CYP2D6*1, CYP2D6*10	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			= 0.000039	OR			
1444709550	CYP2D6*1, CYP2D6*10	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			= 0.00021	OR			
1444709550	CYP2D6*1, CYP2D6*10	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			< 0.001	OR			
1444709550	CYP2D6*1, CYP2D6*10	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.			< 0.001	OR			
1449266547	CYP2B6*1, CYP2B6*6	(S)-methadone	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with increased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*6.			= 0.0001	OR			
1445151949	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with liver transplantation.	*1	*1	< 0.01	OR			
1450823121	CYP3A4*1, CYP3A4*22	endoxifen	Metabolism/PK	yes	CYP3A4 *1/*22 + *22/*22 are associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.			< 0.001	OR			
1450806762	CYP2C19*1, CYP2C19*2	omeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.333	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.01	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.01	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.02	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.03	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.04	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.04	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.04	OR			
1185234452	CYP3A4*1, CYP3A4*22	midazolam	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.04	OR			
1450806712	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *1/*1.	*2	*3	< 0.05	OR			
1185234468	CYP3A4*1, CYP3A4*22	tacrolimus	Dosage	yes	CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.0002	OR			
1185234468	CYP3A4*1, CYP3A4*22	tacrolimus	Dosage	yes	CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.0007	OR			
1185234460	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.001	OR			
1185234460	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.006	OR			
1184513500	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	antidepressants	Efficacy	no	SLC6A4 HTTLPR short form (S allele) is not associated with response to antidepressants in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele).				OR			
1450806785	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	*2	*3	< 0.0001	OR			
1450806845	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.			< 0.05	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.0009	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.007	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.008	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.01	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.02	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.19	OR			
1185234522	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.30	OR			
1451118200	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			< 0.001				
1185234509	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.0006	OR			
1007118673	CYP3A5*1, CYP3A5*3	vincristine	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased metabolism of vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to CYP3A5 *3/*3.	*3		= 4.0E-4	Unknown			
1450823396	CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41	endoxifen	Metabolism/PK	yes	CYP2D6 *9/*4 is associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *4/*10 + *4/*41.			< 0.05	OR			
1451118280	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *22 is associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A4 *1/*1.							
1450823445	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6	endoxifen	Metabolism/PK	yes	CYP2D6 *1/*4 + *1/*5 + *1/*6 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.0001	OR			
1450823459	CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41	endoxifen	Metabolism/PK	yes	CYP2D6 *9/*41 + *10/*10 + *41/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.0001	OR			
1043737399	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.			< 0.001	Unknown			
1450823408	CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41	endoxifen	Metabolism/PK	no	CYP2D6 *10/*4 + *41/*4 is not associated with concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *4/*4 + *4/*5 + *5/*5 (assigned as poor metabolizers phenotype) .			= 0.2	OR			
1447674691	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.005	OR			
1450823431	CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41	endoxifen	Metabolism/PK	yes	CYP2D6 *1/*9 + *1/*10 + *1/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.0001	OR			
1184169832	TPMT*1, TPMT*3A	mercaptopurine	Dosage	yes	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*3A		< 0.001	OR			
1446904589	CYP2D6*1, CYP2D6*81	nortriptyline	Metabolism/PK	not stated	CYP2D6 *1/*81 is associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major.				OR			
1184989053	CYP2D6*5, CYP2D6*100	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *5/*100 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1450823485	CYP2C9*1, CYP2C9*3	fluvastatin	Metabolism/PK	yes	CYP2C9 *3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.			= 8.5e-11				
1451134780	CYP3A4*1, CYP3A4*36	oxycodone	Efficacy	no	CYP3A4 *36 is not associated with response to oxycodone in people with Pain, Postoperative as compared to CYP3A4 *1.	*36		> 0.05				
1184989087	CYP2D6*2, CYP2D6*101	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *2/*101 is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1450971020	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36	methamphetamine	Metabolism/PK	yes	CYP2D6 *4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .			= 0.035				
1450971020	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36	methamphetamine	Metabolism/PK	yes	CYP2D6 *4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .			= 0.48				
1448624865	CYP2C19*1, CYP2C19*2	clopidogrel	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.			< 0.0001	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.001	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.001	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.01	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.01	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.01	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.05	OR			
1446904494	CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5	nortriptyline	Metabolism/PK	yes	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.			< 0.05	OR			
827827648	CYP2A6*1A, CYP2A6*17, CYP2A6*20	nicotine	Other,Metabolism/PK	not stated	CYP2A6 *17/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.	*20			Unknown			
827827654	CYP2A6*1A, CYP2A6*20	coumarin,nicotine	Other,Metabolism/PK	not stated	CYP2A6 *20 is associated with decreased metabolism of coumarin and nicotine in healthy individuals as compared to CYP2A6 *1A.				Unknown			
1450971000	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36	amphetamine	Metabolism/PK	no	CYP2D6 *4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36 (assigned as intermediate metabolizers phenotype) are not associated with concentrations of amphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizers phenotype) .							
827827639	CYP2A6*1A, CYP2A6*20	nicotine	Other,Metabolism/PK	not stated	CYP2A6 *1A/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.	*20			Unknown			
1448428210	CYP2C19*1, CYP2C19*17	valproic acid	Dosage	no	CYP2C19 *17/*17 is not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.			= 0.52	OR			
1448428199	CYP2C19*1, CYP2C19*17	valproic acid	Dosage	no	CYP2C19 *17/*17 is not associated with dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.			= 0.87	OR			
1448428186	CYP2C19*1, CYP2C19*2	valproic acid	Dosage	no	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.	*2		= 0.15	OR			
1448428173	CYP2C19*1, CYP2C19*2	valproic acid	Dosage	no	CYP2C19 *1/*2 + *2/*2 are not associated with dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C19 *1/*1.	*2		= 0.57	OR			
1448641165	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A5 *3/*3.	*1		< 0.001	OR			
1448641165	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A5 *3/*3.	*1		= 0.008	OR			
1448428159	CYP2C9*1, CYP2C9*2, CYP2C9*3	valproic acid	Metabolism/PK	no	CYP2C9 *1/*2 + *1/*3 are not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.			= 0.16	OR			
1448641138	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A4 *1/*1.	*22		= 0.363	OR			
1448641138	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A4 *1/*1.	*22		= 0.473	OR			
1448624746	CYP3A4*1, CYP3A4*22	simvastatin	Efficacy	no	CYP3A4 *22 is not associated with response to simvastatin as compared to CYP3A4 *1.			= 0.726	OR			
1448624746	CYP3A4*1, CYP3A4*22	simvastatin	Efficacy	no	CYP3A4 *22 is not associated with response to simvastatin as compared to CYP3A4 *1.			= 0.898	OR			
1448624736	CYP3A5*1, CYP3A5*3	simvastatin	Efficacy	no	CYP3A5 *3 is not associated with response to simvastatin as compared to CYP3A5 *1.			= 0.669	OR			
1448624736	CYP3A5*1, CYP3A5*3	simvastatin	Efficacy	no	CYP3A5 *3 is not associated with response to simvastatin as compared to CYP3A5 *1.			= 0.726	OR			
1446904423	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10	nortriptyline	Dosage	yes	CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with decreased dose of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.			< 0.001	OR			
1446904423	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10	nortriptyline	Dosage	yes	CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with decreased dose of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.			< 0.002	OR			
1451134960	CYP3A5*1, CYP3A5*3	oxycodone,sufentanil	Efficacy	no	CYP3A5 *3 is not associated with response to oxycodone or sufentanil in people with Pain, Postoperative as compared to CYP3A5 *1.	*3		> 0.387				
1451134960	CYP3A5*1, CYP3A5*3	oxycodone,sufentanil	Efficacy	no	CYP3A5 *3 is not associated with response to oxycodone or sufentanil in people with Pain, Postoperative as compared to CYP3A5 *1.	*3		= 0.937				
1450807298	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.			< 0.01	OR			
1450807307	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 (assigned as normal metabolizers phenotype) .			< 0.01	OR			
1450807373	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with acid-related disorders as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2.			= 0.0001	OR			
1444708852	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	endoxifen	Metabolism/PK	yes	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			= 0.0001	OR			
1444708852	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	endoxifen	Metabolism/PK	yes	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			= 0.0002	OR			
1451135020	CYP2D6*1, CYP2D6*10	oxycodone,sufentanil	Efficacy	no	CYP2D6 *10 is not associated with response to oxycodone or sufentanil in people with Pain, Postoperative as compared to CYP2D6 *1.	*10		> 0.05				
1444708893	CYP2C9*1, CYP2C9*2, CYP2C9*3	endoxifen,tamoxifen	Metabolism/PK	no	CYP2C9 *2 + *3 are not associated with concentrations of endoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2C9 *1/*1.			> 0.05	OR			
1446904319	CYP2D6*1xN, CYP2D6*2	nortriptyline	Metabolism/PK	not stated	CYP2D6 *2/*1xN is associated with increased dose of nortriptyline in people with Depressive Disorder, Major.				OR			
1448641012	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A5 *3/*3.	*1		< 0.001	OR			
1448641012	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A5 *3/*3.	*1		= 0.008	OR			
1450807446	CYP2C19*1, CYP2C19*2, CYP2C19*3	amoxicillin,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.	*2	*3	< 0.001	OR			
1444708801	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	4-hydroxytamoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *3 + *4 + *5 + *6 is not associated with concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			> 0.05	OR			
1450807458	CYP2C19*1, CYP2C19*2, CYP2C19*3	amoxicillin,omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.	*2	*3	= 0.034	OR			
1448624596	NUDT15*1, NUDT15*2, NUDT15*3	mercaptopurine	Toxicity	yes	NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.			= 0.00048	OR			
1448624581	NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5	mercaptopurine	Toxicity	yes	NUDT15 *1/*2 + *1/*3 + *1/*5 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.			= 0.00048	OR			
1448640957	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.001	OR			
1184137325	CYP2D6*1, CYP2D6*2, CYP2D6*10	paroxetine	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.05	OR			
1450807430	CYP2C19*1, CYP2C19*2, CYP2C19*3	amoxicillin,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	*2	*3	= 0.028	OR			
1448640944	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.001	OR			
1447674267	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage,Metabolism/PK	yes	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.05	OR			
1449005291	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.			< 0.001	OR			
1449005313	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	no	CYP3A5 *3 is not associated with metabolism of midazolam in healthy individuals as compared to CYP3A5 *1.				OR			
1449005313	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	no	CYP3A5 *3 is not associated with metabolism of midazolam in healthy individuals as compared to CYP3A5 *1.				OR			
1449005313	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	no	CYP3A5 *3 is not associated with metabolism of midazolam in healthy individuals as compared to CYP3A5 *1.				OR			
1449005313	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	no	CYP3A5 *3 is not associated with metabolism of midazolam in healthy individuals as compared to CYP3A5 *1.				OR			
1449005313	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	no	CYP3A5 *3 is not associated with metabolism of midazolam in healthy individuals as compared to CYP3A5 *1.				OR			
827827796	CYP2A6*1A, CYP2A6*1X2B	nicotine	Other,Metabolism/PK	no	CYP2A6 *1X2B is associated with increased metabolism of nicotine as compared to CYP2A6 *1A.				Unknown			
1183629572	CYP2D6*3, CYP2D6*4	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *3/*4 is associated with metabolism of debrisoquine or dextromethorphan.				Unknown			
1451135223	NAT2*4, NAT2*5, NAT2*6, NAT2*7	hydralazine	Metabolism/PK	yes	NAT2 *4/*5 + *4/*6 + *4/*7 (assigned as rapid acetylator phenotype) are associated with increased metabolism of hydralazine in women with Hypertension as compared to NAT2 *5/*5 + *5/*6 + *5/*7 + *6/*6 (assigned as slow acetylator phenotype) .			< 0.05				
1183629548	CYP2D6*4, CYP2D6*5	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*5 is associated with decreased metabolism of debrisoquine or dextromethorphan.				Unknown			
1183629554	CYP2D6*3, CYP2D6*5	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *3/*5 is associated with decreased metabolism of debrisoquine or dextromethorphan.				Unknown			
1447674165	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.001	OR			
1448263986	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	not stated	CYP3A5 *1/*3 is associated with decreased concentrations of tacrolimus in people with Leukemia.				OR			
1184510322	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1451163993	UGT1A1*1, UGT1A1*28, UGT1A1*36	atazanavir / ritonavir	Toxicity	yes	UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 + *1/*36 + *36/*36.			= 0.005	OR			
1184756094	CYP2D6*4, CYP2D6*15	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*15 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or dextromethorphan in healthy individuals.				OR			
1450934625	SLCO1B1*1, SLCO1B1*5	estrone sulfate	Metabolism/PK	yes	SLCO1B1 *5 is associated with increased estrone sulfate in women with Breast Neoplasms as compared to SLCO1B1 *1/*1.			< 0.001				
1451147625	CYP3A4*1, CYP3A4*3, CYP3A4*20, CYP3A4*22	fesoterodine	Metabolism/PK	not stated	CYP3A4 *3 + *20 + *22 are associated with increased clearance of fesoterodine in healthy individuals as compared to CYP3A4 *1.							
1448268043	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	*3		= 0.001	OR			
1451229484	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10	n,o-didesmethyltramadol,o-desmethyltramadol	Metabolism/PK	no	CYP2D6 *5/*5 + *10/*10 are associated with decreased concentrations of n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1 + *2.			> 0.05				
1444712725	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41	paroxetine	Metabolism/PK	yes	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .			= 0.002	OR			
1444712725	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41	paroxetine	Metabolism/PK	yes	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .			= 0.012	OR			
1184166190	GSTT1 non-null, GSTT1 null	bleomycin,dacarbazine,doxorubicin,vinblastine	Efficacy	no	GSTT1 non-null/non-null is not associated with response to bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTT1 non-null/null + null/null.			= 0.1	OR			
1448431851	CYP2C9*1, CYP2C9*3, CYP2C9*13	celecoxib	Metabolism/PK	yes	CYP2C9 *1/*3 + *1/*13 + *3/*3 are associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.			< 0.001	OR			
1444843695	CYP3A5*1, CYP3A5*3	cyclosporine	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with decreased concentrations of cyclosporine in men as compared to CYP3A5 *3/*3.	*1		= 0.01	OR			
1184510263	CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.001	OR			
1448104167	CYP2A6*4D, CYP2A6*5	coumarin	Metabolism/PK	not stated	CYP2A6 *5/*4D is associated with decreased metabolism of coumarin.				OR			
1184510278	CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.			< 0.001	OR			
1444843717	CYP3A5*1, CYP3A5*3	cyclosporine	Metabolism/PK	yes	CYP3A5 *1/*1 is associated with decreased concentrations of cyclosporine in women as compared to CYP3A5 *3/*3.	*1		= 0.038	OR			
1451147640	CYP3A4*1, CYP3A4*3, CYP3A4*20, CYP3A4*22	fentanyl,imatinib,quetiapine	Metabolism/PK	not stated	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.							
1448267915	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with dose of warfarin.	*3			OR			
1445400722	CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8	endoxifen	Metabolism/PK	yes	CYP2D6 *4 + *6 + *8 are associated with decreased concentrations of endoxifen in women with as compared to CYP2D6 *1/*1.			= 0.002	OR			
1184510497	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	no	CYP2B6 *1/*1 + *1/*6 is not associated with clearance of efavirenz in healthy individuals as compared to CYP2B6 *6/*6.	*6		= 0.23	OR			
1448267890	CYP2C9*1, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *1/*3 + *3/*3 are associated with dose of warfarin.	*3			OR			
1451229680	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*35, CYP2D6*41	n,o-didesmethyltramadol,o-desmethyltramadol	Metabolism/PK	not stated	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with decreased exposure to n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*9 + *1/*35 + *1/*41 + *2/*5 + *2/*35 + *2/*41 + *4/*35 + *4/*41 (assigned as intermediate metabolizer and normal metabolizer phenotype) .							
1451164140	UGT1A1*1, UGT1A1*28	atazanavir / ritonavir	Toxicity	yes	UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.			< 0.0001	HR	9.13	3.38	24.69
1451164161	UGT1A1*1, UGT1A1*28	atazanavir / ritonavir	Toxicity	no	UGT1A1 *1/*28 is not associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.			= 0.158	OR			
1184756346	CYP2D6*18, CYP2D6*21	debrisoquine	Metabolism/PK	not stated	CYP2D6 *18/*21 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals.				OR			
1450934891	SLCO1B1*1, SLCO1B1*5	estrone	Efficacy	yes	SLCO1B1 *5/*5 is associated with increased concentrations of estrone in women with Breast Neoplasms as compared to SLCO1B1 *1/*1 + *1/*5.			= 0.037				
1449165490	CYP2D6*1, CYP2D6*10, CYP2D6*36	dihydrocodeine	Toxicity,Metabolism/PK	not stated	CYP2D6 *1/*10 + *36 is not associated with clearance of dihydrocodeine in children.				OR			
1184756472	CYP2D6*1, CYP2D6*2, CYP2D6*44	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *2/*44 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.				OR			
1184756523	CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*21	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *1/*21 + *10/*21 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.				OR			
1184985784	CYP2C19*1, CYP2C19*2	bupropion	Metabolism/PK	yes	CYP2C19 *2 is associated with increased exposure to bupropion in healthy individuals as compared to CYP2C19 *1.	*2	*1	< 0.05	OR			
1450820343	CYP2B6*1, CYP2B6*6	bupropion	Metabolism/PK	yes	CYP2B6 *1/*6 + *6/*6 are associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.			= 0.004				
1184985811	CYP2C19*1, CYP2C19*17	bupropion	Metabolism/PK	no	CYP2C19 *17 is not associated with exposure to bupropion in healthy individuals as compared to CYP2C19 *1.	*17	*1	> 0.05	OR			
1184985821	CYP2C19*1, CYP2C19*2, CYP2C19*17	bupropion	Efficacy	no	CYP2C19 *2 + *17 are not associated with response to bupropion in people with Tobacco Use Disorder as compared to CYP2C19 *1.	*2	*17	> 0.05	OR			
1447677749	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	no	CYP2D6 *10/*10 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*10.	*10		= 0.097	OR			
1450361662	CYP2C9*1, CYP2C9*2, CYP2C9*3	fluvastatin	Efficacy	no	CYP2C9 *1/*3 + *2/*3 are not associated with response to fluvastatin as compared to CYP2C9 *1/*1 + *1/*2.			> 0.05	OR			
1447677736	CYP2D6*1, CYP2D6*2	haloperidol	Metabolism/PK	yes	CYP2D6 *2/*2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*2.	*2		= 0.003	OR			
1449165650	CYP3A5*1, CYP3A5*3	cyclosporine	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of cyclosporine in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.			= 0.02	OR			
1444712210	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41	n-desmethyltamoxifen	Metabolism/PK	yes	CYP2D6 *4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10.			< 0.001	OR			
1184756628	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 (assigned as intermediate metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.			< 0.001	OR			
1444695840	CYP2C9*1, CYP2C9*8	warfarin	Metabolism/PK	yes	CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.	*8		< 0.01	OR			
1448267502	CYP2C9*2, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *2 + *3 are associated with dose of warfarin.				OR			
1444712127	CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41	endoxifen	Metabolism/PK	yes	CYP2D6 *4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10.			< 0.01	OR			
1184134029	TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C	azathioprine,mercaptopurine,purine analogues	Dosage	not stated	TPMT *2 + *3A + *3B + *3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	*1			OR			
1446907570	CYP2D6*1, CYP2D6*14	simvastatin	Metabolism/PK	yes	CYP2D6 *14 is associated with increased concentrations of simvastatin in healthy individuals as compared to CYP2D6 *1/*1.			= 0.015	OR			
1448267466	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.			= 0.01	OR			
827566510	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	codeine	Metabolism/PK	yes	CYP2D6 *1/*2xN (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.02	Unknown			
827566514	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*6	codeine	Metabolism/PK	yes	CYP2D6 *1xN/*1 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.02	Unknown			
827566502	CYP2D6*1, CYP2D6*1xN, CYP2D6*41	codeine	Metabolism/PK	yes	CYP2D6 *1xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.02	Unknown			
1184510958	CYP2A6*1A, CYP2A6*4A, CYP2A6*7, CYP2A6*9	irinotecan,oxaliplatin,tegafur / gimeracil / oteracil	Efficacy	yes	CYP2A6 *4A + *7 + *9 are associated with decreased response to irinotecan, oxaliplatin and tegafur / gimeracil / oteracil in people with Colorectal Neoplasms as compared to CYP2A6 *1A/*1A.			= 0.05	OR			
1450935251	CYP2C8*1, CYP2C8*3	ibuprofen	Metabolism/PK	not stated	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.							
827566496	CYP2D6*1, CYP2D6*1xN, CYP2D6*10	codeine	Metabolism/PK	yes	CYP2D6 *1xN/*10 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.02	Unknown			
1184510970	CYP2D6*4, CYP2D6*5	donepezil	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) is associated with decreased clearance of donepezil in people with Alzheimer Disease.			< 0.01	OR			
1450935257	CYP2C9*1, CYP2C9*2, CYP2C9*3	ibuprofen	Metabolism/PK	not stated	CYP2C9 *3 + *2 are associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.							
1184986118	CYP2D6*4, CYP2D6*4xN	debrisoquine	Metabolism/PK	not stated	CYP2D6 *4/*4xN is associated with decreased metabolism of debrisoquine in healthy individuals.				OR			
1184756733	CYP2D6*4, CYP2D6*17	debrisoquine	Metabolism/PK	not stated	CYP2D6 *4/*17 is associated with decreased metabolism of debrisoquine.				OR			
1184756755	CYP2D6*4, CYP2D6*38	debrisoquine	Metabolism/PK	not stated	CYP2D6 *4/*38 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine.				OR			
1184134089	TPMT*1, TPMT*2, TPMT*3A	azathioprine,mercaptopurine,purine analogues	Dosage	yes	TPMT *1/*2 + *1/*3A is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	*1		= 0.043	OR			
1451099074	CYP2D6*1, CYP2D6*29	fentanyl	Metabolism/PK	yes	CYP2D6 *29 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.			< 0.01				
1184986142	CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*10x2	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 + *10/*10x2 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10.			< 0.01	OR			
1444711981	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41	endoxifen	Metabolism/PK	yes	CYP2D6 *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.			< 0.01	OR			
1184986040	CYP2D6*4xN, CYP2D6*56	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4xN/*56 is associated with decreased metabolism of dextromethorphan.				OR			
1449165818	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.0001	OR			
1184756664	CYP2D6*1, CYP2D6*5	dextromethorphan	Metabolism/PK	no	CYP2D6 *5/*5 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1184986056	CYP2D6*3, CYP2D6*4xN	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *3/*4xN (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1184986069	CYP2D6*4, CYP2D6*4xN	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*4xN is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1184756685	CYP2D6*4, CYP2D6*31	metoprolol	Metabolism/PK	not stated	CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of metoprolol in healthy individuals.				OR			
1444712023	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41	n-desmethyltamoxifen	Metabolism/PK	yes	CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *2xN/*4 + *1/*1xN + *2/*1xN + *1/*2xN.			< 0.001	OR			
1184986084	CYP2D6*4, CYP2D6*5	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1184756714	CYP2D6*4, CYP2D6*31	dextromethorphan	Metabolism/PK	no	CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.				OR			
1184986233	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*10 + *5/*10 + *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.				OR			
1184986221	CYP2D6*4, CYP2D6*5, CYP2D6*6	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals.				OR			
1184756863	CYP2D6*1, CYP2D6*29	debrisoquine	Metabolism/PK	yes	CYP2D6 *29/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*29.			= 0.02	OR			
1184756875	CYP2D6*1, CYP2D6*17, CYP2D6*29	debrisoquine	Metabolism/PK	yes	CYP2D6 *17/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*17.			= 0.03	OR			
1184511110	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluvoxamine	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with response to fluvoxamine in people with Obsessive-Compulsive Disorder as compared to SLC6A4 HTTLPR short form (S allele).	HTTLPR long form (L allele)		> 0.05	OR			
1451132005	CYP2C9*1, CYP2C9*2, CYP2C9*3	progesterone	Metabolism/PK	no	CYP2C9 *1/*2 + *1/*3 + *2/*2 are not associated with exposure to progesterone in women as compared to CYP2C9 *1/*1.							
1184511121	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	escitalopram	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			= 0.016	OR			
1451131960	CYP2C19*1, CYP2C19*2, CYP2C19*17	progesterone	Metabolism/PK	yes	CYP2C19 *1/*2 + *2/*17 are associated with increased exposure to progesterone in women as compared to CYP2C19 *1/*1.			= 0.05				
1184511132	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	venlafaxine	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			= 0.016	OR			
1448267244	CYP3A5*3, CYP3A5*6, CYP3A5*7	tacrolimus	Metabolism/PK	not stated	CYP3A5 *3 + *6 + *7 are associated with decreased clearance of tacrolimus in people with Kidney Transplantation.				OR			
1184756902	CYP2D6*1, CYP2D6*2, CYP2D6*17	debrisoquine,dextromethorphan,metoprolol	Metabolism/PK	yes	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.005	OR			
1184756902	CYP2D6*1, CYP2D6*2, CYP2D6*17	debrisoquine,dextromethorphan,metoprolol	Metabolism/PK	yes	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.05	OR			
1184167080	CYP2B6*1, CYP2B6*6	chlorambucil	Efficacy	no	CYP2B6 *1/*6 + *6/*6 is not associated with response to chlorambucil in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	*6		> 0.05	OR			
1184511033	CYP2D6*1, CYP2D6*1xN	donepezil	Metabolism/PK	yes	CYP2D6 *1/*1xN + *1xN/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of donepezil in people with Alzheimer Disease.				OR			
1451213980	UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60	labetalol	Metabolism/PK	no	UGT1A1 *1/*6 + *1/*60 + *1/*28 + *28/*28 + *6/*60 is associated with decreased metabolism of labetalol in healthy individuals as compared to UGT1A1 *1/*1.	7			OR			
1451099305	CYP2D6*1, CYP2D6*2, CYP2D6*10	risperidone	Dosage	no	CYP2D6 *10 is not associated with dose of risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.							
1184167044	CYP2B6*1, CYP2B6*6	cyclophosphamide,fludarabine	Efficacy	yes	CYP2B6 *1/*6 + *6/*6 are associated with decreased response to cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	*6		= 0.004	OR	0.27		
1184167044	CYP2B6*1, CYP2B6*6	cyclophosphamide,fludarabine	Efficacy	yes	CYP2B6 *1/*6 + *6/*6 are associated with decreased response to cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	*6		= 0.017	OR	0.35		
1184167044	CYP2B6*1, CYP2B6*6	cyclophosphamide,fludarabine	Efficacy	yes	CYP2B6 *1/*6 + *6/*6 are associated with decreased response to cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	*6		= 0.039	OR	0.37	0.15	0.95
1184511064	CYP3A7*1A, CYP3A7*1C	donepezil	Metabolism/PK	no	CYP3A7 *1C/*1C is not associated with clearance of donepezil in people with Alzheimer Disease as compared to CYP3A7 *1A/*1A.			> 0.01	OR			
1184986212	CYP2D6*5, CYP2D6*7, CYP2D6*8	sparteine	Metabolism/PK	not stated	CYP2D6 *5/*7 + *5/*8 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals.				OR			
1184167146	CYP2C19*1, CYP2C19*2	clopidogrel	Metabolism/PK	yes	CYP2C19 *2 (assigned as poor metabolizer phenotype) is associated with increased dose of clopidogrel in healthy individuals as compared to CYP2C19 *1 (assigned as normal metabolizer phenotype) .	*2		< 0.05	OR			
1451099341	CYP2D6*1, CYP2D6*2, CYP2D6*10	risperidone	Metabolism/PK	no	CYP2D6 *10 is not associated with concentrations of risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.							
1451099349	CYP2D6*1, CYP2D6*2, CYP2D6*10	paliperidone	Metabolism/PK	no	CYP2D6 *10 is not associated with concentrations of paliperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.							
1446907247	CYP2C19*1, CYP2C19*2, CYP2C19*3	cilostazol	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with increased concentrations of cilostazol in healthy individuals as compared to CYP2C19 *1.			= 0.006	OR			
1446907247	CYP2C19*1, CYP2C19*2, CYP2C19*3	cilostazol	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with increased concentrations of cilostazol in healthy individuals as compared to CYP2C19 *1.			= 0.013	OR			
1446907247	CYP2C19*1, CYP2C19*2, CYP2C19*3	cilostazol	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with increased concentrations of cilostazol in healthy individuals as compared to CYP2C19 *1.			= 0.023	OR			
1451230380	SLCO1B1*1, SLCO1B1*15	atorvastatin	Efficacy	no	SLCO1B1 *15 is not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.			> 0.05				
1184511256	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	paroxetine	Efficacy	no	SLC6A4 HTTLPR long form (L allele) is not associated with response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele).			= 0.745	OR			
1184134324	TPMT*1, TPMT*2, TPMT*3A, TPMT*3C	methotrexate,purine analogues	Efficacy	no	TPMT *1/*2 + *1/*3A + *1/*3C is not associated with response to methotrexate and purine analogues in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.562	OR			
1184756913	CYP2D6*1, CYP2D6*5, CYP2D6*17	codeine,debrisoquine,dextromethorphan,metoprolol	Metabolism/PK	yes	CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.			< 0.005	OR			
1184756913	CYP2D6*1, CYP2D6*5, CYP2D6*17	codeine,debrisoquine,dextromethorphan,metoprolol	Metabolism/PK	yes	CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.			< 0.05	OR			
1446907223	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.			< 0.001	OR			
1446907223	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.			< 0.001	OR			
1446907223	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.			= 0.001	OR			
1446907223	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Metabolism/PK	yes	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.			= 0.001	OR			
1446907186	UGT1A1*1, UGT1A1*28	sorafenib	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with increased exposure to sorafenib in people with Neoplasms as compared to UGT1A1 *1/*1.			< 0.0001	OR			
1446907186	UGT1A1*1, UGT1A1*28	sorafenib	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 are associated with increased exposure to sorafenib in people with Neoplasms as compared to UGT1A1 *1/*1.			= 0.32	OR			
1184756941	CYP2D6*1, CYP2D6*2, CYP2D6*29	dextromethorphan,metoprolol	Metabolism/PK	yes	CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.05	OR			
1184756952	CYP2D6*1, CYP2D6*2, CYP2D6*29	codeine,debrisoquine	Metabolism/PK	no	CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			> 0.05	OR			
1184134384	TPMT*1, TPMT*2, TPMT*3A, TPMT*3B	mercaptopurine	Dosage,Toxicity	not stated	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1			OR			
1184511344	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluoxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			< 0.001	OR	8.6	2.8	26.6
1444695287	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.			= 0.014	OR			
1184756965	CYP2D6*17, CYP2D6*29	debrisoquine	Metabolism/PK	no	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *29/*29.			< 0.05	OR			
1184757110	CYP2D6*1, CYP2D6*17	dextromethorphan	Metabolism/PK	yes	CYP2D6 *17 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.			< 0.001	OR			
1184757117	CYP2D6*1, CYP2D6*29	dextromethorphan	Metabolism/PK	no	CYP2D6 *29 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.			= 0.21	OR			
1450935601	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.044				
1444695268	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.			= 0.013	OR			
1449166259	CYP2C19*1, CYP2C19*2, CYP2C19*17	omeprazole	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased clearance of omeprazole in infants with Gastroesophageal Reflux as compared to CYP2C19 *1 + *17.			< 0.01	OR			
981344731	CYP2C19*1, CYP2C19*2	warfarin	Dosage,Metabolism/PK	no	CYP2C19 *2 is not associated with increased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C19 *1.				Unknown			
1444842618	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	not stated	CYP2C19 *1/*2 is associated with increased concentrations of voriconazole.				OR			
1184282060	TPMT*1, TPMT*2, TPMT*3A, TPMT*3C	mercaptopurine	Dosage	yes	TPMT *1/*3C + *1/*2 + *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	*1		= 0.005	OR			
1444695194	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.			< 0.01	OR			
1444695105	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased resistance to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*2	*3	= 0.02	OR			
1451165260	UGT1A1*1, UGT1A1*28	selumetinib	Metabolism/PK	no	UGT1A1 *28 is not associated with increased metabolism of selumetinib in healthy individuals as compared to UGT1A1 *1.	(TA)6	(TA)7	= 0.048	OR			
1451165260	UGT1A1*1, UGT1A1*28	selumetinib	Metabolism/PK	no	UGT1A1 *28 is not associated with increased metabolism of selumetinib in healthy individuals as compared to UGT1A1 *1.			= 0.418	OR		-0.188	0.078
1451165260	UGT1A1*1, UGT1A1*28	selumetinib	Metabolism/PK	no	UGT1A1 *28 is not associated with increased metabolism of selumetinib in healthy individuals as compared to UGT1A1 *1.	(TA)7	(TA)6	= 0.572	OR			
1451165260	UGT1A1*1, UGT1A1*28	selumetinib	Metabolism/PK	no	UGT1A1 *28 is not associated with increased metabolism of selumetinib in healthy individuals as compared to UGT1A1 *1.	(TA)7	(TA)6	= 0.797	OR			
1451116120	CYP3A4*1, CYP3A4*22	lopinavir	Metabolism/PK	yes	CYP3A4 *22/*22 is associated with decreased clearance of lopinavir in people with HIV Infections as compared to CYP3A4 *1/*1 + *1/*22.	*22		= 0.023				
1451116120	CYP3A4*1, CYP3A4*22	lopinavir	Metabolism/PK	yes	CYP3A4 *22/*22 is associated with decreased clearance of lopinavir in people with HIV Infections as compared to CYP3A4 *1/*1 + *1/*22.	*22		= 0.028				
1444695041	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.			< 0.05	OR			
1444695050	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3	= 0.001	OR	9.88	2.47	39.56
1444695050	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3	= 0.002	OR	7.7	2.09	28.32
1444695050	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3	= 0.04	OR	7.83	1.12	54.74
1444695080	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3	= 0.04	OR	6.12	1.05	35.73
1444695080	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3	= 0.05	OR	2.91	0.98	8.6
1444695080	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3	= 0.09	OR	2.53	0.88	7.29
1451230861	CYP2C9*1, CYP2C9*2, CYP2C9*3	siponimod	Metabolism/PK	not stated	CYP2C9 *2/*3 + *3/*3 are associated with increased concentrations of siponimod in healthy individuals as compared to CYP2C9 *1/*1.							
1444694964	CYP2C19*1, CYP2C19*2	clobazam	Metabolism/PK	not stated	CYP2C19 *1/*2 + *2/*2 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.				OR			
827699420	CYP2A6*1A, CYP2A6*9A	nicotine	Metabolism/PK	yes	CYP2A6 *9A/*9A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*9A + *1A/*1A.			< 0.005				
827699420	CYP2A6*1A, CYP2A6*9A	nicotine	Metabolism/PK	yes	CYP2A6 *9A/*9A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*9A + *1A/*1A.	*9A		< 0.05	Unknown			
827699412	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	nicotine	Metabolism/PK	yes	CYP2A6 *4A/*9A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*4A.	*9A		< 0.005	Unknown			
827699412	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	nicotine	Metabolism/PK	yes	CYP2A6 *4A/*9A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*4A.			< 0.05				
1444842443	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*1 (assigned as poor metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.			< 0.05	OR			
1184511561	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.02	OR			
1444694988	CYP2C19*1, CYP2C19*2	clobazam	Metabolism/PK	not stated	CYP2C19 *1/*2 is associated with metabolism of clobazam in people with Epilepsy.				OR			
1444695013	CYP2C19*1, CYP2C19*2	clobazam	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2		= 0.012	OR			
1184511592	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	no	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1.			= 0.01	OR			
1184233189	NAT2*4, NAT2*5B, NAT2*6A, NAT2*6J, NAT2*7B, NAT2*7G, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .			< 0.01	OR			
1184233189	NAT2*4, NAT2*5B, NAT2*6A, NAT2*6J, NAT2*7B, NAT2*7G, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .			< 0.01	OR			
1184233189	NAT2*4, NAT2*5B, NAT2*6A, NAT2*6J, NAT2*7B, NAT2*7G, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .			= 0.021	OR			
1184233189	NAT2*4, NAT2*5B, NAT2*6A, NAT2*6J, NAT2*7B, NAT2*7G, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .			= 0.12	OR			
1184233189	NAT2*4, NAT2*5B, NAT2*6A, NAT2*6J, NAT2*7B, NAT2*7G, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .			= 0.27	OR			
1184233189	NAT2*4, NAT2*5B, NAT2*6A, NAT2*6J, NAT2*7B, NAT2*7G, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .			= 0.4	OR			
1184233225	NAT2*4, NAT2*5B, NAT2*5C, NAT2*6A, NAT2*6J, NAT2*6O, NAT2*7B, NAT2*7G, NAT2*12A, NAT2*13A	isoniazid	Metabolism/PK	yes	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased clearance of isoniazid in children with Tuberculosis as compared to NAT2 *4/*5B + *4/*6A + *4/*5C + *4/*6O + *4/*7G + *5B/*12A + *6A/*13A (assigned as intermediate acetylator phenotype) .			< 0.01	OR			
1444842336	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	*2	*17	< 0.01	OR			
1451214640	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	not stated	UGT1A1 *28 is associated with decreased dose of irinotecan in people with Adenocarcinoma and Gastrointestinal Neoplasms as compared to UGT1A1 *1.				OR			
1449183103	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.			< 0.001	OR			
827813298	CYP2C19*1, CYP2C19*17	tamoxifen	Efficacy,Metabolism/PK	yes	CYP2C19 *17 is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.			= 0.031	Unknown			
827813298	CYP2C19*1, CYP2C19*17	tamoxifen	Efficacy,Metabolism/PK	yes	CYP2C19 *17 is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.				HR	1.1	0.89	1.37
827813293	CYP2D6*1, CYP2D6*4	antineoplastic agents,tamoxifen	Efficacy,Metabolism/PK	no	CYP2D6 *4 is not associated with response to antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.				HR	0.97	0.63	1.52
981754835	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3.			= 0.002	Unknown			
827813279	CYP2C19*1, CYP2C19*2	tamoxifen	Efficacy,Metabolism/PK	yes	CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.			= 0.004	HR	0.72	0.57	0.9
827813279	CYP2C19*1, CYP2C19*2	tamoxifen	Efficacy,Metabolism/PK	yes	CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.				HR	0.74	0.55	0.98
827813279	CYP2C19*1, CYP2C19*2	tamoxifen	Efficacy,Metabolism/PK	yes	CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.				HR	0.7	0.44	1.11
827813279	CYP2C19*1, CYP2C19*2	tamoxifen	Efficacy,Metabolism/PK	yes	CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.				HR	0.65	0.35	1.21
1449576398	CYP2A6*1A, CYP2A6*17	metronidazole	Metabolism/PK	no	CYP2A6 *17 is not associated with clearance of metronidazole in infants as compared to CYP2A6 *1A.				OR			
1184511945	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8	warfarin	Metabolism/PK	yes	CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *1/*8 + *2/*3 + *2/*2 (assigned as poor metabolizers and intermediate metabolizers phenotype) .			= 0.004	OR			
1449003038	CYP3A5*1, CYP3A5*3	oxycodone	Dosage	yes	CYP3A5 *3/*3 is associated with increased dose of oxycodone in people with Neoplasms as compared to CYP3A5 *1/*1 + *1/*3.			= 0.02	OR			
1448495665	CYP1A1*1, CYP1A1*2A	exemestane	Metabolism/PK	no	CYP1A1 *1/*2A + *2A/*2A are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to CYP1A1 *1/*1.	*2A		= 0.20	OR			
1444710914	CYP3A5*1, CYP3A5*3	4-hydroxytamoxifen,endoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP3A5 *3 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP3A5 *1.				OR			
1444841988	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*1 + *1/*17 is associated with decreased trough concentration of voriconazole in people with Hematologic Diseases as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3.	*2	*3	= 0.001	OR			
1449576511	UGT1A3*1, UGT1A3*2	montelukast	Metabolism/PK	yes	UGT1A3 *2 is associated with decreased concentrations of montelukast in healthy individuals as compared to UGT1A3 *1/*1.	*2		= 2.99e-10	OR			
1444710925	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	4-hydroxytamoxifen,endoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2C19 *2 + *3 + *17 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.				OR			
1450969140	CYP2C9*1, CYP2C9*2	phenytoin	Metabolism/PK	yes	CYP2C9 *1/*2 is associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.			< 0.01				
1444710945	CYP2C9*1, CYP2C9*3	4-hydroxytamoxifen,endoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2C9 *3 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2C9 *1.				OR			
1183954989	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*3		< 0.05	OR			
1447954876	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41	primaquine	Efficacy	yes	CYP2D6 *4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.			= 0.05	OR			
1450969200	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenytoin	Metabolism/PK	yes	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.			< 0.01				
1450969293	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenytoin	Dosage	yes	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of phenytoin as compared to CYP2C9 *1/*1.			= 0.02	OR	1.11	1.02	1.22
1444710781	CYP2D6*1, CYP2D6*10	n-desmethyltamoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 + *1/*10 is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			< 0.001	OR			
1444710781	CYP2D6*1, CYP2D6*10	n-desmethyltamoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 + *1/*10 is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.			= 0.006	OR			
1447954841	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41	tafenoquine	Efficacy	no	CYP2D6 *4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.			= 0.57	OR			
1447954841	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41	tafenoquine	Efficacy	no	CYP2D6 *4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41 is not associated with decreased response to tafenoquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.			= 0.79	OR			
1447954815	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41	primaquine	Metabolism/PK	yes	CYP2D6 *4/*41 + *5/*6 are associated with decreased clearance of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.			= 0.007	OR			
1444710805	CYP2D6*1, CYP2D6*41	4-hydroxytamoxifen,endoxifen,n-desmethyltamoxifen,tamoxifen	Metabolism/PK	no	CYP2D6 *41 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.				OR			
1184348458	TPMT*1, TPMT*3C	mercaptopurine	Dosage,Toxicity	not stated	TPMT *1/*3C is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.				OR			
1184348438	TPMT*1, TPMT*3A	mercaptopurine	Dosage,Toxicity	not stated	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.				OR			
1446906210	CYP3A5*1, CYP3A5*3	cilostazol	Metabolism/PK	yes	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of cilostazol in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			< 0.001	OR			
1446906210	CYP3A5*1, CYP3A5*3	cilostazol	Metabolism/PK	yes	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of cilostazol in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			< 0.001	OR			
1446906210	CYP3A5*1, CYP3A5*3	cilostazol	Metabolism/PK	yes	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of cilostazol in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			= 0.002	OR			
1446906210	CYP3A5*1, CYP3A5*3	cilostazol	Metabolism/PK	yes	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of cilostazol in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .			= 0.017	OR			
1447954774	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41	primaquine	Metabolism/PK	yes	CYP2D6 *4/*41 + *5/*6 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.			= 0.01	OR			
1449576724	CYP3A5*1, CYP3A5*3	tamsulosin	Efficacy	no	CYP3A5 *1 (assigned as poor metabolizer genotype phenotype) is not associated with response to tamsulosin in healthy individuals as compared to CYP3A5 *3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.636	OR			
1449576724	CYP3A5*1, CYP3A5*3	tamsulosin	Efficacy	no	CYP3A5 *1 (assigned as poor metabolizer genotype phenotype) is not associated with response to tamsulosin in healthy individuals as compared to CYP3A5 *3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.636	OR			
1449576724	CYP3A5*1, CYP3A5*3	tamsulosin	Efficacy	no	CYP3A5 *1 (assigned as poor metabolizer genotype phenotype) is not associated with response to tamsulosin in healthy individuals as compared to CYP3A5 *3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.636	OR			
1449576724	CYP3A5*1, CYP3A5*3	tamsulosin	Efficacy	no	CYP3A5 *1 (assigned as poor metabolizer genotype phenotype) is not associated with response to tamsulosin in healthy individuals as compared to CYP3A5 *3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.993	OR			
1449576724	CYP3A5*1, CYP3A5*3	tamsulosin	Efficacy	no	CYP3A5 *1 (assigned as poor metabolizer genotype phenotype) is not associated with response to tamsulosin in healthy individuals as compared to CYP3A5 *3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.993	OR			
1449576724	CYP3A5*1, CYP3A5*3	tamsulosin	Efficacy	no	CYP3A5 *1 (assigned as poor metabolizer genotype phenotype) is not associated with response to tamsulosin in healthy individuals as compared to CYP3A5 *3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .			= 0.993	OR			
1444710751	CYP2D6*1, CYP2D6*5, CYP2D6*10	endoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 + *5/*10 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*5.			< 0.001	OR			
1444710751	CYP2D6*1, CYP2D6*5, CYP2D6*10	endoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 + *5/*10 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*5.			= 0.001	OR			
1451153742	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	(R)-methadone,(S)-methadone	Metabolism/PK	yes	CYP2D6 *3/*4 + *4/*4 + *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .			= 0.024				
1451153742	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	(R)-methadone,(S)-methadone	Metabolism/PK	yes	CYP2D6 *3/*4 + *4/*4 + *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .			= 0.033				
1450809654	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*1 + *1/*2 + *1/*3 are not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*2	*3		OR			
1449171337	CYP2D6*1, CYP2D6*10	celecoxib	Metabolism/PK	no	CYP2D6 *1/*10 + *10/*10 are not associated with decreased metabolism of celecoxib in healthy individuals as compared to CYP2D6 *1/*1.			= 0.233	OR			
1449171352	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.05	OR			
1451153800	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*6	methadone	Dosage,Efficacy	no	CYP2D6 *1/*1xN is associated with increased dose of methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .			= 0.131				
1451153800	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*6	methadone	Dosage,Efficacy	no	CYP2D6 *1/*1xN is associated with increased dose of methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .			= 0.221				
1183623652	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole,pantoprazole	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	*1		= 0.016	Unknown			
1449171382	CYP3A7*1A, CYP3A7*1C	tacrolimus	Metabolism/PK	yes	CYP3A7 *1A/*1A is associated with decreased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A7 *1A/*1C + *1C/*1C.	*1C		< 0.05	OR			
1450809796	CYP2A6*1A, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*12	cotinine,nicotine	Metabolism/PK	yes	CYP2A6 *2 + *4A + *9 + *12 are associated with decreased clearance of cotinine and nicotine in healthy individuals as compared to CYP2A6 *1A.			< 0.01				
1444698157	CYP2B6*1, CYP2B6*6	ketamine	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased clearance of ketamine in people with Neoplasms and Pain as compared to CYP2B6 *1.	*1	*6	< 0.001	OR			
1444698157	CYP2B6*1, CYP2B6*6	ketamine	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased clearance of ketamine in people with Neoplasms and Pain as compared to CYP2B6 *1.	*1	*6	< 0.001	OR			
1447991368	CYP2D6*1, CYP2D6*10	debrisoquine	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1183623663	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole,pantoprazole	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.016	Unknown			
1183623774	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole,lansoprazole,omeprazole,pantoprazole,rabeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.002	OR	1.73	1.23	2.44
1183623786	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole,lansoprazole,omeprazole,pantoprazole,rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.0001	OR	2.0	1.47	2.71
1183623748	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.0005	Unknown			
1183623748	CYP2C19*1, CYP2C19*2, CYP2C19*3	esomeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1448417273	CYP1A2*1A, CYP1A2*1F	clomipramine	Efficacy	not stated	CYP1A2 *1A/*1F is associated with decreased response to clomipramine in women with Depression.				OR			
1448417266	CYP3A5*1, CYP3A5*3	clomipramine	Efficacy	not stated	CYP3A5 *1/*3 is associated with decreased response to clomipramine in women with Depression.				OR			
981565071	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in men with Granulomatous Disease, Chronic.				Unknown			
1448417245	CYP2C19*1, CYP2C19*17	clomipramine	Efficacy	not stated	CYP2C19 *1/*17 is associated with decreased response to clomipramine in women with Depression.				OR			
1183623820	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.160	OR	1.62	0.82	3.2
1183623810	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.04	OR	1.95	1.03	3.7
1183623852	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.			= 0.0001	OR	3.22	1.91	5.42
1183623865	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 is not associated with response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.420	OR	1.43	0.6	3.43
1183689399	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*3	< 0.03	OR			
1444697908	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41	endoxifen	Metabolism/PK	not stated	CYP2D6 *1/*1 + *2/*2 + *1/*2 (assigned as normal metabolizers phenotype) is associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *3/*41 + *4/*9 + *4/*10 + *4/*41 + *3/*4 + *4/*4.			< 0.0001	OR			
1183689468	UGT2B15*1, UGT2B15*2	sipoglitazar	Metabolism/PK	yes	UGT2B15 *2 is associated with decreased clearance of sipoglitazar in healthy individuals as compared to UGT2B15 *1.	*2		< 0.0001	OR			
1447991084	CYP2C19*1, CYP2C19*2, CYP2C19*3	brivaracetam	Metabolism/PK	not stated	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of brivaracetam in healthy individuals as compared to CYP2C19 *1/*1.				OR			
1183624077	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with increased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.011	HR	0.19	0.05	0.69
1183624062	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	*1		= 0.021	HR	0.4	0.19	0.87
1185000272	UGT1A6*1a, UGT1A6*2a	acetaminophen	Metabolism/PK	yes	UGT1A6 *2a is associated with increased clearance of acetaminophen in people with beta-Thalassemia as compared to UGT1A6 *1a.			< 0.05	OR			
1185000284	UGT1A1*1, UGT1A1*28	acetaminophen	Metabolism/PK	no	UGT1A1 *28 is not associated with metabolism of acetaminophen in healthy individuals as compared to UGT1A1 *1.			> 0.05	OR			
1449188274	CYP2C9*1, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.			< 0.0001	OR	0.12	0.014	0.05
1185000439	UGT1A6*1a, UGT1A6*2a	acetaminophen	Metabolism/PK	yes	UGT1A6 *2a/*2a + *1a/*2a is associated with increased metabolism of acetaminophen in healthy individuals as compared to UGT1A6 *1a.			= 0.02	OR			
1185000474	UGT2B15*1, UGT2B15*2	acetaminophen	Metabolism/PK	yes	UGT2B15 *2 is associated with decreased metabolism of acetaminophen in healthy individuals as compared to UGT2B15 *1.			< 0.0001	OR			
1183624234	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	*10		= 0.028	Unknown			
1184754650	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	not stated	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.				OR			
1447990832	CYP2D6*1, CYP2D6*2, CYP2D6*17	debrisoquine	Metabolism/PK	yes	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17.			< 0.001	OR			
1447990816	CYP2D6*1, CYP2D6*2, CYP2D6*17	debrisoquine	Metabolism/PK	yes	CYP2D6 *1/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.001	OR			
1449172013	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.000	OR			
1448285727	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.05	OR			
1183689806	CYP2D6*1, CYP2D6*3, CYP2D6*4	tolterodine	Metabolism/PK	yes	CYP2D6 *3 + *4 are associated with decreased metabolism of tolterodine in women as compared to CYP2D6 *1/*1.			< 0.02	OR			
1447990805	CYP2D6*1, CYP2D6*2	debrisoquine	Metabolism/PK	no	CYP2D6 *1/*2 is not associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.			> 0.7	OR			
1183624260	CYP2D6*1xN, CYP2D6*2xN	citalopram,mianserin,mirtazapine,nortriptyline,paroxetine,venlafaxine	Efficacy	yes	CYP2D6 *1xN + *2xN are associated with decreased response to citalopram, mianserin, mirtazapine, nortriptyline, paroxetine or venlafaxine in people with Mood Disorders.			= 0.026	Unknown			
1447990776	CYP2D6*1, CYP2D6*4, CYP2D6*10	sparteine	Metabolism/PK	not stated	CYP2D6 *10/*10 + *4/*10 are associated with decreased metabolism of sparteine as compared to CYP2D6 *1/*1.				OR			
1449172092	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of tacrolimus in people with Autoimmune Diseases as compared to CYP3A5 *3/*3.				OR			
1183624311	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 is associated with decreased clearance of rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1448285615	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.001	OR			
1447990710	CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	debrisoquine	Metabolism/PK	not stated	CYP2D6 *3/*3 + *4/*4 + *4/*5 + *4/*6 are associated with decreased metabolism of debrisoquine in healthy individuals.				OR			
1449565369	CYP2C9*1, CYP2C9*3	phenytoin	Dosage,Metabolism/PK	no	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in children.				OR			
1448285601	SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T	fluoxetine	Efficacy	no	SLC6A4 L allele-rs25531T/L allele-rs25531T is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531T + L allele-rs25531C/L allele-rs25531T.	HTTLPR long form (L allele)		= 0.0818	OR	3.5	0.91	13.43
1448285579	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluoxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	HTTLPR long form (L allele)		= 0.0066	OR	4.0	1.45	11.03
1183771932	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	not stated	CYP2B6 *1/*6 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.				OR			
1449172248	CYP3A5*1, CYP3A5*3	tacrolimus	Efficacy	no	CYP3A5 *1/*1 + *1/*3 is not associated with response to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.				OR			
1449172236	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in people with Autoimmune Diseases as compared to CYP3A5 *3/*3.			= 0.698	OR			
1183690079	CYP2C9*1, CYP2C9*3	warfarin	Efficacy	yes	CYP2C9 *1/*3 is associated with increased response to warfarin as compared to CYP2C9 *1/*1.	*3	*3	< 0.028	OR			
1450417472	CYP2D6*1, CYP2D6*10	propafenone	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased metabolism of propafenone in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.			= 0.05	OR			
1450417453	CYP2D6*1, CYP2D6*2	pioglitazone	Metabolism/PK	no	CYP2D6 *1/*2 + *2/*2 are not associated with metabolism of pioglitazone in healthy individuals as compared to CYP2D6 *1/*1.			= 0.07	OR			
1183690032	CYP3A5*1, CYP3A5*6	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*6 is associated with increased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *6/*6.			= 3.0E-4	OR			
1183690042	CYP3A5*1, CYP3A5*7	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*7 is associated with increased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *7/*7.			= 3.0E-4	OR			
1448269030	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *1/*3.	*3		< 0.0001	OR			
1450253685	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *2 + *3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.			< 0.0001	OR	1.34	1.2	1.5
1450253685	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *2 + *3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.			= 0.0029	OR	1.42	1.13	1.79
1448268948	CYP2C9*2, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *2 + *3 is associated with dose of warfarin in people with Atrial Fibrillation and venous thromboembolism.				OR			
1447679078	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 *1.			> 0.05	OR			
1447679078	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 *1.			> 0.05	OR			
1447679078	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 *1.			> 0.05	OR			
1447679054	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1447679054	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1447679054	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1447990337	CYP2D6*3, CYP2D6*4	debrisoquine,sparteine	Metabolism/PK	not stated	CYP2D6 *4/*4 + *3/*4 are associated with decreased metabolism of debrisoquine or sparteine.				OR			
1448612933	CYP2C19*1, CYP2C19*2	phenytoin	Toxicity	no	CYP2C19 *1/*2 is not associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C19 *1/*1.			= 0.33	OR	1.67	0.89	3.14
1444713552	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *1/*2 + *1/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*17	= 0.01	OR			
1448612922	CYP2C9*1, CYP2C9*3	phenytoin	Toxicity	yes	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	*3		= 0.002	OR	3.36	1.61	7.01
1444713578	SLCO1B1*1, SLCO1B1*5, SLCO1B1*15	lovastatin acid	Metabolism/PK	yes	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.			< 0.005	OR			
1444828163	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole.				OR			
1449565832	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenytoin	Metabolism/PK	yes	CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.	*3		= 0.009	OR			
1444828093	CYP2C9*1, CYP2C9*3	flurbiprofen	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with increased concentrations of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.			= 0.0002	OR			
1447678931	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17	ambrisentan	Metabolism/PK	yes	CYP2C19 *2 + *3 + *4 are associated with decreased clearance of ambrisentan in healthy individuals as compared to CYP2C19 *1 + *17.			< 0.01	OR			
1444828107	CYP2C9*1, CYP2C9*3	flurbiprofen	Metabolism/PK	yes	CYP2C9 *1/*1 is associated with increased clearance of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*3.			< 0.0001	OR			
1449565846	CYP2C9*1, CYP2C9*2	phenytoin	Metabolism/PK	no	CYP2C9 *1/*2 is not associated with concentrations of phenytoin in children with as compared to CYP2C9 *1/*1.	*2		= 0.74	OR			
981858924	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *1/*2 + *1/*3 is not associated with dose of warfarin in children as compared to CYP2C9 *1/*1.			= 0.17	Unknown			
1447678899	CYP2B6*1, CYP2B6*6	cyclophosphamide	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased clearance of cyclophosphamide in children with Lymphoma, B-Cell as compared to CYP2B6 *1/*1.			= 0.0028	OR			
1447678899	CYP2B6*1, CYP2B6*6	cyclophosphamide	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased clearance of cyclophosphamide in children with Lymphoma, B-Cell as compared to CYP2B6 *1/*1.			= 0.033	OR			
1184509540	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	sertraline	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with posttraumatic stress disorder as compared to SLC6A4 HTTLPR short form (S allele).			< 0.001	OR			
1449565855	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenytoin	Metabolism/PK	no	CYP2C9 *1/*3 + *2/*3 are not associated with dose of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.	*3		= 0.12	OR			
1449565868	CYP2C9*1, CYP2C9*2	phenytoin	Metabolism/PK	no	CYP2C9 *1/*2 is not associated with dose of phenytoin in children with as compared to CYP2C9 *1/*1.	*2		= 0.89	OR			
1184165591	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.	*1		< 0.001	OR			
827783312	CYP2C9*1, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.				Unknown			
1184165572	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	not stated	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of midazolam in people with Gastrointestinal Neoplasms as compared to CYP3A5 *3/*3.				OR			
1451335345	CYP1A2*1A, CYP1A2*1B, CYP1A2*1C, CYP1A2*1F	olanzapine	Metabolism/PK	no	CYP1A2 *1B + *1C + *1F are not associated with exposure to olanzapine in healthy individuals as compared to CYP1A2 *1A.			> 0.05				
1444827950	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	no	CYP2C19 *2/*2 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3.	*2	*3	= 0.062	OR			
1184755389	CYP2D6*5, CYP2D6*7	sparteine	Metabolism/PK	not stated	CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1444827966	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) is associated with increased trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	*2	*3	= 0.043	OR			
1444827984	CYP2C19*1, CYP2C19*2	carisoprodol	Metabolism/PK	yes	CYP2C19 *1/*2 (assigned as intermediate metabolizers phenotype) is associated with increased concentrations of carisoprodol in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05	OR			
1444827984	CYP2C19*1, CYP2C19*2	carisoprodol	Metabolism/PK	yes	CYP2C19 *1/*2 (assigned as intermediate metabolizers phenotype) is associated with increased concentrations of carisoprodol in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05	OR			
1449713428	CYP2C8*1, CYP2C8*3	pioglitazone	Metabolism/PK	yes	CYP2C8 *1/*1 is associated with increased concentrations of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.			= 0.01	OR			
1451335420	CYP3A4*1, CYP3A4*22	olanzapine	Metabolism/PK	no	CYP3A4 *22 is not associated with exposure to olanzapine in healthy individuals as compared to CYP3A4 *1.	*22		> 0.05				
1451335424	CYP3A5*1, CYP3A5*3	olanzapine	Metabolism/PK	no	CYP3A5 *3 is not associated with exposure to olanzapine in healthy individuals as compared to CYP3A5 *1.	*3		> 0.05				
1184755565	CYP2D6*1, CYP2D6*5, CYP2D6*9	debrisoquine	Metabolism/PK	not stated	CYP2D6 *5/*9 (assigned as normal metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.				OR			
1448530690	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.001	OR			
1444827924	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		< 0.01	OR			
1184509852	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.05	OR			
1448104673	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.			= 0.003	OR			
1448104659	CYP2C9*1, CYP2C9*2	warfarin	Dosage	no	CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.			= 0.193	OR			
1448530650	CYP2D6*1, CYP2D6*10	risperidone	Efficacy,Toxicity	no	CYP2D6 *10/*10 is not associated with response to risperidone in people with Schizophrenia as compared to CYP2D6 *1/*1.			> 0.05	OR			
1451335587	UGT1A1*1, UGT1A1*28	olanzapine	Metabolism/PK	no	UGT1A1 *28 is not associated with exposure to olanzapine in healthy individuals as compared to UGT1A1 *1.			> 0.05				
1451138980	CYP2C9*1, CYP2C9*3	dipyrone	Metabolism/PK	no	CYP2C9 *3 is associated with decreased metabolism of dipyrone in healthy individuals as compared to CYP2C9 *1/*1.			= 0.027				
1448530624	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.004	OR			
1448530620	CYP2D6*1, CYP2D6*10	risperidone	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1448530601	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6	risperidone	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 + *4/*6 are associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1445401203	CYP2D6*1, CYP2D6*4, CYP2D6*5	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.			= 0.009	OR			
1445401203	CYP2D6*1, CYP2D6*4, CYP2D6*5	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *4/*4 + *4/*5 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.			= 0.019	OR			
1450942421	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased exposure to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.001				
1451253720	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*2 + *1/*3 are not associated with metabolism of rabeprazole as compared to CYP2C19 *1/*1.							
1451253729	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.							
1450811368	CYP2B6*1, CYP2B6*6	bupropion	Efficacy	yes	CYP2B6 *1/*6 + *6/*6 are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1.	*6		= 0.04	OR	2.97	1.05	8.4
1447989908	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1447989908	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1447989908	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1451253733	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	not stated	CYP2C19 *1/*1 is associated with increased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.							
1451253680	CYP2C19*1, CYP2C19*2	rabeprazole	Metabolism/PK	yes	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05				
1184755725	CYP2D6*4, CYP2D6*12	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1451139000	CYP2C19*1, CYP2C19*2	dipyrone	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of dipyrone in healthy individuals as compared to CYP2C19 *1/*1.			= 0.001				
1448612457	CYP2D6*1, CYP2D6*4	colchicine	Efficacy	not stated	CYP2D6 *1/*1 is associated with increased response to colchicine in people with Familial Mediterranean Fever as compared to CYP2D6 *1/*4.				OR			
1184509880	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluoxetine,sertraline	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).			= 0.004	OR			
982006805	CYP2D6*1xN, CYP2D6*2xN, CYP2D6*5	ondansetron	Efficacy	no	CYP2D6 *1xN + *2xN are not associated with response to ondansetron in women as compared to CYP2D6 *5.	*5		= 0.21	Unknown			
1184509891	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	escitalopram	Efficacy	yes	SLC6A4 HTTLPR short form (S allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	HTTLPR long form (L allele)		= 0.026	OR	6.24	1.24	31.26
1448530511	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41	risperidone	Metabolism/PK	no	CYP2D6 *10/*10 + *10/*41 + *1/*4 + *1/*5 are not associated with metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.			> 0.05	OR			
827700544	CYP2A6*1A, CYP2A6*7	tegafur	Metabolism/PK	yes	CYP2A6 *7/*7 is associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1A/*1A.	*7		= 3.33E-5	Unknown			
827700542	CYP2A6*1A, CYP2A6*4A, CYP2A6*7	tegafur	Metabolism/PK	yes	CYP2A6 *4A/*7 is associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1A/*1A.	*4A		= 3.33E-5	Unknown			
827864375	CYP2A6*1A, CYP2A6*2, CYP2A6*4E, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35	letrozole	Metabolism/PK	yes	CYP2A6 *1A/*17 + *20/*23 + *9/*9 + *1A/*4E + *1A/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1A/*9 + *1A/*12 are associated with decreased clearance of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1A/*1A.			< 1.0E-4	Unknown			
827864375	CYP2A6*1A, CYP2A6*2, CYP2A6*4E, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35	letrozole	Metabolism/PK	yes	CYP2A6 *1A/*17 + *20/*23 + *9/*9 + *1A/*4E + *1A/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1A/*9 + *1A/*12 are associated with decreased clearance of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1A/*1A.			< 1.0E-4				
1451237374	GSTM1 non-null, GSTM1 null	azathioprine	Efficacy	yes	GSTM1 null is associated with decreased clinical benefit to azathioprine in children with Colitis, Ulcerative or Crohn Disease as compared to GSTM1 non-null.			= 0.0031				
1448530486	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10	risperidone	Metabolism/PK	yes	CYP2D6 *4/*10 + *5/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.			< 0.05	OR			
1446908451	UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28	nilotinib	Dosage	yes	UGT1A1 *6/*6 + *6/*28 is associated with decreased dose of nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to UGT1A1 *1/*1 + *1/*6 + *1/*28 + *27/*28.	*6	*28	= 0.002	HR	7.52	2.07	27.3
1450811499	CYP2B6*1, CYP2B6*6	cotinine,nicotine	Metabolism/PK	yes	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.			< 0.004				
1450811499	CYP2B6*1, CYP2B6*6	cotinine,nicotine	Metabolism/PK	yes	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.			< 0.011				
1450811499	CYP2B6*1, CYP2B6*6	cotinine,nicotine	Metabolism/PK	yes	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.	*6		< 0.022				
1450811499	CYP2B6*1, CYP2B6*6	cotinine,nicotine	Metabolism/PK	yes	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.	*6		< 0.039				
1450811499	CYP2B6*1, CYP2B6*6	cotinine,nicotine	Metabolism/PK	yes	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.			> 0.05				
1450811499	CYP2B6*1, CYP2B6*6	cotinine,nicotine	Metabolism/PK	yes	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.			> 0.05				
1184510108	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1184755882	CYP2D6*5, CYP2D6*13	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *5/*13 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.				OR			
1448104418	CYP2B6*1, CYP2B6*6	methadone	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1.	*6		< 0.001	OR			
1445401015	CYP2D6*1, CYP2D6*4	endoxifen	Metabolism/PK	not stated	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizers phenotype) .				OR			
1448612320	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.05	OR			
1445401027	CYP2C9*1, CYP2C9*2, CYP2C9*3	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2C9 *2 + *3 (assigned as poor metabolizers phenotype) are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) .			= 0.0006	OR			
1445401027	CYP2C9*1, CYP2C9*2, CYP2C9*3	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2C9 *2 + *3 (assigned as poor metabolizers phenotype) are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) .			= 0.0032	OR			
1448530382	CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41	risperidone	Metabolism/PK	yes	CYP2D6 *5/*10 + *4/*10 + *10/*10 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .			< 0.001	OR			
1451237580	TPMT*1, TPMT*2, TPMT*3A, TPMT*3C	azathioprine	Dosage	no	TPMT *1/*2 + *1/*3A + *1/*3C + *3A/*3A is associated with decreased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.							
1447711105	GSTM1 non-null, GSTM1 null	paclitaxel,Platinum compounds	Efficacy	yes	GSTM1 non-null is associated with decreased response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTM1 null.			= 0.001	OR			
1447711105	GSTM1 non-null, GSTM1 null	paclitaxel,Platinum compounds	Efficacy	yes	GSTM1 non-null is associated with decreased response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTM1 null.			= 0.013	OR			
1447711105	GSTM1 non-null, GSTM1 null	paclitaxel,Platinum compounds	Efficacy	yes	GSTM1 non-null is associated with decreased response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTM1 null.			= 0.039	HR	2.29	1.04	5.03
1184510232	CYP2C9*1, CYP2C9*3, CYP2C9*13	warfarin	Dosage	not stated	CYP2C9 *3/*13 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1444712755	CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41	paroxetine	Metabolism/PK	yes	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .			= 0.001	OR			
1446908239	CYP2C19*1, CYP2C19*17	citalopram	Metabolism/PK	no	CYP2C19 *1/*17 is not associated with metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			> 0.05	OR			
1184166178	GSTM1 non-null, GSTM1 null	bleomycin,dacarbazine,doxorubicin,vinblastine	Efficacy	yes	GSTM1 non-null/non-null is associated with increased response to bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTM1 non-null/null + null/null.			= 0.05	HR	3.7	1.0	13.0
1449271538	CYP3A5*1, CYP3A5*3	methadone	Metabolism/PK	not stated	CYP3A5 *1/*3 is associated with decreased concentrations of methadone.				OR			
1449713930	CYP3A5*1, CYP3A5*3	norfentanyl	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with concentrations of norfentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	*3			OR			
1448104272	CYP2A6*1A, CYP2A6*2	nicotine	Dosage	yes	CYP2A6 *1A/*2 + *2/*2 is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to CYP2A6 *1A/*1A.			= 0.02	OR			
1448268118	CYP2C9*2, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *2 + *3 are associated with dose of warfarin.	*1			OR			
1449271568	CYP3A5*1, CYP3A5*3	S-EDDP	Metabolism/PK	not stated	CYP3A5 *1/*3 is associated with increased concentrations of (S)-EDDP.				OR			
1446908220	CYP2C19*1, CYP2C19*2	citalopram	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.			< 0.05	OR			
1448255771	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*3 + *3/*3 are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	*1		< 0.05	OR			
1446895857	CYP2C19*1, CYP2C19*2	escitalopram	Dosage	no	CYP2C19 *1/*2 + *2/*2 are not associated with dose of escitalopram in people with Autistic Disorder as compared to CYP2C19 *1/*1.			= 0.26	OR			
1450807702	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	not stated	CYP2C19 *2/*3 + *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.				OR			
1446895835	CYP2C19*1, CYP2C19*2	escitalopram	Efficacy	no	CYP2C19 *1/*2 + *2/*2 are not associated with response to escitalopram in people with Autistic Disorder as compared to CYP2C19 *1/*1.			> 0.18	OR			
1446895835	CYP2C19*1, CYP2C19*2	escitalopram	Efficacy	no	CYP2C19 *1/*2 + *2/*2 are not associated with response to escitalopram in people with Autistic Disorder as compared to CYP2C19 *1/*1.			= 0.39	OR			
1448255703	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	no	CYP2C9 *2 + *3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.			= 0.8	OR			
1183621485	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	trimipramine	Metabolism/PK	yes	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	Unknown			
1183621496	CYP2C19*1, CYP2C19*2, CYP2C19*17	pantoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*17 + *17/*17 + *2/*17.	*17		= 0.584	OR	2.7	0.77	3.75
1447944355	CYP2B6*1, CYP2B6*4, CYP2B6*6	methadone	Metabolism/PK	yes	CYP2B6 *1/*4 + *4/*6 is associated with increased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.			< 0.05	OR			
1450807761	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	= 0.0394	OR			
1450807761	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	= 0.9496	OR			
1450807773	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	= 0.0001	OR			
1450807773	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	= 0.0362	OR			
1450824161	CYP2A6*1A, CYP2A6*2, CYP2A6*9	nicotine	Metabolism/PK	not stated	CYP2A6 *1A/*2 + *1A/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.							
1450807784	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*2	*3	= 0.028	OR			
1450807784	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*2	*3	= 0.0314	OR			
1447944325	CYP2B6*1, CYP2B6*6	methadone	Metabolism/PK	yes	CYP2B6 *1/*6 + *6/*6 is associated with decreased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.			< 0.05	OR			
1183621560	CYP2C19*1, CYP2C19*2	trimipramine	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.			= 0.01	Unknown			
1183621560	CYP2C19*1, CYP2C19*2	trimipramine	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.			= 0.012	OR			
1183621560	CYP2C19*1, CYP2C19*2	trimipramine	Metabolism/PK	yes	CYP2C19 *2 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.			= 0.058	OR			
1447944241	CYP3A4*1, CYP3A4*22	endoxifen	Metabolism/PK	no	CYP3A4 *22 is associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.	*22		< 0.357	OR			
1184997863	UGT1A1*1, UGT1A1*28	raltegravir	Metabolism/PK	no	UGT1A1 *28 is not associated with concentrations of raltegravir in people with HIV as compared to UGT1A1 *1.				OR			
1448255545	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to CYP2C9 *1/*1.			= 0.008	OR			
1447944228	CYP3A4*1, CYP3A4*22	4-hydroxytamoxifen	Metabolism/PK	yes	CYP3A4 *22 is associated with increased concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.	*22		< 0.05	OR			
1447944217	CYP3A4*1, CYP3A4*22	tamoxifen	Metabolism/PK	yes	CYP3A4 *22 is associated with increased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.	*22		< 0.05	OR			
1450807854	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3.	*2	*3	< 0.0001	OR			
1450807854	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3.	*2	*3	< 0.0001	OR			
1450807854	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3.	*2	*3	= 0.0298	OR			
1447944162	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*3	= 0.153	OR			
1445584831	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in children as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .				OR			
1184473659	CYP2C9*1, CYP2C9*14	warfarin	Dosage	not stated	CYP2C9 *1/*14 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1447944149	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*3	= 0.039	OR			
1447944137	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*3 + *2/*3.	*2	*3	= 0.046	OR			
1448615861	CYP2D6*1, CYP2D6*10	hydroxyamitriptyline	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased concentrations of hydroxyamitriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.			= 0.002	OR			
1448615842	CYP2C19*1, CYP2C19*2, CYP2C19*3	amitriptyline	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased exposure to amitriptyline in healthy individuals as compared to CYP2C19 *1/*1.			= 0.0003	OR			
1447223182	CYP2C9*1, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.675	OR			
1447223171	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.01	OR			
1447944033	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2.	*2	*3	> 0.05	OR			
1183622039	CYP2C19*1, CYP2C19*2	mephenytoin	Metabolism/PK	not stated	CYP2C19 *1/*2 is associated with increased metabolism of mephenytoin in healthy individuals.				Unknown			
1447681725	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10	risperidone	Metabolism/PK	no	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *4/*10 + *5/*10.			= 0.055	OR			
1447681711	CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*41	risperidone	Metabolism/PK	no	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*5 + *10/*10 + *10/*41.			= 0.08	OR			
1447681693	CYP2D6*1, CYP2D6*10, CYP2D6*41	risperidone	Metabolism/PK	no	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*10 + *1/*41.			= 0.67	OR			
1447943838	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41	atomoxetine	Metabolism/PK	yes	CYP2D6 *4/*4xN + *4/*4 are associated with decreased clearance of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29.			< 0.05	OR			
1184654356	CYP2C9*1, CYP2C9*3	warfarin	Dosage,Efficacy	yes	CYP2C9 *3/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.				OR			
1184654374	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage,Efficacy	not stated	CYP2C9 *2/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.				OR			
1447943783	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41	atomoxetine	Metabolism/PK	yes	CYP2D6 *4/*4xN + *4/*4 are associated with increased concentrations of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29 + *5/*17 + *4/*9.			< 0.0001	OR			
1447943783	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41	atomoxetine	Metabolism/PK	yes	CYP2D6 *4/*4xN + *4/*4 are associated with increased concentrations of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29 + *5/*17 + *4/*9.			< 0.0001	OR			
1447943783	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41	atomoxetine	Metabolism/PK	yes	CYP2D6 *4/*4xN + *4/*4 are associated with increased concentrations of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29 + *5/*17 + *4/*9.			< 0.0001	OR			
1183491069	CYP2C9*1, CYP2C9*30	losartan	Efficacy	no	CYP2C9 *1/*30 is associated with decreased response to losartan in people with Hypertension as compared to CYP2C9 *1/*1.	*30			Unknown			
1183491076	CYP2C9*1, CYP2C9*33	losartan	Efficacy	no	CYP2C9 *1/*33 is associated with increased response to losartan in people with Hypertension.	*33			Unknown			
1183622207	CYP2C19*1, CYP2C19*3	mephenytoin	Metabolism/PK	not stated	CYP2C19 *3/*3 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.				Unknown			
1183622217	CYP2C19*1, CYP2C19*2, CYP2C19*5	mephenytoin	Metabolism/PK	not stated	CYP2C19 *2/*5 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.				Unknown			
1184998561	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	atazanavir	Metabolism/PK	yes	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.			= 0.017	OR			
1184998561	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	atazanavir	Metabolism/PK	yes	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.			= 0.15	OR			
1184998561	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	atazanavir	Metabolism/PK	yes	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.			= 0.75	OR			
1183622300	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*2 + *1/*3 is not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	*1		= 0.05	Unknown			
1183622310	CYP2C19*1, CYP2C19*2	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	*1		= 0.05	Unknown			
1184654392	CYP2C9*1, CYP2C9*3	warfarin	Dosage,Efficacy	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.				OR			
1183622290	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1184654401	CYP2C9*1, CYP2C9*2	warfarin	Dosage,Efficacy	yes	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.				OR			
1445125604	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus as compared to CYP3A5 *1/*1 + *1/*3.	*1		= 0.01	OR			
1183622261	CYP2C19*1, CYP2C19*2	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	*1		= 0.05	Unknown			
1448123818	CYP2C19*1, CYP2C19*2, CYP2C19*3	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3 are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2	*3	= 0.859	OR			
1450808537	CYP2C19*1, CYP2C19*2	omeprazole	Metabolism/PK	yes	CYP2C19 *2/*2 are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	*2		< 0.05	OR			
1183622336	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *1/*2 + *1/*3 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	*1		= 0.05	Unknown			
1183622346	CYP2C19*1, CYP2C19*2, CYP2C19*6	mephenytoin	Metabolism/PK	not stated	CYP2C19 *2/*6 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.				Unknown			
1444699553	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.			= 0.000	OR			
1444699553	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.			= 0.000	OR			
1451250880	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.			= 0.004				
1451250880	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.048	OR			
1451250880	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.049	OR			
1451250880	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.267	OR			
1451250880	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.335	OR			
1451250880	CYP3A4*1, CYP3A4*22	tacrolimus	Metabolism/PK	no	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	*22		= 0.490	OR			
1183622435	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622435	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622435	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622435	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622435	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622435	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1450415351	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3.			= 0.014	OR			
1450415351	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3.			= 0.12	OR			
1450808617	CYP2C19*1, CYP2C19*2, CYP2C19*3	pantoprazole	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*2	*3	< 0.05	OR			
1183622397	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.009	Unknown			
1183622397	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.012	Unknown			
1183622397	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.028	Unknown			
1183622397	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622397	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183622397	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1450808566	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 are associated with increased response to omeprazole in people with Esophagitis and Gastroesophageal Reflux as compared to CYP2C19 *1/*1.			< 0.05	OR			
1183622382	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.009	Unknown			
1183622382	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.012	Unknown			
1183622382	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.037	Unknown			
1183622382	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622382	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622382	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1448123702	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with clearance of voriconazole in people with hematopoietic stem cell transplantation as compared to CYP2C19 *1/*1.	*2		> 0.05	OR			
1450415520	CYP2C19*1, CYP2C19*2	thalidomide	Dosage	yes	CYP2C19 *2 is associated with increased dose of thalidomide in people with Erythema Nodosum and Leprosy as compared to CYP2C19 *1/*1.			= 0.01	OR			
1450939860	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to CYP2C9 *1/*1.			= 0.006				
1449170380	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		< 0.001	OR			
1447681119	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.0002	OR			
1447681119	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.002	OR			
1447681119	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.0042	OR			
1447681119	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.007	OR			
1447681119	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.026	OR			
1447681119	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.047	OR			
1451152920	CYP2D6*1, CYP2D6*4	dihydrocodeine	Metabolism/PK	not stated	CYP2D6 *4/*4 is associated with decreased metabolism of dihydrocodeine as compared to CYP2D6 *1/*1 + *1/*4.							
1451120160	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001				
1183622669	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622669	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622669	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622669	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622669	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622669	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine,omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1449170428	CYP3A5*1, CYP3A5*3, CYP3A5*6	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.	*1		= 0.04	OR			
1447681077	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.017	OR			
1447681077	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.023	OR			
1447681077	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.047	OR			
1183704662	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	*1	*3	= 0.00	OR			
1183704662	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	*1	*3	< 0.001	OR			
1447681020	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 2.44E-6	OR			
1447681020	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.00018	OR			
1183622726	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.006	Unknown			
1183622726	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.13	Unknown			
1183622726	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.32	Unknown			
1183622712	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.001	Unknown			
1183622712	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.003	Unknown			
1183622712	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.048	Unknown			
1183622820	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.05	Unknown			
1450186374	SLCO1B1*5, SLCO1B1*15	paclitaxel	Metabolism/PK	yes	SLCO1B1 *5 + *15 is associated with increased exposure to paclitaxel in women with Breast Neoplasms.			= 0.012	OR			
1183622809	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.01	Unknown			
1183622781	CYP2C19*1, CYP2C19*2, CYP2C19*3	imipramine	Metabolism/PK	yes	CYP2C19 *2/*3 + *2/*2 are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	*3	*2	< 0.01	Unknown			
1183622774	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	no	CYP2D6 *10/*10 is not associated with decreased metabolism of haloperidol as compared to CYP2D6 *1/*1 + *1/*10.	*10			Unknown			
1444666225	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.			< 0.001	OR			
1183622885	CYP2C19*1, CYP2C19*2, CYP2C19*3	pantoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.023	Unknown			
1183622885	CYP2C19*1, CYP2C19*2, CYP2C19*3	pantoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183622953	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.048	Unknown			
1183622935	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.037	Unknown			
1183622896	CYP2C19*1, CYP2C19*2, CYP2C19*3	pantoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.026	Unknown			
1183622896	CYP2C19*1, CYP2C19*2, CYP2C19*3	pantoprazole	Efficacy	yes	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1447680794	CYP2C19*1, CYP2C19*17	voriconazole	Dosage	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased dose of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 4.3E-11	OR			
1447680794	CYP2C19*1, CYP2C19*17	voriconazole	Dosage	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased dose of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.00074	OR			
1447680776	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 9.2E-5	OR			
1447680776	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		< 0.01	OR			
1447680776	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2		= 0.484	OR			
1184819093	CYP2D6*4, CYP2D6*69	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*69 is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1447680755	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.00031	OR			
1447680755	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		< 0.01	OR			
1447680755	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*17		= 0.082	OR			
1183622965	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.164	Unknown			
1450809160	CYP2C9*1, CYP2C9*2, CYP2C9*3	tolbutamide	Metabolism/PK	yes	CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1.			< 0.05				
1449564017	CYP2B6*1, CYP2B6*6	bupropion	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.			< 0.05	OR			
1444698809	CYP3A5*1, CYP3A5*3	everolimus	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with dose-adjusted trough concentrations of everolimus in people with lung transplantation as compared to CYP3A5 *3/*3.	*1		= 0.5	OR			
1449564030	CYP2B6*1, CYP2B6*4, CYP2B6*6	bupropion	Metabolism/PK	yes	CYP2B6 *1/*4 + *4/*6 are associated with increased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.			> 0.05	OR			
1448123039	CYP2C9*1, CYP2C9*3, CYP2C9*13	zafirlukast	Metabolism/PK	yes	CYP2C9 *1/*3 + *1/*13 are associated with increased exposure to zafirlukast in healthy individuals as compared to CYP2C9 *1/*1.			< 0.0001	OR			
1451136980	CYP2C19*1, CYP2C19*2, CYP2C19*3	dexlansoprazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 are associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.			< 0.05				
1448123026	CYP2C9*1, CYP2C9*3, CYP2C9*13	zafirlukast	Metabolism/PK	yes	CYP2C9 *1/*3 + *1/*13 are associated with decreased clearance of zafirlukast in healthy individuals as compared to CYP2C9 *1/*1.			< 0.001	OR			
1184753704	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	not stated	CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased concentrations of voriconazole in men with Hepatitis C, Lymphoma and Shock, Septic.				OR			
981201935	CYP2A6*1A, CYP2A6*4A	nicotine	Other,Metabolism/PK	no	CYP2A6 *4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.				Unknown			
1444698677	CYP2C19*1, CYP2C19*2	nelfinavir	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with decreased metabolism of nelfinavir in people with as compared to CYP2C19 *1/*1.			< 0.05	OR			
1451350020	CYP2B6*1, CYP2B6*6	hydroxybupropion	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with decreased concentrations of hydroxybupropion as compared to CYP2B6 *1/*1 + *1/*6.			= 0.003				
1183623160	CYP2C19*1, CYP2C19*2	amitriptyline	Toxicity,Metabolism/PK	not stated	CYP2C19 *2/*2 + *1/*2 is associated with decreased metabolism of amitriptyline in postmortem toxicology cases as compared to CYP2C19 *1/*1.			= 0.013	Unknown			
1183623160	CYP2C19*1, CYP2C19*2	amitriptyline	Toxicity,Metabolism/PK	not stated	CYP2C19 *2/*2 + *1/*2 is associated with decreased metabolism of amitriptyline in postmortem toxicology cases as compared to CYP2C19 *1/*1.			= 0.055	OR			
1444698605	CYP2C19*1, CYP2C19*2	nelfinavir	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with increased concentrations of nelfinavir in people with Pancreatic Neoplasms as compared to CYP2C19 *1/*1.			< 0.05	OR			
1447680551	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 2.05e-30	OR			
1447680533	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1445403153	CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22	bupropion	Metabolism/PK	yes	CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.			= 0.027	OR			
1445403174	CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22	bupropion	Metabolism/PK	yes	CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.			= 0.001	OR			
1445403174	CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22	bupropion	Metabolism/PK	yes	CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.			= 0.01	OR			
981201993	CYP2A6*1A, CYP2A6*4A	nicotine	Other,Metabolism/PK	yes	CYP2A6 *4A/*4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.			< 0.02	Unknown			
1183623301	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	no	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1448122820	CYP2C19*1, CYP2C19*2, CYP2C19*3	warfarin	Dosage	yes	CYP2C19 *1/*2 + *1/*3 are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *2/*2 + *2/*3.			< 0.05	OR			
1183623395	CYP2C19*1, CYP2C19*2	lansoprazole,omeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.141	Unknown			
1183623395	CYP2C19*1, CYP2C19*2	lansoprazole,omeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.282	Unknown			
1450809558	CYP2C9*1, CYP2C9*2	tolbutamide	Metabolism/PK	no	CYP2C9 *1/*2 + *2/*2 are not associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1.			> 0.05				
1450809573	CYP2C9*1, CYP2C9*2, CYP2C9*3	tolbutamide	Efficacy	no	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 + *3/*3 are not associated with response to tolbutamide in healthy individuals as compared to CYP2C9 *1/*1.							
1448122772	CYP2C19*1, CYP2C19*2, CYP2C19*3	warfarin	Dosage	yes	CYP2C19 *1/*1 is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.			< 0.05	OR			
1183688895	CYP2D6*1, CYP2D6*2, CYP2D6*10	atomoxetine	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10.			= 0.001	OR			
1449171185	CYP3A5*1, CYP3A5*3, CYP3A5*6	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.	*1		< 0.01	OR			
1450809629	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Metabolism/PK	yes	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*2	*3	< 0.05	OR			
1183623444	CYP2C19*1, CYP2C19*2	lansoprazole,omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.289	Unknown			
1183623444	CYP2C19*1, CYP2C19*2	lansoprazole,omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.532	Unknown			
1183623444	CYP2C19*1, CYP2C19*2	lansoprazole,omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.602	Unknown			
1183623444	CYP2C19*1, CYP2C19*2	lansoprazole,omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.627	Unknown			
1183623411	CYP2C19*1, CYP2C19*17	omeprazole,pantoprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.314	Unknown			
1183623411	CYP2C19*1, CYP2C19*17	omeprazole,pantoprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.365	Unknown			
1183623411	CYP2C19*1, CYP2C19*17	omeprazole,pantoprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.374	Unknown			
1183623411	CYP2C19*1, CYP2C19*17	omeprazole,pantoprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.465	Unknown			
1450809604	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Metabolism/PK	yes	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*2	*3	< 0.01	OR			
1447952622	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1451134841	CYP3A4*1, CYP3A4*36	oxycodone	Dosage	no	CYP3A4 *36 is not associated with dose of oxycodone in people with Pain, Postoperative as compared to CYP3A4 *1.	*36		> 0.05				
1447681848	CYP2C9*1, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	*3		= 0.03	OR			
1448994001	CYP2B6*1, CYP2B6*18	efavirenz	Metabolism/PK	yes	CYP2B6 *18 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.0045	OR			
1449157006	CYP2B6*1, CYP2B6*2	efavirenz	Metabolism/PK	no	CYP2B6 *2 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			> 0.05	OR			
827807187	CYP2C9*1, CYP2C9*2, CYP2C9*3	carvedilol	Other,Metabolism/PK	no	CYP2C9 *2/*3 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
827807184	CYP2C9*1, CYP2C9*3	carvedilol	Other,Metabolism/PK	no	CYP2C9 *1/*3 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
827807179	CYP2C9*1, CYP2C9*2	carvedilol	Other,Metabolism/PK	no	CYP2C9 *2/*2 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
827806085	CYP3A7*1A, CYP3A7*1C	cortisone acetate	Dosage	yes	CYP3A7 *1C is associated with decreased dose of cortisone acetate in children with Adrenal Hyperplasia, Congenital as compared to CYP3A7 *1A.	*1C	*1C	= 0.001	Unknown			
827700537	CYP2A6*1A, CYP2A6*4A	tegafur	Metabolism/PK	yes	CYP2A6 *4A/*4A is associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1A/*1A.	*4A		< 0.05	Unknown			
981202013	CYP2A6*1A, CYP2A6*4A, CYP2A6*7	nicotine	Other,Metabolism/PK	yes	CYP2A6 *4A/*7 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.			< 0.05	Unknown			
981202028	CYP2A6*1A, CYP2A6*4A	coumarin	Other,Metabolism/PK	yes	CYP2A6 *4A/*4A is associated with decreased metabolism of coumarin as compared to CYP2A6 *1A/*1A.			< 0.001	Unknown			
827807118	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6	carvedilol	Other,Metabolism/PK	not stated	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *4/*4.				Unknown			
981501896	CYP3A4*1, CYP3A4*36	simvastatin	Efficacy	no	CYP3A4 *36/*36 is not associated with response to simvastatin in people with Hypercholesterolemia as compared to CYP3A4 *1/*1.				Unknown			
981344990	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	dexmedetomidine	Metabolism/PK	no	CYP2A6 *1A/*4A + *1A/*4A + *9A/*9A are not associated with clearance of dexmedetomidine in ICU patients as compared to CYP2A6 *1A/*1A.				Unknown			
981483998	CYP2C9*1, CYP2C9*3	warfarin	Dosage,Efficacy	yes	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 *1/*1.	*3		< 0.001	Unknown		1.3	1.7
981501607	NAT2*5B, NAT2*6A	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*6A is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501607	NAT2*5B, NAT2*6A	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*6A is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
1043818082	CYP2C9*1, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*3		< 4.0E-4	Unknown			
1134736215	CYP2C9*1, CYP2C9*8	losartan	Metabolism/PK	no	CYP2C9 *1/*8 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*5		= 0.01	Unknown			
1451129584	CYP3A5*1, CYP3A5*3	efavirenz	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with exposure to efavirenz in healthy individuals as compared to CYP3A5 *1/*3.			> 0.05				
1041237161	CYP3A4*1, CYP3A4*36	simvastatin	Efficacy	no	CYP3A4 *1/*1 is not associated with response to simvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*36.			= 0.858	Unknown			
1040863313	CYP3A4*1, CYP3A4*36	atorvastatin	Efficacy	yes	CYP3A4 *1/*1 is associated with decreased response to atorvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*36.			= 0.031	Unknown			
1133417241	CYP2C9*1, CYP2C9*5, CYP2C9*6	losartan	Metabolism/PK	yes	CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*5		= 0.01	Unknown			
982031278	CYP2C19*1, CYP2C19*2	acenocoumarol	Dosage	no	CYP2C19 *1/*2 + *2/*2 is not associated with dose of acenocoumarol as compared to CYP2C19 *1/*1.			= 0.61	Unknown			
982037353	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *1/*3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 *1/*1.			= 0.01	Unknown			
1183618465	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.038	Unknown			
981344548	NAT2*4, NAT2*5B, NAT2*6A, NAT2*7B	isoniazid	Metabolism/PK	yes	NAT2 *6A/*6A + *6A/*7B + *7B/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*5B + *4/*6A + *4/*7B.	*6A		< 0.001	Unknown			
981501514	NAT2*4, NAT2*6A	sulfapyridine	Metabolism/PK	yes	NAT2 *6A is associated with decreased metabolism of sulfapyridine in healthy individuals as compared to NAT2 *4.			< 0.001	Unknown			
981934319	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.				Unknown			
981344716	CYP2C9*1, CYP2C9*3	warfarin	Dosage,Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	*3			Unknown			
1451135060	CYP2D6*1, CYP2D6*10	oxycodone,sufentanil	Dosage	no	CYP2D6 *10 is not associated with dose of oxycodone or sufentanil in people with Pain, Postoperative as compared to CYP2D6 *1.	*10		> 0.05				
1183623462	CYP2D6*1, CYP2D6*2	haloperidol	Metabolism/PK	no	CYP2D6 *2 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	*2			Unknown			
1183679290	CYP2C19*1, CYP2C19*2	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.07	OR			
1183679290	CYP2C19*1, CYP2C19*2	rabeprazole	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.13	OR			
1183681446	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	clopidogrel	Efficacy	yes	CYP2C19 *1/*1 + *1/*17 + *2/*17 + *3/*17 is associated with increased response to clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.			< 0.001	OR			
1183679273	CYP2C19*1, CYP2C19*2	esomeprazole	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with clearance of esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.16	OR			
1183689285	CYP2D6*1, CYP2D6*4	olanzapine	Efficacy	no	CYP2D6 *4 is not associated with response to olanzapine in people with Schizophrenia as compared to CYP2D6 *1.				OR			
982023773	NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6A, NAT2*6C, NAT2*7B	caffeine	Metabolism/PK	not stated	NAT2 *5A/*5B + *5B/*5B + *5B/*5C + *5B/*6A + *5B/*6C + *5B/*7B + *6A/*6A + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of caffeine in men.				Unknown			
1183689318	CYP1A2*1A, CYP1A2*1C	olanzapine	Efficacy	no	CYP1A2 *1C is not associated with response to olanzapine in people with Schizophrenia as compared to CYP1A2 *1A.				OR			
1040387995	CYP3A4*1, CYP3A4*36	atorvastatin	Efficacy	yes	CYP3A4 *1/*1 is associated with decreased response to atorvastatin in people with Hyperlipidemias as compared to CYP3A4 *36/*36.			= 0.0	Unknown			
1183688829	CYP2C19*1, CYP2C19*2, CYP2C19*3	diazepam	Other,Metabolism/PK	yes	CYP2C19 *2 + *3 is associated with decreased metabolism of diazepam as compared to CYP2C19 *1.	*2	*3	< 0.001	OR			
981202038	CYP2A6*1A, CYP2A6*4A, CYP2A6*10	coumarin	Other,Metabolism/PK	no	CYP2A6 *4A/*10 is associated with decreased metabolism of coumarin as compared to CYP2A6 *1A/*1A.				Unknown			
981851608	NAT2*4, NAT2*5A, NAT2*6A, NAT2*6B, NAT2*7A	isoniazid	Metabolism/PK	not stated	NAT2 *5A/*5A + *5A/*6A + *5A/*7A + *6B/*6B + *7A/*7A (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Lupus Erythematosus, Systemic as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	*5			Unknown			
827690709	CYP3A4*1, CYP3A4*18	nifedipine	Metabolism/PK	no	CYP3A4 *18 is not associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.				Unknown			
827700762	CYP2A6*1A, CYP2A6*4A	valproic acid	Metabolism/PK	yes	CYP2A6 *4A is associated with decreased metabolism of valproic acid in people with Epilepsy as compared to CYP2A6 *1A/*1A.	*4A		= 0.0055	Unknown			
827700560	CYP2A6*1A, CYP2A6*7, CYP2A6*9A	tegafur	Metabolism/PK	no	CYP2A6 *7/*9A is not associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1A/*1A.	*9A			Unknown			
827700558	CYP2A6*1A, CYP2A6*9A	tegafur	Metabolism/PK	no	CYP2A6 *9A/*9A is not associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1A/*1A.	*9A			Unknown			
827700554	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	tegafur	Metabolism/PK	no	CYP2A6 *4A/*9A is not associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1A/*1A.	*9A			Unknown			
827705096	CYP2A6*1A, CYP2A6*1B1	nicotine	Metabolism/PK	yes	CYP2A6 *1B1/*1B1 is associated with increased clearance of nicotine as compared to CYP2A6 *1A/*1A.			< 0.05	Unknown			
827698727	CYP2A6*1A, CYP2A6*4A	tegafur	Metabolism/PK	yes	CYP2A6 *4A is associated with decreased metabolism of tegafur.	*4A		= 0.0133	Unknown			
827698978	CYP2A6*1A, CYP2A6*7	nicotine	Metabolism/PK	yes	CYP2A6 *1A/*7 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.	*7		< 0.05	Unknown			
827783868	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.			< 1.0E-4	Unknown			
827783860	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.			< 1.0E-4	Unknown			
827807099	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6	carvedilol	Other,Metabolism/PK	not stated	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *3/*3.				Unknown			
1183689255	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *2 + *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	*2	*3	< 0.022	OR	11.67	1.21	78.83
827807126	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6	carvedilol	Other,Metabolism/PK	not stated	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *6/*6.				Unknown			
827783872	CYP4F2*1, CYP4F2*3	warfarin	Dosage	yes	CYP4F2 *3/*3 is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP4F2 *1/*1.	*3		< 0.0155	Unknown			
827783863	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.			= 1.0E-4	Unknown			
827807176	CYP2C9*1, CYP2C9*2	carvedilol	Other,Metabolism/PK	no	CYP2C9 *1/*2 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
827922780	CYP2C8*1, CYP2C8*3	paclitaxel	Efficacy	yes	CYP2C8 *1/*3 + *3/*3 is associated with increased response to paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1/*1.	*3		= 0.046	OR	3.92	1.46	10.48
827922780	CYP2C8*1, CYP2C8*3	paclitaxel	Efficacy	yes	CYP2C8 *1/*3 + *3/*3 is associated with increased response to paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1/*1.	*3		= 0.049	OR	5.31	1.59	17.67
827807123	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	carvedilol	Other,Metabolism/PK	not stated	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *5/*5.				Unknown			
1447963349	CYP2C19*1, CYP2C19*2	mephenytoin	Metabolism/PK	not stated	CYP2C19 *2/*2 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.				OR			
827812881	CYP2A6*1A, CYP2A6*4A, CYP2A6*9A	caffeine	Other,Metabolism/PK	yes	CYP2A6 *1A/*4A + *1A/*9A + *4A/*4A + *4A/*9A are associated with decreased metabolism of caffeine as compared to CYP2A6 *1A/*1A.			< 0.01	Unknown			
827827685	CYP2A6*1A, CYP2A6*12A	coumarin	Other,Metabolism/PK	not stated	CYP2A6 *12A is associated with decreased metabolism of coumarin as compared to CYP2A6 *1A.	*12A			Unknown			
827827685	CYP2A6*1A, CYP2A6*12A	coumarin	Other,Metabolism/PK	not stated	CYP2A6 *12A is associated with decreased metabolism of coumarin as compared to CYP2A6 *1A.				Unknown			
827925130	CYP2C9*1, CYP2C9*3	warfarin	Dosage,Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 *1/*1.	*3		= 0.001	Unknown			
827922827	CYP2C8*1, CYP2C8*3	cyclophosphamide,doxorubicin	Efficacy	no	CYP2C8 *1/*3 + *3/*3 is not associated with increased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to CYP2C8 *1/*1.			= 0.872	OR	1.14	0.62	15.96
1039730449	CYP3A4*1, CYP3A4*36	atorvastatin	Efficacy	yes	CYP3A4 *36/*36 is associated with increased response to atorvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*36.			= 0.011	Unknown			
1041015512	CYP3A4*1, CYP3A4*36	simvastatin	Efficacy	no	CYP3A4 *36/*36 is not associated with response to simvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*36.			= 0.796	Unknown			
827863698	CYP2C9*1, CYP2C9*2	warfarin	Other,Metabolism/PK	not stated	CYP2C9 *2 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.	*2			Unknown			
827863693	CYP2C9*1, CYP2C9*3	warfarin	Other,Metabolism/PK	not stated	CYP2C9 *3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.	*3			Unknown			
1449716717	CYP3A4*1, CYP3A4*36	sufentanil	Dosage	no	CYP3A4 *1/*36 + *36/*36 is associated with decreased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	*36		< 0.001	OR			
827864335	CYP2A6*1A, CYP2A6*26	letrozole	Metabolism/PK	not stated	CYP2A6 *1A/*26 is associated with metabolism of letrozole in women with Breast Neoplasms.				Unknown			
827864338	CYP2A6*1A, CYP2A6*35A			not stated	CYP2A6 *1A/*35A is associated with metabolism of in women with Breast Neoplasms.				Unknown			
1450823501	CYP2C9*1, CYP2C9*2	fluvastatin	Metabolism/PK	yes	CYP2C9 *2 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.			= 0.00213				
981477848	NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A	sulfamethoxazole	Metabolism/PK	yes	NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased metabolism of sulfamethoxazole in people with Kidney Transplantation as compared to NAT2 *5D/*6B + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) .			= 0.043	Unknown			
981478337	CYP2C9*1, CYP2C9*3	naproxen	Metabolism/PK	no	CYP2C9 *1/*3 is not associated with clearance of naproxen in men with no disease as compared to CYP2C9 *1/*1.				Unknown			
981501603	NAT2*5B, NAT2*5C	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*5C is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501603	NAT2*5B, NAT2*5C	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*5C is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501611	NAT2*5B, NAT2*7B	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*7B is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501611	NAT2*5B, NAT2*7B	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*7B is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501518	NAT2*4, NAT2*5B	sulfapyridine	Metabolism/PK	yes	NAT2 *5B is associated with decreased metabolism of sulfapyridine in healthy individuals as compared to NAT2 *4.			< 0.001	Unknown			
981501499	NAT2*4, NAT2*7B	sulfapyridine	Metabolism/PK	yes	NAT2 *7B is associated with decreased metabolism of sulfapyridine in healthy individuals as compared to NAT2 *4.			< 0.001	Unknown			
981344709	CYP2C9*1, CYP2C9*2	warfarin	Dosage,Metabolism/PK	yes	CYP2C9 *2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	*2			Unknown			
981419341	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased metabolism of efavirenz in human liver microsomes as compared to CYP2B6 *1.			< 0.05	Unknown			
981934332	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	no	CYP2C9 *2 + *3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.				Unknown			
1134807206	CYP2C9*1, CYP2C9*11	losartan	Metabolism/PK	no	CYP2C9 *1/*11 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*5		= 0.01	Unknown			
1134049001	CYP2C9*1, CYP2C9*6	losartan	Metabolism/PK	not stated	CYP2C9 *1/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*5		= 0.01	Unknown			
1043880897	CYP2C9*1, CYP2C9*2	losartan	Metabolism/PK	no	CYP2C9 *1/*2 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*2			Unknown			
1444714172	CYP2C19*1, CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with trough concentration of voriconazole.				OR			
1183490988	CYP2C9*1, CYP2C9*2, CYP2C9*3	losartan	Efficacy	yes	CYP2C9 *1/*3 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1.	*3		< 0.05	Unknown			
982028496	CYP2C9*1, CYP2C9*3	losartan	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.001	Unknown			
982028496	CYP2C9*1, CYP2C9*3	losartan	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.01	Unknown			
982028496	CYP2C9*1, CYP2C9*3	losartan	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.01	Unknown			
982045328	CYP2D6*4, CYP2D6*5, CYP2D6*6	carvedilol,metoprolol	Efficacy	no	CYP2D6 *4/*5 + *4/*6 is not associated with response to carvedilol or metoprolol in people with Heart Failure.			= 0.75	Unknown			
1183490976	CYP2C9*1, CYP2C9*2, CYP2C9*3	losartan	Efficacy	yes	CYP2C9 *1/*2 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1.	*2		< 0.05	Unknown			
1027521661	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Metabolism/PK	yes	CYP2C9 *2 + *3 are associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1.			= 0.005	Unknown			
1043858738	SLCO1B1*15, SLCO1B1*37	olmesartan	Metabolism/PK	yes	SLCO1B1 *15 is associated with decreased clearance of olmesartan in healthy individuals as compared to SLCO1B1 *37.	*15		< 0.05	Unknown			
982047143	CYP2C19*1, CYP2C19*2	tacrolimus	Dosage	yes	CYP2C19 *2/*2 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.	*2		= 0.028	Unknown			
1184509867	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	sertraline	Efficacy	no	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).			= 0.10	OR			
982047169	CYP2C19*1, CYP2C19*2	tacrolimus	Dosage	no	CYP2C19 *2/*2 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.	*2			Unknown			
982043801	SLCO1B1*15, SLCO1B1*37	rosuvastatin	Metabolism/PK	yes	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*37.			= 0.0707	Unknown			
982045166	CYP3A4*1, CYP3A4*4	simvastatin	Efficacy	yes	CYP3A4 *1/*4 is associated with increased response to simvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*1.	*4		= 0.0015	Unknown			
982028504	CYP2C9*1, CYP2C9*13	losartan	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.001	Unknown			
982028504	CYP2C9*1, CYP2C9*13	losartan	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.001	Unknown			
982028504	CYP2C9*1, CYP2C9*13	losartan	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.01	Unknown			
982028504	CYP2C9*1, CYP2C9*13	losartan	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.01	Unknown			
982028504	CYP2C9*1, CYP2C9*13	losartan	Metabolism/PK	yes	CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.01	Unknown			
982046660	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Metabolism/PK	yes	CYP2C9 *2 + *3 are associated with decreased metabolism of phenprocoumon as compared to CYP2C9 *1.			< 0.001	Unknown			
982006758	CYP2D6*1, CYP2D6*1xN, CYP2D6*2xN	ondansetron	Efficacy	yes	CYP2D6 *1xN + *2xN are associated with decreased response to ondansetron in women as compared to CYP2D6 *1.			= 0.034	Unknown			
1041119744	CYP3A4*1, CYP3A4*36	simvastatin	Efficacy	no	CYP3A4 *1/*1 is not associated with response to simvastatin in people with Hyperlipidemias as compared to CYP3A4 *36/*36.			= 0.867	Unknown			
982047452	CYP2C9*1, CYP2C9*3	nateglinide	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of nateglinide in healthy individuals as compared to CYP2C9 *1/*1.	*1		< 0.003	Unknown			
981954763	CYP2D6*2, CYP2D6*10	metoclopramide	Efficacy	no	CYP2D6 *2/*2 + *2/*10 are not associated with response to metoclopramide in people with Neoplasms.			= 0.93	Unknown			
1043818092	CYP2C9*1, CYP2C9*2, CYP2C9*3	phenprocoumon	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	*2		< 0.0017	Unknown			
1451132020	CYP2C19*1, CYP2C19*17	progesterone	Metabolism/PK	no	CYP2C19 *1/*17 + *17/*17 are not associated with exposure to progesterone in women as compared to CYP2C19 *1/*1.							
1183619945	CYP2D6*1, CYP2D6*10	risperidone	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	*10		= 0.004	Unknown			
1183630106	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.			= 0.05	Unknown			
1183620832	CYP2D6*1, CYP2D6*10	risperidone	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1.	*10		= 0.01	Unknown			
1183629618	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	no	CYP2D6 *10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	*10		= 0.52	Unknown			
1183629560	CYP2D6*4, CYP2D6*6	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*6 is associated with decreased metabolism of debrisoquine or dextromethorphan.				Unknown			
1183618528	CYP2C19*1, CYP2C19*2, CYP2C19*3	famotidine	Efficacy	no	CYP2C19 *1/*1 is not associated with response to famotidine in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	*1			Unknown			
1183618478	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*3 + *2/*2.	*1		= 0.006	Unknown			
1183620682	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
1183620682	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	*1		= 0.05	Unknown			
982044314	CYP2D6*1, CYP2D6*4	carvedilol	Metabolism/PK	yes	CYP2D6 *1/*4 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.			< 0.001	Unknown			
1183619427	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	*1			OR	3.45	1.11	10.7
1183621536	CYP2C19*1, CYP2C19*2, CYP2C19*17	pantoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *2/*17 + *2/*2.	*2		= 0.015	OR	4.2	1.35	13.05
1183619401	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
1183624295	CYP2C19*1, CYP2C19*2	esomeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.079	Unknown			
1183624295	CYP2C19*1, CYP2C19*2	esomeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.369	Unknown			
1183618316	CYP2C19*1, CYP2C19*17	escitalopram	Metabolism/PK	no	CYP2C19 *17/*17 is associated with increased clearance of escitalopram in healthy individuals as compared to CYP2C19 *1/*1.	*17		= 0.08	Unknown			
982046974	CYP2D6*1, CYP2D6*2xN	citalopram	Metabolism/PK	no	CYP2D6 *1/*2xN is not associated with increased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	*2XN			Unknown			
1183622326	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.05	Unknown			
982045318	CYP2D6*4, CYP2D6*5, CYP2D6*6	carvedilol	Dosage	yes	CYP2D6 *4/*5 + *4/*6 is associated with increased dose of carvedilol in people with Heart Failure.			= 0.02	Unknown			
1183623479	CYP2C19*1, CYP2C19*2, CYP2C19*17	omeprazole,pantoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.204	Unknown			
1183623479	CYP2C19*1, CYP2C19*2, CYP2C19*17	omeprazole,pantoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.822	Unknown			
1183623479	CYP2C19*1, CYP2C19*2, CYP2C19*17	omeprazole,pantoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.900	Unknown			
1183623479	CYP2C19*1, CYP2C19*2, CYP2C19*17	omeprazole,pantoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	*17		= 0.981	Unknown			
1183620957	CYP2C19*1, CYP2C19*2	omeprazole,pantoprazole	Efficacy	yes	CYP2C19 *1/*2 is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	*1		= 0.05	OR	5.78	1.27	26.25
982044321	CYP2D6*1, CYP2D6*5	carvedilol	Metabolism/PK	yes	CYP2D6 *1/*5 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.			< 0.001	Unknown			
1183618939	CYP2D6*1, CYP2D6*2	aripiprazole	Metabolism/PK	no	CYP2D6 *2 is not associated with decreased metabolism of aripiprazole in healthy individuals as compared to CYP2D6 *1.	*2		= 0.01	Unknown			
1183618318	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*1		= 0.0278	Unknown			
1183618318	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*1		= 0.0359	Unknown			
1183618318	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*1		= 0.0491	Unknown			
1183618318	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*1		= 0.0676	Unknown			
1183618318	CYP2C19*1, CYP2C19*2, CYP2C19*3	rabeprazole	Efficacy	yes	CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	*1		= 0.1190	Unknown			
982043452	CYP2D6*1, CYP2D6*2, CYP2D6*10	carvedilol	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.01	Unknown			
982043452	CYP2D6*1, CYP2D6*2, CYP2D6*10	carvedilol	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.			< 0.01	Unknown			
1183617247	CYP2D6*1, CYP2D6*3	zuclopenthixol	Metabolism/PK	yes	CYP2D6 *3 is associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1.	*3		= 0.03	Unknown			
1183491053	CYP2C9*1, CYP2C9*3	losartan	Efficacy	no	CYP2C9 *1/*3 is not associated with decreased response to losartan in people with Hypertension as compared to CYP2C9 *1/*1.	*3			Unknown			
1183620420	CYP2C9*1, CYP2C9*2	risperidone	Metabolism/PK	no	CYP2C9 *2 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2C9 *1.	*2		= 0.05	Unknown			
1183615619	CYP2D6*1, CYP2D6*4	risperidone	Efficacy	yes	CYP2D6 *4/*4 is associated with increased response to risperidone in people with Schizophrenia as compared to CYP2D6 *1/*1.			= 0.049	OR	0.05	0.002	0.982
1183624182	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	no	CYP2C19 *1/*2 is not associated with response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.158	Unknown			
1183624182	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	no	CYP2C19 *1/*2 is not associated with response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.165	Unknown			
1183624182	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	no	CYP2C19 *1/*2 is not associated with response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.568	Unknown			
1183624182	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	no	CYP2C19 *1/*2 is not associated with response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	*2		= 0.590	Unknown			
1183630934	CYP2D6*1, CYP2D6*10, CYP2D6*17	haloperidol	Metabolism/PK	no	CYP2D6 *1/*10 + *17/*17 are not associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1.				Unknown			
1183617426	CYP2D6*1, CYP2D6*4	amitriptyline,clomipramine,doxepin,imipramine,maprotiline,nortriptyline,opipramol	Dosage,Efficacy	yes	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	*1		= 0.03	Unknown			
1183617426	CYP2D6*1, CYP2D6*4	amitriptyline,clomipramine,doxepin,imipramine,maprotiline,nortriptyline,opipramol	Dosage,Efficacy	yes	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.			> 0.05	OR			
1451135000	CYP3A5*1, CYP3A5*3	oxycodone	Dosage	no	CYP3A5 *3 is not associated with dose of oxycodone in people with Pain, Postoperative as compared to CYP3A5 *1.	*3		> 0.05				
1451134983	CYP3A5*1, CYP3A5*3	sufentanil	Dosage	yes	CYP3A5 *1/*3 + *3/*3 are associated with increased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A5 *1/*1.	*3		< 0.05				
982046981	CYP2C19*1, CYP2C19*2, CYP2C19*3	citalopram	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	*2			Unknown			
982046960	CYP2D6*1, CYP2D6*4	citalopram	Metabolism/PK	no	CYP2D6 *1/*4 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	*4			Unknown			
1183621939	CYP2D6*1, CYP2D6*10	risperidone	Metabolism/PK	no	CYP2D6 *10 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	*10			Unknown			
1183622066	CYP2C19*2, CYP2C19*3	mephenytoin	Metabolism/PK	not stated	CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin in healthy individuals.				Unknown			
1183619675	CYP2D6*1, CYP2D6*1xN	risperidone	Metabolism/PK	no	CYP2D6 *1xN is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	*1XN		= 0.05	Unknown			
1183620508	CYP2D6*1, CYP2D6*4	risperidone	Efficacy	no	CYP2D6 *4 is not associated with decreased response to risperidone in people with Schizophrenia as compared to CYP2D6 *1.	*4			Unknown			
1183622172	CYP2C19*1, CYP2C19*2	mephenytoin	Metabolism/PK	not stated	CYP2C19 *2/*2 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.				Unknown			
1183620517	CYP2D6*1, CYP2D6*10	risperidone	Efficacy,Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	*10		= 0.012	Unknown			
1183622057	CYP2C19*1, CYP2C19*3	mephenytoin	Metabolism/PK	not stated	CYP2C19 *1/*3 is associated with increased metabolism of mephenytoin in healthy individuals.				Unknown			
1183623471	CYP2D6*1, CYP2D6*5	haloperidol	Metabolism/PK	no	CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	*5			Unknown			
1183629566	CYP2D6*4, CYP2D6*15	debrisoquine,dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*15 is associated with decreased metabolism of debrisoquine or dextromethorphan.				Unknown			
1448995859	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.05	OR			
1183620440	CYP2C9*1, CYP2C9*3	risperidone	Metabolism/PK	no	CYP2C9 *3 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2C9 *1.	*3		= 0.05	Unknown			
1183623437	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	no	CYP2D6 *10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	*10			Unknown			
1183623172	CYP2D6*1, CYP2D6*10	debrisoquine	Metabolism/PK	no	CYP2D6 *1/*10 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.	*10		= 0.05	Unknown		1.17	1.85
1183624136	CYP2C19*1, CYP2C19*2, CYP2C19*3	mephenytoin,omeprazole	Metabolism/PK	yes	CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.			= 1.0E-4	Unknown			
1183629749	CYP2D6*1, CYP2D6*10	haloperidol	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	*10		= 0.05	Unknown			
1183620411	CYP2D6*1, CYP2D6*4	risperidone	Metabolism/PK	yes	CYP2D6 *4 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	*4		= 0.05	Unknown			
1183703250	CYP2C9*1, CYP2C9*3	lornoxicam	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.			< 0.01	OR			
1183623283	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *1/*2 + *1/*3.	*1		= 0.0439	Unknown			
1183623799	CYP2C19*1, CYP2C19*2, CYP2C19*3	lansoprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.001	OR	3.06	1.56	6.0
1183679247	CYP2C19*1, CYP2C19*2	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.032	OR			
1183679247	CYP2C19*1, CYP2C19*2	rabeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.037	OR			
1183679229	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.007	OR			
1183679229	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.016	OR			
1183679229	CYP2C19*1, CYP2C19*2	esomeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	*2		= 0.026	OR			
1183680395	CYP2D6*1, CYP2D6*3, CYP2D6*4	tramadol	Metabolism/PK	yes	CYP2D6 *4/*4 is associated with decreased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1.			< 0.001	OR			
1183681642	CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased response to clopidogrel in people with Cardiovascular Diseases.			= 0.03	OR			
1183629838	CYP2C19*1, CYP2C19*2	lansoprazole	Metabolism/PK	yes	CYP2C19 *1/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	*2		= 0.05	Unknown			
1451136960	CYP2C19*1, CYP2C19*2	dexlansoprazole	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.			< 0.05				
1183623842	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			= 0.0005	OR	4.28	1.88	9.74
1183689298	CYP1A2*1A, CYP1A2*1F	olanzapine	Efficacy	no	CYP1A2 *1F is not associated with response to olanzapine in people with Schizophrenia as compared to CYP1A2 *1A.				OR			
1183697377	CYP2D6*1, CYP2D6*5, CYP2D6*10	lovastatin	Metabolism/PK	yes	CYP2D6 *10 + *5 are associated with decreased metabolism of lovastatin in healthy individuals as compared to CYP2D6 *1/*1.	*10	*5	< 0.01	OR			
1183680188	CYP2C9*1, CYP2C9*3	benzbromarone	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased clearance of benzbromarone in healthy individuals as compared to CYP2C9 *1/*1.	*3		< 0.05	OR			
1183682115	CYP2B6*1, CYP2B6*6	sibutramine	Metabolism/PK	no	CYP2B6 *6/*6 is not associated with metabolism of sibutramine in healthy individuals as compared to CYP2B6 *1/*1.	*6		= 0.210	OR			
1183682115	CYP2B6*1, CYP2B6*6	sibutramine	Metabolism/PK	no	CYP2B6 *6/*6 is not associated with metabolism of sibutramine in healthy individuals as compared to CYP2B6 *1/*1.	*6		= 0.303	OR			
1183682257	CYP2C19*1, CYP2C19*2	labetalol	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased metabolism of labetalol in healthy individuals as compared to CYP2C19 *1/*1.	*2	*3	< 0.05	OR			
1183680745	CYP2C9*1, CYP2C9*2	celecoxib	Metabolism/PK	yes	CYP2C9 *1/*2 is associated with increased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	*2		< 0.05	OR			
1183680624	CYP2D6*1, CYP2D6*1xN	codeine	Metabolism/PK	not stated	CYP2D6 *1/*1 + *1xN/*1xN is associated with increased metabolism of codeine in healthy individuals.				OR			
1183680606	CYP2D6*3, CYP2D6*4	codeine	Metabolism/PK	not stated	CYP2D6 *3/*4 is associated with decreased metabolism of codeine in healthy individuals.				OR			
1183693363	CYP2C19*1, CYP2C19*2, CYP2C19*3	icotinib	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 (assigned as heterozygous normal metabolizer phenotype) is associated with decreased metabolism of icotinib in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2	*3	< 0.047	OR			
1183701549	CYP2C9*1, CYP2C9*2	warfarin	Dosage	no	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2			OR			
1183701320	CYP2C9*1, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.				OR			
1183700648	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	*2	*3	< 0.0001	OR			
1183700730	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	*2	*3	< 0.001	OR			
1183700669	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	*2	*3	< 0.0001	OR			
1183679411	CYP2C19*1, CYP2C19*2, CYP2C19*3	omeprazole	Efficacy	yes	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.			< 0.0001	OR	0.23	0.11	0.52
1447963480	CYP2B6*1, CYP2B6*22	bupropion	Metabolism/PK	yes	CYP2B6 *1/*22 is associated with increased metabolism of bupropion as compared to CYP2B6 *1/*1.			= 0.007	OR			
1447963480	CYP2B6*1, CYP2B6*22	bupropion	Metabolism/PK	yes	CYP2B6 *1/*22 is associated with increased metabolism of bupropion as compared to CYP2B6 *1/*1.			= 0.042	OR			
1183685442	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2.	*2	*17	< 0.01	OR			
1183697432	CYP2C19*2, CYP2C19*3, CYP2C19*17	axitinib	Metabolism/PK	no	CYP2C19 *17 + *2 + *3 are not associated with metabolism of axitinib in healthy individuals.			= 0.37	OR			
1183629846	CYP2C19*1, CYP2C19*2	lansoprazole	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*2.	*2		= 0.05	Unknown			
1184168878	CYP2C19*1, CYP2C19*17	clopidogrel	Efficacy	no	CYP2C19 *1/*17 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	*17		= 0.15	HR			
1184167098	CYP2B6*1, CYP2B6*6	fludarabine	Efficacy	no	CYP2B6 *1/*6 + *6/*6 is not associated with response to fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	*6		> 0.05	OR			
1184510172	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1184483514	UGT1A1*1, UGT1A1*6, UGT1A1*28	bevacizumab,fluorouracil,irinotecan,leucovorin	Efficacy	no	UGT1A1 *1/*1 is not associated with response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to UGT1A1 *1/*28 + *1/*6 + *6/*28.	*28		= 0.0813	OR			
1184174521	NAT2*5D, NAT2*6B, NAT2*7A, NAT2*14A	hydralazine	Efficacy	yes	NAT2 *5D/*14A + *5D/*5D + *5D/*6B + *5D/*7A + *6B/*14A + *6B/*6B + *7A/*6B (assigned as slow acetylator phenotype) is associated with increased response to hydralazine in people with resistant hypertension.			< 0.05	OR			
1184484028	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	fluoxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			= 0.007	OR			
1183849138	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	paroxetine	Efficacy	no	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) are not associated with response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).				OR			
1183852291	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Dosage	yes	CYP2C19 *1/*2 is associated with decreased dose of voriconazole in people with Cystic Fibrosis and lung transplantation as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	*2	*17	< 0.05	OR			
1183852291	CYP2C19*1, CYP2C19*2, CYP2C19*17	voriconazole	Dosage	yes	CYP2C19 *1/*2 is associated with decreased dose of voriconazole in people with Cystic Fibrosis and lung transplantation as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	*2	*17	> 0.05	OR			
1184508133	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	paroxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in women with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).			< 0.02	OR			
1184472857	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.			= 0.013	OR			
1184472379	CYP2C19*1, CYP2C19*2	aspirin,clopidogrel	Efficacy	no	CYP2C19 *2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	*2		> 0.05	HR	0.8	0.2	1.1
1184473587	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1.			= 0.008	OR			
1184472114	CYP2C19*1, CYP2C19*17	clopidogrel	Efficacy	yes	CYP2C19 *1/*17 + *17/*17 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.			= 0.0003	OR	0.6	0.45	0.79
1184469816	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy,Toxicity	yes	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	*2	*3	= 0.001	OR	3.412	1.694	6.871
1184468543	CYP2D6*1, CYP2D6*10	nortriptyline	Metabolism/PK	not stated	CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.				OR			
1449713390	CYP2C8*1, CYP2C8*3	pioglitazone	Metabolism/PK	yes	CYP2C8 *1/*1 is associated with decreased clearance of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.			= 0.002	OR			
1184471526	CYP2B6*1, CYP2B6*6, CYP2B6*9, CYP2B6*13	prasugrel	Efficacy	no	CYP2B6 *1/*6 + *1/*9 + *1/*6 + *1/*9 + *1/*13 + *6/*9 + *9/*9 (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .			= 0.15	HR	1.45	0.96	2.18
1184471526	CYP2B6*1, CYP2B6*6, CYP2B6*9, CYP2B6*13	prasugrel	Efficacy	no	CYP2B6 *1/*6 + *1/*9 + *1/*6 + *1/*9 + *1/*13 + *6/*9 + *9/*9 (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .				OR			
1184470393	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*8, CYP2C19*17	prasugrel	Efficacy	no	CYP2C19 *1/*2 + *1/*3 + *1/*4 + *1/*8 + *2/*2 + *2/*3 + *2/*4 + *2/*5 + *2/*8 (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP2C19 *17/*17 + *1/*17 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .			= 0.27	HR	0.89	0.6	1.31
1184470393	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*8, CYP2C19*17	prasugrel	Efficacy	no	CYP2C19 *1/*2 + *1/*3 + *1/*4 + *1/*8 + *2/*2 + *2/*3 + *2/*4 + *2/*5 + *2/*8 (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP2C19 *17/*17 + *1/*17 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .				OR			
1444696719	CYP2C19*2, CYP2C19*8	mephenytoin	Metabolism/PK	no	CYP2C19 *2/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of mephenytoin.				OR			
1184653974	CYP2C19*1, CYP2C19*2, CYP2C19*16	methylphenobarbital	Metabolism/PK	no	CYP2C19 *2/*16 is associated with decreased metabolism of methylphenobarbital as compared to CYP2C19 *1/*1.				OR			
1184512692	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	citalopram,fluoxetine,paroxetine	Efficacy	yes	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).			= 0.032	OR			
1451147629	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	amlodipine	Metabolism/PK	not stated	CYP3A5 *3 + *6 + *7 are associated with decreased clearance of amlodipine in healthy individuals as compared to CYP3A5 *1.							
1184754833	CYP3A4*1, CYP3A4*22	sunitinib	Metabolism/PK	yes	CYP3A4 *1/*22 + *22/*22 are associated with decreased clearance of sunitinib as compared to CYP3A4 *1/*1.			= 0.01	OR			
1184755514	CYP2D6*1, CYP2D6*9	debrisoquine	Metabolism/PK	not stated	CYP2D6 *1/*9 (assigned as normal metabolizers phenotype) is not associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.				OR			
1184755450	CYP2D6*5, CYP2D6*8	debrisoquine,sparteine	Metabolism/PK	not stated	CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.				OR			
1184757079	CYP2D6*4, CYP2D6*6, CYP2D6*40	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *6/*40 + *4/*40 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1184756116	CYP2D6*5, CYP2D6*18	sparteine	Metabolism/PK	not stated	CYP2D6 *5/*18 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1184757143	CYP2D6*40, CYP2D6*42	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *40/*42 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.				OR			
1184757252	CYP2D6*41, CYP2D6*62	sparteine	Metabolism/PK	not stated	CYP2D6 *41/*62 is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1184755702	CYP2D6*4, CYP2D6*11	sparteine	Metabolism/PK	not stated	CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1184764296	CYP2D6*5, CYP2D6*7	sparteine	Metabolism/PK	not stated	CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.				OR			
1444936339	CYP2C19*1, CYP2C19*2	aspirin,clopidogrel	Efficacy	yes	CYP2C19 *2/*2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*2.	*2	*1	< 0.001	OR	11.625	3.498	38.633
1444704705	CYP2C19*1, CYP2C19*2, CYP2C19*3	clopidogrel	Efficacy	yes	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) is associated with decreased response to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.			< 0.001	OR			
1444706944	CYP2C9*1, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.			< 0.001	OR			
1444707144	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.			< 0.001	OR			
1444936127	CYP2D6*1, CYP2D6*5, CYP2D6*10	4-hydroxytamoxifen,endoxifen	Metabolism/PK	yes	CYP2D6 *10/*10 + *5/*5 are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.			< 0.0001	OR			
1447024584	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *2/*3 + *3/*3 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.0001	OR			
1444695622	CYP2C19*1, CYP2C19*2, CYP2C19*17	warfarin	Metabolism/PK	yes	CYP2C19 *1/*17 + *17/*17 are associated with increased clearance of warfarin as compared to CYP2C19 *1/*2 + *2/*2.			= 0.01	OR			
1444695230	CYP2C19*1, CYP2C19*2, CYP2C19*3	clobazam	Metabolism/PK	not stated	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	*2	*3		OR			
1445296627	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1445296627	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1445296627	CYP2C9*1, CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.59	OR			
1185235188	UGT1A1*1, UGT1A1*28	SN-38	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 is associated with increased concentrations of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	*28		= 0.01	OR			
1185235201	UGT1A1*1, UGT1A1*28	irinotecan	Metabolism/PK	no	UGT1A1 *1/*28 + *28/*28 is not associated with concentrations of irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	*28		= 0.62	OR			
1445296671	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1445296671	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1445296671	CYP2C9*1, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.001	OR			
1444705825	CYP2C9*1, CYP2C9*2, CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.			< 0.001	OR			
1444706610	CYP2C9*1, CYP2C9*5, CYP2C9*8, CYP2C9*9, CYP2C9*11	acenocoumarol	Metabolism/PK	no	CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.				OR			
1444707383	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.0001	OR			
1444827994	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased concentrations of voriconazole as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	*2		= 0.0029	OR			
1444608478	CYP2C9*1, CYP2C9*3	valproic acid	Metabolism/PK	no	CYP2C9 *3 is not associated with clearance of valproic acid in people with Epilepsy as compared to CYP2C9 *1.	*3	*1		OR			
1447672753	UGT1A1*1, UGT1A1*60	belinostat	Metabolism/PK	yes	UGT1A1 *1/*60 + *60/*60 is associated with increased concentrations of Belinostat in people with Neoplasms.			= 0.003	OR			
1447672753	UGT1A1*1, UGT1A1*60	belinostat	Metabolism/PK	yes	UGT1A1 *1/*60 + *60/*60 is associated with increased concentrations of Belinostat in people with Neoplasms.			= 0.0037	OR			
1447672760	UGT1A1*1, UGT1A1*60	belinostat	Metabolism/PK	yes	UGT1A1 *1/*60 + *60/*60 is associated with decreased metabolism of Belinostat in people with Neoplasms.			= 0.0017	OR			
1447672760	UGT1A1*1, UGT1A1*60	belinostat	Metabolism/PK	yes	UGT1A1 *1/*60 + *60/*60 is associated with decreased metabolism of Belinostat in people with Neoplasms.			= 0.0077	OR			
1446897132	CYP2D6*4, CYP2D6*36	dextromethorphan	Metabolism/PK	not stated	CYP2D6 *4/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.				OR			
1446896493	CYP2C19*1, CYP2C19*3	clopidogrel	Efficacy	no	CYP2C19 *3 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.			= 0.009	OR			
1446896483	CYP2C19*1, CYP2C19*2	clopidogrel	Efficacy	no	CYP2C19 *2 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.			= 0.009	OR			
1447715709	GSTT1 non-null, GSTT1 null	paclitaxel,Platinum compounds	Efficacy	no	GSTT1 non-null is not associated with response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTT1 null.			> 0.05	OR			
1447715709	GSTT1 non-null, GSTT1 null	paclitaxel,Platinum compounds	Efficacy	no	GSTT1 non-null is not associated with response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTT1 null.			= 0.536	OR			
1446905865	CYP2C19*1, CYP2C19*2	doxepin	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased clearance of doxepin in healthy individuals as compared to CYP2C19 *1/*1.			= 0.009	OR			
1446905865	CYP2C19*1, CYP2C19*2	doxepin	Metabolism/PK	yes	CYP2C19 *2/*2 is associated with decreased clearance of doxepin in healthy individuals as compared to CYP2C19 *1/*1.			= 0.009	OR			
1446904458	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10	nortriptyline	Metabolism/PK	yes	CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.			< 0.005	OR			
1447519652	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.01	OR			
1447519652	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11	warfarin	Dosage	yes	CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.12	OR			
1447520623	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.01	OR			
1447520623	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			< 0.01	OR			
1447520623	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.81	OR			
1446899759	CYP2D6*1, CYP2D6*10	nortriptyline	Metabolism/PK	no	CYP2D6 *1/*10 is not associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	*10		> 0.05	Unknown		1.17	1.85
1447991285	CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*35xN	sparteine	Metabolism/PK	not stated	CYP2D6 *35xN/*1 + *2xN/*2 are associated with increased metabolism of sparteine in healthy individuals.				OR			
1446848557	CYP2C9*1, CYP2C9*3	warfarin	Dosage	no	CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.29	OR			
1446901519	CYP2C19*1, CYP2C19*2, CYP2C19*3	amitriptyline	Metabolism/PK	yes	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.			< 0.05	OR			
1448258935	CYP2C19*2, CYP2C19*3	acenocoumarol,phenprocoumon	Dosage	not stated	CYP2C19 *2 + *3 are associated with dose of acenocoumarol and phenprocoumon.				OR			
1448258935	CYP2C19*2, CYP2C19*3	acenocoumarol,phenprocoumon	Dosage	not stated	CYP2C19 *2 + *3 are associated with dose of acenocoumarol and phenprocoumon.				OR			
1448112553	CYP2C19*1, CYP2C19*2	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*1 is associated with increased clearance of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.			= 0.03	OR			
1448276433	CYP2C9*2, CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *2 + *3 are associated with dose of warfarin.	*2	*3		OR			
1447980312	CYP2C19*1, CYP2C19*2	tolperisone	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with exposure to tolperisone in healthy individuals as compared to CYP2C19 *1/*1.			= 0.0268	OR			
1447980312	CYP2C19*1, CYP2C19*2	tolperisone	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with exposure to tolperisone in healthy individuals as compared to CYP2C19 *1/*1.			= 0.0692	OR			
1447980312	CYP2C19*1, CYP2C19*2	tolperisone	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with exposure to tolperisone in healthy individuals as compared to CYP2C19 *1/*1.			= 0.0757	OR			
1447980312	CYP2C19*1, CYP2C19*2	tolperisone	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with exposure to tolperisone in healthy individuals as compared to CYP2C19 *1/*1.			= 0.1601	OR			
1447980312	CYP2C19*1, CYP2C19*2	tolperisone	Metabolism/PK	no	CYP2C19 *1/*2 is not associated with exposure to tolperisone in healthy individuals as compared to CYP2C19 *1/*1.			= 0.4483	OR			
1448104199	CYP2A6*1A, CYP2A6*6	coumarin	Metabolism/PK	not stated	CYP2A6 *6 is associated with decreased metabolism of coumarin as compared to CYP2A6 *1A.				OR			
1448109250	CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41	3,4-methylenedioxymethamphetamine	Efficacy	yes	CYP2D6 *4/*4 + *3/*5 is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *4/*10 + *4/*41 + *5/*10 + *5/*41 + *10/*41 + *10/*10 + *4/*9 (assigned as intermediate metabolizers phenotype) .			< 0.02	OR			
1448262588	GSTM1 non-null, GSTM1 null	azathioprine	Efficacy	no	GSTM1 null is associated with decreased response to azathioprine in people with Inflammatory Bowel Diseases as compared to GSTM1 non-null.	non-null	non-null	= 0.053	OR			
1447959918	UGT1A1*1, UGT1A1*28	deferasirox	Metabolism/PK	yes	UGT1A1 *1/*28 + *28/*28 is associated with decreased concentrations of deferasirox in people with Anemia as compared to UGT1A1 *1/*1.	*28		= 0.03	OR			
1447989858	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *1/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1447989858	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *1/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1447989858	CYP2D6*1, CYP2D6*10	dextromethorphan	Metabolism/PK	yes	CYP2D6 *1/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.			< 0.05	OR			
1448997246	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	not stated	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.				OR			
1448604391	CYP2C19*1, CYP2C19*2	clopidogrel	Efficacy	yes	CYP2C19 *2/*2 is associated with increased resistance to clopidogrel in people with Acute coronary syndrome and Stroke as compared to CYP2C19 *1/*1.			= 0.011	OR	20.92	9.87	44.6
1448995884	CYP2B6*1, CYP2B6*11	efavirenz	Metabolism/PK	yes	CYP2B6 *11 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.				OR			
1448428115	CYP2C9*1, CYP2C9*2, CYP2C9*3	valproic acid	Dosage	yes	CYP2C9 *1/*2 + *1/*3 are associated with decreased dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.			< 0.01	OR			
1448492087	CYP3A4*1, CYP3A4*36	exemestane	Metabolism/PK	no	CYP3A4 *1/*36 + *36/*36 are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to CYP3A4 *1/*1.	*36		= 0.65	OR			
1448995983	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6/*6 + *1/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.			= 0.01	OR			
1448522373	UGT1A1*1, UGT1A1*28	fluorouracil,irinotecan,oxaliplatin	Efficacy	no	UGT1A1 *28/*28 is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	*28		> 0.01	OR			
1448994017	CYP2B6*1, CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *1/*6 + *6/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.				OR			
1448281118	UGT1A1*1, UGT1A1*28	irinotecan	Dosage	not stated	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.				OR			
1449188252	CYP2C9*1, CYP2C9*2	acenocoumarol	Dosage	yes	CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1.			= 0.004	OR	0.28	0.06	0.6
1449165805	CYP3A4*1, CYP3A4*18	tacrolimus	Metabolism/PK	yes	CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*18 + *18/*18.	*18B		< 0.0001	OR			
1449192891	CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*33, CYP2D6*41	methadone	Metabolism/PK	no	CYP2D6 *9 + *10 + *41 are not associated with clearance of methadone in people with Opioid-Related Disorders and Pain as compared to CYP2D6 *1 + *2 + *33.				OR			
1449192908	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*33	methadone	Metabolism/PK	no	CYP2D6 *3 + *4 + *5 are not associated with clearance of methadone in people with Opioid-Related Disorders and Pain as compared to CYP2D6 *1 + *2 + *33.				OR			
1449171322	CYP2C9*1, CYP2C9*3	celecoxib	Metabolism/PK	yes	CYP2C9 *1/*3 is associated with decreased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.			< 0.05	OR			
1449189944	CYP2D6*2, CYP2D6*41	hydrocodone	Metabolism/PK	not stated	CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.				OR			
1449266467	CYP2C9*2, CYP2C9*3	methadone	Metabolism/PK	no	CYP2C9 *2 + *3 are not associated with concentrations of methadone in people with Opioid-Related Disorders.			> 0.3	OR			
1449271251	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	buprenorphine,methadone	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	HTTLPR short form (S allele)		= 0.027	OR			
1447520031	CYP2C9*1, CYP2C9*2, CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.			= 0.02	OR			
1450823212	CYP3A4*1, CYP3A4*36	fentanyl	Dosage	yes	CYP3A4 *36 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.			< 0.00001				
1450370871	CYP2C19*1, CYP2C19*2, CYP2C19*17	clopidogrel	Efficacy	yes	CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .			= 0.013	OR			
1450372517	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2	*3	= 0.014	OR			
1450372517	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	voriconazole	Metabolism/PK	yes	CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	*2	*3	= 0.034	OR			
1449749531	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.				OR			
1184998461	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	atazanavir	Metabolism/PK	yes	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.			< 0.003	OR			
1184998461	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	atazanavir	Metabolism/PK	yes	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.			= 0.045	OR			
1184998461	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	atazanavir	Metabolism/PK	yes	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.			= 0.28	OR			
1449146864	CYP3A5*1, CYP3A5*3	clozapine	Dosage	yes	CYP3A5 *1/*3 is associated with decreased concentrations of clozapine in people with schizoaffective disorder or Schizophrenia as compared to CYP3A5 *3/*3.	*1		< 0.0001	OR			
1184514634	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.	*1		< 0.001	OR			
1184514634	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.	*1		= 0.005	OR			
1184514634	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.	*1		= 0.045	OR			
1184514634	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.	*1		> 0.05	OR			
1450806320	CYP3A5*1, CYP3A5*3	clopidogrel	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with exposure to clopidogrel in healthy individuals as compared to CYP3A5 *1/*1.			= 0.335	OR			
1449170393	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.04	OR			
1450823248	CYP3A5*1, CYP3A5*3	fentanyl	Dosage	no	CYP3A5 *3 is not associated with dose of fentanyl in people with Pain as compared to CYP3A5 *1/*1.			< 0.52				
1448427598	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.			= 0.034	OR			
1447520826	CYP3A5*1, CYP3A5*3	sirolimus,tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1447520826	CYP3A5*1, CYP3A5*3	sirolimus,tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1448573323	CYP3A5*1, CYP3A5*3	tacrolimus	Efficacy	not stated	CYP3A5 *1/*1 is not associated with response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	*1			OR			
1184514971	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	no	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	*3		> 0.05	OR			
1445125156	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A5 *1/*1 + *1/*3.	*1		< 0.001	OR			
1184470953	CYP3A5*1, CYP3A5*3	cyclosporine,everolimus	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with clearance of cyclosporine or everolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.151	OR			
1184470953	CYP3A5*1, CYP3A5*3	cyclosporine,everolimus	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with clearance of cyclosporine or everolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.32	OR			
1447949204	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	*1		< 0.001	OR			
981501901	CYP3A5*1, CYP3A5*3	simvastatin	Efficacy	no	CYP3A5 *3/*3 is not associated with response to simvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1/*1.				Unknown			
1450812359	CYP3A5*1, CYP3A5*3	nimodipine	Efficacy	yes	CYP3A5 *3/*3 is associated with increased exposure to nimodipine in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.008			0.131	0.775
1450812359	CYP3A5*1, CYP3A5*3	nimodipine	Efficacy	yes	CYP3A5 *3/*3 is associated with increased exposure to nimodipine in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.031			0.033	0.623
1450812359	CYP3A5*1, CYP3A5*3	nimodipine	Efficacy	yes	CYP3A5 *3/*3 is associated with increased exposure to nimodipine in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.033			-419.763	-19.544
1450377052	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3 + *1/*1.				OR			
1444708907	CYP3A5*1, CYP3A5*3	tamoxifen	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP3A5 *1.			> 0.05	OR			
1445584925	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.			< 0.0001	OR			
1449749453	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.			= 0.032	OR			
1184514946	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	*1		= 0.001	OR			
1184470932	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.00001	OR			
1447520665	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.01	OR			
1449748903	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.05	OR			
1184514901	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.009	OR			
1444936677	CYP3A5*1, CYP3A5*3	sunitinib	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with exposure to sunitinib in people with Carcinoma, Renal Cell as compared to CYP3A5 *3/*3.	*1		> 0.05	OR			
981501747	CYP3A5*1, CYP3A5*3	carbamazepine	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.037	Unknown			
981501747	CYP3A5*1, CYP3A5*3	carbamazepine	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1/*1 + *1/*3.	*3			Unknown			
981844214	CYP3A5*1, CYP3A5*3	erythromycin	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 is not associated with metabolism of erythromycin in people with Neoplasms as compared to CYP3A5 *3/*3.				Unknown			
1449713910	CYP3A5*1, CYP3A5*3	fentanyl	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.05	OR			
1447674595	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.	*1		= 0.002	OR			
1449576683	CYP3A5*1, CYP3A5*3	tamsulosin	Metabolism/PK	no	CYP3A5 *1 (assigned as intermediate metabolizer and normal metabolizer phenotype) is not associated with concentrations of tamsulosin in healthy individuals as compared to CYP3A5 *3.			= 0.227	OR			
1449576683	CYP3A5*1, CYP3A5*3	tamsulosin	Metabolism/PK	no	CYP3A5 *1 (assigned as intermediate metabolizer and normal metabolizer phenotype) is not associated with concentrations of tamsulosin in healthy individuals as compared to CYP3A5 *3.			= 0.227	OR			
1449576683	CYP3A5*1, CYP3A5*3	tamsulosin	Metabolism/PK	no	CYP3A5 *1 (assigned as intermediate metabolizer and normal metabolizer phenotype) is not associated with concentrations of tamsulosin in healthy individuals as compared to CYP3A5 *3.			= 0.336	OR			
1449576683	CYP3A5*1, CYP3A5*3	tamsulosin	Metabolism/PK	no	CYP3A5 *1 (assigned as intermediate metabolizer and normal metabolizer phenotype) is not associated with concentrations of tamsulosin in healthy individuals as compared to CYP3A5 *3.			= 0.336	OR			
1449576683	CYP3A5*1, CYP3A5*3	tamsulosin	Metabolism/PK	no	CYP3A5 *1 (assigned as intermediate metabolizer and normal metabolizer phenotype) is not associated with concentrations of tamsulosin in healthy individuals as compared to CYP3A5 *3.			= 0.506	OR			
1449576683	CYP3A5*1, CYP3A5*3	tamsulosin	Metabolism/PK	no	CYP3A5 *1 (assigned as intermediate metabolizer and normal metabolizer phenotype) is not associated with concentrations of tamsulosin in healthy individuals as compared to CYP3A5 *3.			= 0.506	OR			
1449716462	CYP3A5*1, CYP3A5*3	fentanyl	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.013	OR			
1449716462	CYP3A5*1, CYP3A5*3	fentanyl	Metabolism/PK	yes	CYP3A5 *3/*3 is associated with decreased clearance of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.015	OR			
1449716450	CYP3A5*1, CYP3A5*3	norfentanyl	Metabolism/PK	no	CYP3A5 *3/*3 is not associated with concentrations of norfentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.	*3		= 0.520	OR			
981844200	CYP3A5*1, CYP3A5*3	midazolam	Metabolism/PK	yes	CYP3A5 *1/*3 is associated with increased metabolism of midazolam in people with Neoplasms as compared to CYP3A5 *3/*3.	*3		= 0.001	Unknown			
1184470237	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.				OR			
1448358509	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.				OR			
1447948600	CYP3A5*1, CYP3A5*3	gefitinib	Metabolism/PK	no	CYP3A5 *1/*3 is not associated with concentrations of gefitinib in healthy individuals as compared to CYP3A5 *3/*3.	*1			OR			
1447948379	CYP3A5*1, CYP3A5*3	gefitinib	Metabolism/PK	no	CYP3A5 *1/*1 + *1/*3 are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP3A5 *3/*3.			> 0.05	OR			
1183689883	CYP3A5*1, CYP3A5*3	cyclosporine	Dosage	yes	CYP3A5 *3 is associated with decreased dose of cyclosporine in people with Kidney Transplantation as compared to CYP3A5 *1.	*3		< 0.04	OR			
1448427616	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.			= 0.041	OR			
1448567961	CYP3A5*1, CYP3A5*6	sirolimus	Metabolism/PK	no	CYP3A5 *1/*1 is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*6 + *6/*6.	*6		= 0.0551	OR			
1184989793	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.			< 0.0001	OR			
1451099067	CYP2D6*1, CYP2D6*9	fentanyl	Metabolism/PK	yes	CYP2D6 *9 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.			< 0.01				
1448308421	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	yes	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	*1		< 0.001	OR			
1184515187	CYP3A5*1, CYP3A5*3	tacrolimus	Metabolism/PK	not stated	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *1/*3.	*1			OR			
1448285878	CYP3A5*1, CYP3A5*3	tacrolimus	Dosage	yes	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	*1		= 0.002	OR			
